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Abstract 
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder which is thought to 
affect 26.6 million individuals worldwide. There is growing concern over a worldwide 
dementia epidemic that is predicted to develop over the coming decades. The evidence thus 
far suggests that increased levels of oxidative stress and vascular risk factors are two major 
contributors, amongst others, to AD development.  
 
The thesis aimed to investigate markers of oxidative stress in AD plasma. Moreover, the 
oxidative status of specific proteins was investigated using both hypothesis driven and 
proteomic approaches. Results presented in this thesis suggest that global plasma protein 
oxidation levels are not different when AD and control subjects are compared, but that 
individual plasma proteins are specific targets for oxidative modification in AD. The thesis 
explores different methodologies to assess oxidative changes in AD. In addition it 
demonstrates that emerging novel and powerful mass spectrometry techniques can be 
employed successfully to identify several proteins modified by oxidation, providing an initial 
starting point for further investigation. 
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1.1 Alzheimer’s disease 
The most common form of dementia is Alzheimer’s disease (AD): a devastating 
neurodegenerative disorder which affects the brain.  This devastating disease typically leaves 
sufferers exhibiting severe memory deficits and having difficulty performing everyday tasks. 
As people are living longer, and the population is becoming more elderly, the prevalence of 
AD is predicted to increase dramatically, thus causing an increased burden to society. 
Alarmingly, in 2006 it was reported that 26.6 million individuals were suffering from AD 
worldwide, and predicted that this figure would increase to 106.2 million by 2050 worldwide 
(Brookmeyer et al., 2007).  
 
1.2 Neuropathological hallmarks of AD 
It has been over 100 years since the first case of AD was reported in 1907 (Alzheimer, 1907; 
Alzheimer et al., 1995; Burns et al., 2002), yet it still remains true that definitive AD 
diagnosis is only possible by assessing the neuropathological hallmarks post-mortem. 
Extracellular senile plaques, which comprise mainly amyloid-β (Aβ) peptide, and 
intracellular hyper-phosphorylated tau (τ) are the two major brain pathologies associated 
with AD (Katzman and Saitoh, 1991; Selkoe, 2001). In general, Aβ is considered to play an 
important role in the development of AD and this is mainly based on early genetic 
experiments which pointed to abnormal mutations in the amyloid precursor protein (APP) as 
being responsible for the increased deposition of Aβ in AD brain (Hardy and Selkoe, 2002; 
Butterfield et al., 2001).  
 
The toxic Aβ peptide evident in AD is generated during the abnormal proteolytic processing 
of the APP; this is commonly referred to as the amyloidogenic pathway (see figure 1.1) and 
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two major forms of the peptide are produced, Aβ40 and Aβ42, the latter being the most toxic 
form (Cole and Vassar, 2008). During this process APP is cleaved by the β-secretase enzyme 
(BACE1) to produce a N terminal Aβ fragment, APPsβ and a C terminal fragment named 
C99 (Cole and Vassar, 2008).  Cleavage of this C99 fragment by the γ-secretase enzyme 
produces an APP intracellular domain (AICD) and Aβ peptides of various lengths, which 
include Aβ40 and Aβ42. On the other hand, APP processing can follow a non-amyloidogenic 
pathway (see figure 1.1) where it is cleaved by the enzyme α-secretase to produce an APPsα 
and C terminal fragment of 83 residues, as subsequent γ-secretase processing generates a p3 
fragment and an AICD (Cole and Vassar, 2008). It is likely that Aβ serves an important 
physiological role under normal conditions, given that the peptide is produced by various cell 
types and is conserved between species (Moreira et al., 2007). Indeed, secreted forms of APP 
(APPs) have been shown to promote neuronal cell survival, aid the migration and 
differentiation of neurons, and protect neurons against oxidative challenges (Araki et al., 
1991; Goodman and Mattson, 1994; Mattson, 1997). 
 
The second characteristic neuropathology associated with AD is the presence of paired 
helical filaments which are formed mainly of the hyperphosphorylated form of the 
microtubule associated protein τ, and commonly referred to as neurofibrillary tangles. Early 
work revealed levels of abnormally phosphorylated τ to be elevated in AD brain tissue 
compared to normally aged controls (Khatoon et al., 1992), with this increase being a likely 
cause of microtubule breakdown evident in AD (Alonso et al., 1994) leading to this ‘tangle’ 
like pathology. The microtubule system is an important network along which material can be 
transported within nerve cells, impairment or damage to this system can ultimately lead to 
cell death.  
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Figure 1.1. Proteolytic processing of APP. Diagram is based on that of Mattson 
(2004) and Cole and Vassar (2008) and describes the amyloidogenic (top) and non-
amyloidogenic (bottom) pathways of APP processing.  
APPsβ 
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 Several hypotheses have been proposed to contribute to AD and these include the amyloid 
(Hardy and Selkoe, 2002), vascular (de la Torre, 2002), inflammatory (Akiyama et al., 2000)  
and oxidative stress hypotheses (Markesbery, 1997). The oxidative stress hypothesis will be 
the focus of this thesis. 
 
1.3 Reactive Oxygen Species (ROS), Antioxidants and Oxidative stress 
Free radicals (FR) are molecules which possess at least one unpaired electron in their outer 
shell, and therefore they are highly reactive as they desire further electrons from other 
molecules for their stability. Reactive oxygen species (ROS) is a term used to describe 
reactive forms of oxygen, as well as FR which are derived from oxygen. Examples of ROS 
include the superoxide anion (O2•-), hydroxyl radical (OH•), peroxynitrite (ONOO-) and 
hydrogen peroxide (H2O2). H2O2 is classed as a reactive form of oxygen and not a FR as it 
does not possess an unpaired electron (Finaud et al., 2006).  
 
Production of ROS occurs during energy metabolism reactions which routinely take place in 
the cell.  Specific sites for ROS generation include the mitochondria and peroxisomes 
(Beckman and Ames, 1998). In addition they are produced by neutrophils and macrophages 
as a protective mechanism against foreign material, which is commonly referred to as the 
respiratory or oxidative burst (Bedard and Krause, 2007). Historically, these unstable and 
highly reactive biological molecules were believed to have a detrimental effect on cellular 
components. However, it has become apparent that they also have an important role in cell 
signalling as they can induce various biological processes (e.g., cell growth and cell 
apoptosis) by acting as secondary messengers and through stimulation of protein 
phosphorylation and transcription factors (Suzuki et al., 1997).  
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Antioxidants were elegantly defined by Barry Halliwell and John Gutteridge, as ‘a substance, 
that when present at low concentrations compared to those of an oxidizable substrate, 
significantly delays, or prevents oxidation of that substrate’ (Halliwell and Gutteridge, 1989). 
The body has an extensive and complex enzymatic antioxidant defence system in place to 
neutralise ROS. The enzymatic antioxidant system includes superoxide dismutase (SOD), 
catalase (CAT) and glutathione peroxidase (GPx). These proteins provide a means of 
breaking down radical species into less harmful products. SOD promotes the dismutation of 
the superoxide radical to hydrogen peroxide which can then be converted to water by either 
CAT or GPx (Finkel and Holbrook, 2000). In addition to this, non-enzymatic antioxidants 
derived from fruit and vegetables can add to these defences (Sies, 1997; Beckman and Ames, 
1998). They are able to scavenge free radicals and can be divided into lipid soluble (e.g., α-
tocopherol, carotenoids and flavonoids) and water soluble based molecules (e.g., glutathione, 
uric acid and ascorbic acid). In situations where these antioxidant defences become depleted 
or overwhelmed by ROS a state of ‘oxidative stress’ can occur (Sies, 1997), and if prolonged 
and sustained, oxidative damage to proteins, lipids and DNA can ensue.  
 
1.4 General indices of oxidative stress 
1.4.1 Protein oxidation 
Proteins are highly susceptible to free radical insults, and such events can lead to irreversible 
oxidative modification.  However, mildly oxidized proteins are degraded and removed from 
cells via the proteasome, and enzymes (e.g., methionine sulfoxide reductases, thioredoxin 
and glutathione reductases) have evolved which reduce oxidized methionine and cysteine 
returning them to their native state (Berlett and Stadtman, 1997). Free radicals can oxidize a 
protein’s backbone and the side chains of particular amino acids (e.g., lysine, arginine, 
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proline, tyrosine, tryptophan and threonine), as well as induce protein fragmentation. In all of 
these instances carbonyl groups (C=O) may be introduced into the protein’s structure. In 
addition the reaction of proteins with aldehyde compounds produced by lipid peroxidation 
(e.g., 4-hydroxynonenal (4-HNE) and malonaldehyde (MDA)) can lead to carbonyl 
formation (Berlett and Stadtman, 1997). As a consequence protein carbonyl groups are 
considered to be an index of protein oxidation. Since Levine and colleagues (1994) 
demonstrated that protein carbonyl groups could be derivatized with 2, 4-
dinitrophenylhydrazine (2, 4-DNPH) to form a 2,4-dinitrophenyl group, which could be 
detected by the use of a specific antibody (i.e. anti-DNP), enzyme-linked immunosorbent 
assay (ELISA) and Western blotting has been used to provide a quantitative and qualitative 
measurement of protein oxidation respectively  (Shacter et al., 1994; Aldred et al., 2004).   
 
1.4.2 Protein nitration 
Peroxynitrite (ONOO-) is a highly potent reactive nitrogen species (RNS) formed during the 
reaction between nitric oxide (NO•) and O2•-. In addition to oxidizing proteins ONOO- has 
the ability to nitrate proteins: a nitro group (-NO2) replaces a hydrogen atom at the 3’ 
position of a tyrosine residue, forming a 3-nitrotyrosine adduct (Souza et al., 2008). This post 
translational modification can impact protein function; in renal allografts the enzyme 
MnSOD exhibits increased nitration in parallel with a reduction in its activity (Millan-Crow 
et al., 1996). Additionally, the presence of 3-nitrotyrosine on tyrosine residues prevents their 
phosphorylation by tyrosine kinases. This has an impact on signalling pathways mediated by 
tyrosine kinases, such as brain derived neurotrophic factor (BDNF) and nerve growth factor 
(NGF) resulting in possible cell apoptosis (Berlett and Stadtman, 1997; Mangialasche et al., 
2009). Quantification of this modification is typically measured using high performance 
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liquid chromatography with electrochemical detection (HPLC-ECD), although ELISA and 
Western blotting using a 3-nitrotyrosine antibody is also frequently used (Duncan, 2003).  
 
1.4.3 Lipid peroxidation  
Polyunsaturated fatty acids (PUFA) are components of cell membranes which are highly 
susceptible to oxidative damage by free radicals: such damage is referred to as free radical-
mediated lipid peroxidation (LPO) (Buettner, 1993; Niki, 2009).  The initial step of LPO 
involves the free radical-mediated abstraction of hydrogen atoms from PUFA to form lipid 
radicals which react with molecular oxygen to form the highly reactive peroxyl radical. This 
extremely unstable species can further oxidize lipids to produce new lipid radicals and 
thereby propagate a chain reaction (Buettner, 1993; Niki, 2009). LPO can be terminated if 
lipid radicals (e.g., lipid peroxides) react with themselves to form stable lipid peroxide 
products, or if lipid-soluble antioxidants (e.g., vitamin E)  are available to reduce peroxyl 
radicals to lipid hydroperoxides, albeit these can be cleaved by reduced metals to form 
harmful alkoxyl radical species which may initiate further lipid peroxidation reactions 
(Buettner, 1993). 
 
MDA, 4-HNE and F2-isoprostanes are three products which are routinely used as an index of 
lipid peroxidation. In a recent study, Spickett and co-workers (2010) assessed the 
reproducibility of these measures in fifteen different laboratories, from plasma samples 
exposed to varying degrees of UVA irradiation. The authors reported that the measurement 
of MDA by HPLC was the most sensitive and reproducible measure of the three lipid 
peroxidation products (Breusing et al., 2010). In addition, a widely used index of lipid 
peroxidation is the thiobarbituric acid reactive substances assay (TBARS) which measures 
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the reaction between MDA, the breakdown product of lipid peroxides, and thiobarbituric 
acid (TBA) (Esterbauer et al., 1991; Sayre et al., 2001). A simple spectrophotometric method 
has been described by El-Saadani et al. (1989) which measures total lipid peroxide levels in 
tissues, such as plasma.  
 
1.4.4 Antioxidants 
Measurement of endogenous and exogenous antioxidants such as various vitamins, 
polyphenols and carotenoids, activities of enzymatic antioxidants and total antioxidant 
capacity (TAC) of biological samples are routinely used as an index of the body’s 
antioxidant defences. The Ferric Reducing Ability in Plasma (FRAP), as a measure of 
antioxidant power, is a common measure of TAC which includes all endogenous and 
exogenous antioxidants. In addition, the balance between levels of the small antioxidant 
molecule glutathione (GSH), and its oxidized counterpart (GSSG), provide an indication of 
cellular levels of oxidative stress. Under oxidative stress GSH levels are reduced and GSSG 
levels are increased (Sies, 1999; Bermejo et al., 2008).  
 
1.5 Ageing and Oxidative stress 
In 1956, Harman published The Free Radical Theory of Ageing. He suggested that free 
radical species, formed predominately as a by-product of cellular redox reactions, could 
contribute to oxidative damage to bio-molecules and accelerate ageing (Harman, 1956). A 
decade ago Beckman and Ames (1998) comprehensively reviewed the free radical theory 
and highlighted that ROS indeed play a role in the functional changes characteristic of 
ageing. However, they suggested that the theory should be broadened to encompass 
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oxidative stress as a phenomenon not just involved in events concerning determination of 
lifespan but associated with the whole process of ageing. 
 
Later studies in animals and humans are in agreement with these theories. For example liver 
and brain tissue from aged Fisher male rat exhibited increased oxidative damage to proteins 
when compared to young rats. Furthermore, some antioxidant activities show an age 
dependent decrease (Tian et al., 1998) and in human plasma it has been reported that there is 
a linear increase in oxidative markers with respect to age and a decline in antioxidant 
defences after 45 years of age (Jones et al., 2002). Levels of plasma MDA and protein 
carbonyls have also been observed as increased in elderly compared to young subjects in 
parallel with a decrease in antioxidant capacity (Mutlu-Turkoglu et al., 2003). Moreover, in 
transgenic Drosophila melanogaster fruit flies which over express genes encoding for 
cytosolic and mitochondrial SOD, lifespan has been shown to be increased (Parkes et al., 
1998; Sun et al., 2002). Taken together these data provide evidence to suggest oxidative 
stress should be considered as a contributor of ageing.  
 
1.6 Oxidative stress is increased in AD 
AD is an age-related disease and extensive data comprehensively show that there are 
increased levels of oxidative damage in brain tissue from AD sufferers (Markesbery, 1997; 
Aksenov et al., 2001), above that of healthily aged individuals, and thus it is now considered 
that increased levels of oxidative stress are associated with AD. These increased levels 
appear to be brain region specific; for example an early study revealed no differences in 
protein oxidation between AD and age matched controls in the frontal and occipital lobe 
brain regions (Smith et al., 1991). Lyras and colleagues (1997) comprehensively investigated 
Chapter 1                                                                                                   General Introduction 
 
11 
oxidative damage to proteins, lipids and DNA in various brain regions. They found a 
tentative increase in protein oxidation in several brain regions and a significant increase in 
protein and DNA oxidation in the parietal lobe brain region in AD compared to controls. In 
contrast they found no change in lipid peroxidation levels. Aksenov et al. (2001) later 
demonstrated that protein oxidation was increased in the hippocampus and superior temporal 
middle gyrus brain regions in AD compared to age matched controls, but not in the 
cerebellum. Interestingly, increased levels of protein oxidation were reported in AD brain 
regions dense in Aβ plaques, such as the hippocampus and inferior parietal lobule, when 
compared to the cerebellum, a region virtually devoid of this pathology (Hensley et al., 
1995). Similarly, protein nitration is increased in AD and is region specific with the 
hippocampus, inferior parietal lobule (IPL) and superior/middle temporal gyri most affected, 
while the cerebellum and cerebral cortex remain unaffected (Smith et al., 1997b; Hensley et 
al., 1998). Furthermore, 4HNE, an aldehyde product of lipid peroxidation, is increased in the 
amygala, hippocampus and parahippocampal gyrus regions of AD brain compared to 
controls (Markesbery and Lovell, 1998).  
 
It has also emerged that specific proteins in AD brain tissue are targets for oxidative 
modification. In the IPL brain region, cytoskeletal proteins, such as β-actin, and proteins 
involved in energy metabolism and proteolytic degradation, such as α-enolase and ubiquitin 
carboxyl-terminal hydrolase L-1 respectively, are targets of oxidation and nitration in AD 
(Castegna et al., 2002a; Castegna et al., 2002b; Castegna et al., 2003). Pamplona and 
colleagues (2005) have also shown that a small number of cytoskeletal proteins in the brain 
cortex and proteins involved in energy metabolism exhibit increased lipoxidation. 
Furthermore, in the entorhinal cortex, a brain region involved in the earliest stages of AD, 
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the α-mitochondrial ATP synthase subunit is modified by 4-HNE concurrent with a decrease 
in its activity (Terni et al., 2009). These specific oxidative alterations may have a detrimental 
impact on protein function, for example in the hippocampus, Pin1, a protein which regulates 
phosphorylation and dephosphorylation of tau, exhibits increased oxidation in parallel with 
reduced activity in AD (Sultana et al., 2006a). Pin1 has been shown to be downregulated in 
AD and could be crucial in neurofibrillary tangle formation (Sultana et al., 2006a). 
 
1.7 Oxidative stress is an early event in AD development  
It is thought that oxidative stress is an early event in AD, and this was elegantly 
demonstrated in a study undertaken by Nunomura and colleagues (2001) which set out to 
determine the stage of AD at which oxidative damage occurs. The study assessed neuronal 
oxidative damage from subjects who had suffered with AD for various durations, with their 
primary outcome measurement of oxidative damage being modifications to RNA. The 
authors suggested that this modification does not accumulate as seen with modifications to 
proteins, and as such, provides a better measure of the steady state balance of oxidative 
damage (Nunomura et al., 2001). The authors reported that levels of oxidative damage were 
inversely correlated to both disease duration and deposition of Aβ, and thus concluded that 
oxidative damage is an early event in AD (Nunomura et al., 2001). Later studies have 
assessed markers of oxidative damage in mild cognitive impairment (MCI). MCI is 
considered a transitional disease state which occurs between normal healthy aging and mild 
dementia.  In 10-15% of cases, individuals affected by MCI will convert to AD, which is in 
contrast to the normally aged population which progress to AD at a 1-2% rate (Petersen et 
al., 2001). Studies in MCI brain demonstrate increased protein carbonylation, lipid 
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peroxidation and 3-nitrotyrosine (Keller et al., 2005; Butterfield et al., 2007) and are in 
agreement with the concept that oxidative stress is an early event in this disease. 
 
1.8 Aβ is central feature of oxidative stress in AD 
It is commonly perceived that Aβ has pro-oxidant properties which contribute to the elevated 
levels of oxidative stress evident in AD. For example, Mattson and co-workers (1997) 
reported that in hippocampal neurons Aβ induced the production of 4-HNE which led to their 
degeneration. However, studies have shown that Aβ has antioxidant capacity. Within its 
sequence, a methionine residue exists at position 35, and as well as being responsible for 
reducing transition metals to their highly active form and thus increasing radical production, 
it also functions as a free radical scavenger (Kontush, 2001; Moreira et al., 2007).    
 
It appears that Aβ is anti-oxidant in diffuse plaques, then as Aβ becomes more fibrillar it 
becomes pro-oxidant. For example Nunomura et al. (1999) reported reduced oxidative 
damage in the brain cortex in parallel with the deposition of early diffuse Aβ plaques, which 
indicates that the presence of these early diffuse plaques maybe a compensatory response to 
reduce oxidative damage (Moreira et al., 2007). For Aβ to be a pro-oxidant a high 
concentration of fibrillar Aβ, the presence of transition metals and a methionine at residue 35 
are required (Moreira et al., 2007). Due to the observed antioxidant nature of Aβ it has been 
suggested that it may become a pro-oxidant from an antioxidant if the aforementioned 
conditions are satisfied (Kontush, 2001). Further evidence is supplied by Tamagno and 
colleagues who have demonstrated that oxidative stressors promoted the amyloidogenic 
processing of the amyloid precursor protein leading to increased Aβ production (Tamagno et 
al., 2002; Tamagno et al., 2003).  
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1.9 Vascular nature of AD 
There are several data, from population based studies, which associate an increased 
incidence of AD with various vascular risk factors, suggesting that AD may not just be a 
disease confined to the brain. The report that AD is associated with atherosclerosis (Hofman 
et al., 1997), further substantiated by a recent follow-up study (van et al., 2007) is suggestive 
of this. Furthermore, diabetes and peripheral vascular disease (Ott et al., 1996; Newman et 
al., 2005) have also been associated with AD. Moreover, in a review, Launer (2002) 
discussed existing data which links vascular disease with AD and concluded from this 
commentary that there are clinical, experimental and epidemiological data supporting a role 
for vascular risk factors in AD. More recently Dede and colleagues (2007) reported that 
endothelial function was impaired in AD patients when compared to healthy controls, 
providing further evidence that vascular factors have a role in the pathogenesis of AD. It has 
also been suggested that over 30% of AD cases exhibit cerebrovascular pathology, and that 
cerebrovascular disease worsens cognitive function in the early stages of AD subjects (Esiri 
et al., 1999; Kalaria and Ballard, 1999), where levels of oxidative stress are thought to be 
increased. In addition clinically diagnosed AD patients at post-mortem examination have 
significant lesion formation present in the main artery to brain (Roher et al., 2003). 
 
1.9.1 Nitric oxide is instrumental to vascular changes  
The free radical nitric oxide (NO•) is synthesised by the enzyme nitric oxide synthase (NOS), 
of which three isoforms have been identified and these include neuronal (nNOS) inducible 
(iNOS) and endothelial (eNOS). In AD brain, altered NO• regulation is evident with 
increased NOS activity being demonstrated in brain micro vessels compared to control 
subjects (Dorheim et al., 1994). Changes to NO• status may also in part contribute to elevated 
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levels of oxidative stress present in AD brain tissue. Lűth and colleagues (2002) reported that 
iNOS and eNOS are highly expressed in astrocytes and that nNOS was co-localised with 3-
nitrotyrosine in pyramidal cells in AD. The authors suggested that increased expression of all 
NOS isoforms in astrocytes and neurons contribute to peroxyntitrite synthesis and likely 3-
nitrotyrosine formation. 
 
In blood vessels NO• impacts on vascular disease such as atherosclerosis, a risk factor for 
AD (Hofman et al., 1997). In endothelial and smooth muscle cells, NO• is produced at 
relatively low levels and acts in response to various stimuli to maintain blood vessel 
architecture and homeostasis. It possesses anti-atherosclerotic properties which are attributed 
to its ability to reduce intracellular levels of oxidative stress and prevent signalling processes 
integral to atherosclerosis development (Maxwell, 2002). It is well recognized that high 
blood pressure or hypertension increases the vascular production of ROS, which can result in 
the loss of endothelium-derived NO• by reaction with radicals (e.g., superoxide anion) and 
thus ROS in the vasculature are firmly established as initiators of atherosclerosis and 
cardiovascular disease (Taniyama and Griendling, 2003; Landmesser et al., 2003). In general 
reported plasma and serum levels of NO• in AD are reduced compared with control subjects 
(Selley, 2003; Corzo et al., 2007).  
 
1.9.2 Specific oxidative vascular changes in AD   
It is hardly surprising that increased oxidative damage is evident in AD brain tissue if 
oxidative stress is indeed part of AD pathology. However peripheral tissue oxidative changes 
have also been identified in AD.  These changes may reflect processes which occur in the 
brain, but equally they could represent whole body changes which accompany, or contribute 
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to, this disease. Given the strong link between vascular risk factors and AD these whole body 
changes seen in the AD periphery are highly likely to involve vascular pathology.  
 
For example, the oxidative modification of alpha 1-antitrypsin (α1-AT) in the vasculature 
may contribute to AD. α1-AT is a protease inhibitor responsible for preventing tissue 
damage by inactivating proteinases released during inflammation, and in its oxidized form 
(Ox α1-AT) has been shown to activate primary monocytes and induce pro-inflammatory 
cytokine expression (Moraga and Janciauskiene, 2000). It is also considered a marker of 
oxidative stress (Ueda et al., 2002). Increased levels of plasma Ox α1-AT have been reported 
in AD (Choi et al., 2002; Yu et al., 2003) and hence such modifications may contribute to 
inflammatory processes associated with this neurodegenerative disease (Akiyama et al., 
2000). Indeed, a role for α1-AT in AD has been previously suggested given that elevated 
levels are found localised to neuropathologies associated with AD (Gollin et al., 1992). 
 
A further finding reported by Choi et al. (2002) was the increased oxidation to fibrinogen in 
AD subjects compared to controls. The authors suggested that this modification may result in 
increased activation of plasminogen and therefore contribute to fibrinolysis and proteolysis 
at sites of inflammation (Choi et al., 2002). Several molecules of the coagulation and 
fibrinolysis system have been detected in AD brain and Aβ plaques. The observation that 
heparin enhances the actions of these proteins, coupled to the presence of heparin sulphate 
glycoprotein in Aβ plaques and neurofibrillary tangles has led to the suggestion that these 
proteins maybe actively involved in AD neuroinflammation (Strohmeyer and Rogers, 2001). 
The observed increase in fibrinogen oxidation in AD is also interesting from the viewpoint 
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that the oxidized form of fibrinogen has been shown in particular to play an important role in 
the development of  atherosclerosis (Azizova et al., 2007). 
 
A further example of an oxidative vascular pathology associated with AD is low density 
lipoprotein (LDL) oxidation. LDL is responsible for the transport of triglycerides and 
cholesterol from the blood and surrounding tissues to the liver and is highly susceptible to 
oxidation (Steinberg et al., 1989). In this oxidized state, LDL has been shown to facilitate the 
loading of cholesterol into macrophages and promote smooth muscle cell proliferation, 
platelet adhesion and foam cell formation (Holvoet et al., 2001; Parthasarathy et al., 1989; 
Witztum and Steinberg, 1991), indicative of early atherosclerosis. The demonstration that 
LDL susceptibility to oxidation is increased in cerebrospinal fluid (CSF) and plasma from 
AD subjects, in parallel with reduced levels of antioxidants, further indicates a role for LDL 
oxidation in AD (Schippling et al., 2000). More recently Aβ (peptides Aβ40 and Aβ42) has 
also been shown to bind modified forms of LDL in vitro, including oxidized LDL, and 
increase foam cell formation in vascular lesions (Schulz et al., 2007). 
 
1.10 Peripheral oxidative stress may contribute to AD biomarkers 
Vascular oxidative changes may represent a potential cause of AD and therefore assessing 
such changes enables greater understanding of underlying vascular pathologies which may 
contribute to this dementia. On the other hand, such changes may also be present in 
peripheral tissue as a consequence of AD itself, and hence could be viewed as potential 
biomarkers. There is an increased urgency to develop a biomarker, or series of biomarkers 
for AD given that the only definitive way to diagnose AD at present is at post-mortem 
(Mattson, 2004). The challenge remains to be able to diagnose AD at a much earlier stage, 
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ideally earlier than the onset of clinical symptoms so that treatment, therapies or 
interventions can be deployed and consequently symptoms can be alleviated or delayed.  
 
A consensus report published in 1998 by the Ronald and Nancy Reagan Research Institute of 
the Alzheimer's Association and the National Institute on Aging Working Group 
recommended that a biomarker for AD should be characteristic of AD pathology, reliable, 
cheap, non-invasive and simple to undertake and analyse (1998). Additionally, in a recent 
review by Aluise at al. (2008) the authors described a biomarker as a change or abnormal 
signal that occurs in tissue or fluid excreted or secreted in the body which is distinguishable 
in a patient population.  
 
The two bodily fluids used for biomarker discovery in AD are cerebrospinal fluid (CSF) and 
plasma. CSF is acquired via lumbar puncture which is an invasive process, nonetheless it 
provides an ideal bodily fluid to assess changes which occur in the brain as it is in direct 
contact with the brain extracellular space (Davidsson et al., 2002; Davidsson and Sjogren, 
2006). Plasma on the other hand provides a less invasive, accessible route to investigate 
processes which take place in the body. It is often regarded as the ‘dustbin’ for the human 
body, and as such, hallmarks of processes and reactions which take place in the body, such 
as the brain, can be exported in the plasma. Plasma contains proteins from the periphery that 
may affect the brain (Aluise et al., 2008),  and it has been suggested that approximately half 
a litre of CSF is absorbed into plasma on a daily basis (Hye et al., 2006). 
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 1.10.1 Broad markers  
1.10.1.1 Protein oxidation 
Existing studies assessing the extent of plasma protein carbonylation in AD continue to 
present an unclear picture (see Table 1.1). For example, no change in plasma protein 
oxidation between AD and age matched controls subjects has been reported when analysing 
a specific product of protein oxidation in plasma (Pulido et al., 2005), which is in contrast to 
work by Conrad and colleagues (2000) and Bermejo et al. (2008) who showed that plasma 
protein oxidation was increased in AD by Western blotting and a spectrophotometric assay 
respectively. There is the potential possibility that the disease time course may influence 
plasma protein oxidation levels as oxidative stress is most prevalent in the earliest stages of 
the disease (Nunomura et al., 2001). Indeed, Greilberger et al. (2008)  reported increased 
protein oxidation in a patient group consisting of both MCI and AD subjects and Bermejo et 
al. (2008) revealed a severity dependent increase in plasma protein oxidation. However no 
differences were reported in mild to moderate, and advanced AD (Zafrilla et al., 2006) or in 
mild AD patients (Baldeiras et al., 2008) in two separate studies. Evidently further 
investigation into CSF and plasma protein oxidation levels is warranted. 
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 1.10.1.2 Protein nitration 
From the limited studies which investigate CSF protein nitration levels in AD it is apparent 
that generally levels are increased in AD subjects compared to controls, with two groups 
reporting this finding. However Ryberg et al. (2004) have shown there is no difference in 
Free 3-nitrotyrosine levels between AD and control subjects. Studies of protein nitration in 
plasma are extremely limited. One study used Western blotting to show an increase in 
plasma protein nitration, but the authors did not include any statistical analysis (Calabrese et 
al., 2006). A more recent comprehensive study by Korolainen and Pirttilä (2009) revealed no 
differences in plasma protein nitration between AD and control subjects. Further 
investigations into peripheral protein nitration levels are therefore required. 
 
1.10.1.3 Antioxidant status 
In general, measurements of antioxidant defences are reduced in AD patient populations 
compared with control groups. TAC, as measured by FRAP, has been reported to be reduced 
in AD (Sekler et al., 2008). Further, a 24% decrease in TAC in plasma from probable AD 
compared to controls (Repetto et al., 1999) has been reported using tert-butyl hydroperoxide 
chemiluminescence. It has been suggested that reduction of antioxidant defences occurs in 
only the most advanced cases of AD as these reductions are evident in severe, but not in 
moderate cases (Zafrilla et al., 2006; Sekler et al., 2008). In contrast to these studies other 
groups have reported no differences (Sinclair et al., 1998; Pulido et al., 2005; Baldeiras et al., 
2008). Additional antioxidant defence measures are in support of antioxidants being reduced 
in AD: one study showed that the activity of superoxide dismutase (SOD) and glutathione 
peroxidase (GPx) were reduced in plasma (Rinaldi et al., 2003). Furthermore, studies which 
assessed levels of specific antioxidants in AD plasma revealed a depletion in several 
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compounds compared to control, these include: vitamins A, C and E; Zeaxanthin; β-
Cryptoxanthin; Lycopene; and α and β-carotene (Mecocci et al., 2002; Polidori et al., 2004; 
Rinaldi et al., 2003). 
 
1.10.1.4 Lipid oxidation 
Studies assessing oxidative damage to lipids in plasma suggest that there is increased 
damage in AD compared to control subjects. One study reports comparable levels of lipid 
peroxidation, from AD and control plasma, and a further study supports these findings, albeit 
4-HNE is shown to be increased (McGrath et al., 2001; Polidori et al., 2004). In contrast, 
studies have reported increased plasma levels of MDA in light to moderate cases of AD, and 
in AD (Greilberger et al., 2008; Martin-Aragon et al., 2009; Zafrilla et al., 2006). MDA is 
also found to be increased in red blood cells in AD compared to control subjects (Baldeiras 
et al., 2008). 
 
1.11 Methodologies used to identify specific plasma proteins modified by oxidation  
There are a number of ways to assess the oxidation status of specific proteins. For example a 
protein of interest can be isolated (e.g., immunoprecipitation) and then assessed for a 
particular oxidative adducts for example by Western blotting or ELISA. This approach 
allows hypothesis driven research. In contrast, 2-DE is commonly used to assess the whole 
proteome of a particular biological sample at a given moment in time. It may then be coupled 
to Western blotting and mass spectrometry (MS) in order to identify which proteins are 
oxidized.   
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1.11.1 2-DE and Western blotting 
During 2-DE proteins are initially separated according to their charge by isoelectric 
focussing and then based on their mass by polyacrylamide gel electrophoresis (Aldred et al., 
2004). Separated proteins are then either stained (e.g., Coomassie staining and silver 
staining) and their expression assessed, or they are transferred to membrane (e.g., PVDF or 
nitrocellulose) where Western blotting can then be employed to identify specific proteins 
which contain oxidation adducts. Proteins whose degree of expression or oxidation is 
significantly altered are then excised from 2-DG gels and identified by MS. 
 
1.11.2 Mass Spectrometry 
Mass spectrometry is an analytical technique which is typically used to determine the 
molecular mass of proteins within a particular sample. Protein samples are firstly digested 
into peptides enzymatically using trypsin, a serine protease which cleaves peptides at the 
carboxyl end of arginine and lysine amino acid residues. They are then ionised, separated 
according to their mass to charge (m/z) ratio in a MS analyzer and detected. The m/z ratios 
for all detected ions are represented in the form of a mass spectrum. 
 
MS using multiple analyzers is referred to as tandem mass spectrometry (MS/MS) and 
allows for the generation of structural information from a particular biological sample. It is 
therefore used for protein identification purposes (Wysocki et al., 2005). During MS/MS 
specific precursor ions (e.g., the most abundant) from initial MS are selected and fragmented 
to form product ions which are analysed by a separate analyzer. As shown in figure 1.2 there 
are several sites along the peptide backbone which are cleaved during fragmentation. The 
major site of cleavage is at the peptide bond (CO-NH), and this gives rise to either ‘b’ or ‘y’ 
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ions, which is dependent on whether charge is retained on the amino or carboxyl fragment 
respectively. Further fragment ions can also be formed by cleavage at the CH-CO (e.g., ‘a’ 
and ‘x’) and NH-CH (e.g., ‘c’ and ‘z’) bond. This information is particularly useful as the 
mass difference between adjacent ‘b’ or ‘y’ ions can be used to deduce the amino acid 
sequence of a particular peptide (see figure 1.3), and in theory these ion fragmentation 
patterns can therefore be assembled to form an original peptide sequence (Wysocki et al., 
2005).  
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C 
R1 
C NH2 
H O 
N 
H 
C COOH 
H 
R1 
b 
 
y 
a 
 
x 
c 
 
z 
Figure 1.2 Nomenclature for peptide backbone fragmentation. Peptide 
backbone fragmentation typically occurs at the peptide bond to produces 
‘b’ and ‘y’ ions. If the charge remains at the amino (NH2) end ‘b’ ions are 
produced and if the charge remains at the carboxyl end (COOH) ‘y’ ions 
are produced. Other ions can also be observed during fragmentation and 
these include a, c, x and z ions. 
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L    S    S     P    A    T     L    N    S    R 
y9 y8 y7 y6 y5 y2 y3 y4 y1 
b1 b2 b3 b4 b5 b8 b7 b6 b9 
m/z 
Intensity 
(%) 
A 
B 
Figure 1.3. Peptide sequencing from MS/MS spectra. Most abundant 
precursor ions generated from a survey MS scan are taken forward for CID 
fragmentation. (A) Example of spectra for peptide LSSPATLNSR, produced from 
fragmentation of one selected precursor ion. (B) The mass difference between 
adjacent fragments of a series can be calculated to deduce a peptide sequence, for 
example b7– b6 = 670.4 – 557.3 = 113.10Da corresponds to the amino acid residue 
Leucine (L) and y7- y6 = 758.4 – 661.4 = 97Da corresponds to the amino acid 
residue Proline (P). This peptide sequence covers part of the amino acid sequence 
for trypsin precursor protein P00761/136429.  
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1.12 Specific markers using redox proteomics  
The use of 2-DE coupled to Western blotting to enable the identification of specific proteins 
modified by oxidation was termed ‘redox’ proteomics by Butterfield and colleagues 
(Butterfield et al., 2006). This group and others have used this approach extensively  
(Korolainen et al., 2002; Pamplona et al., 2005; see table 1.2) to identify proteins that are 
specific targets of oxidation in AD brain and thus the group has increased knowledge of the 
possible molecular mechanisms underlying AD development and progression. For example, 
as the brain is a metabolically active tissue, with glucose being its primary fuel source, 
disturbances or problems with metabolizing glucose may lead to cognitive decline associated 
with AD (Costantini et al., 2008). Enolase is an enzyme responsible for the interconversion 
of 2-phosphoglycerate and phosphoenolpyruvate in the glycolytic pathway and consists of α, 
β and γ subunits. It has been shown that the α-subunit is oxidized and nitrated, and the γ 
subunit lipoxidized in AD brain (Castegna et al., 2002b; Castegna et al., 2003; Pamplona et 
al., 2005). In light of these observations impairment of glycolytic enzymes maybe linked to 
the decreased glucose metabolism seen in AD (Castegna et al., 2002b; Costantini et al., 
2008). 
 
In peripheral tissue such studies are limited (see table 1.2). In a recent pilot study Korolainen 
et al. (2007) demonstrated that the CSF protein λ chain precursor and an unidentified CSF 
protein exhibited increased oxidation in AD compared to control patients. In plasma Choi 
and colleagues (2002) identified two oxidized proteins: fibrinogen γ-chain precursor protein 
and α-1-antitrypsin precursor protein. The authors suggested that in their oxidized state these 
two proteins may contribute to increased inflammation in AD (Choi et al., 2002). Increased 
oxidation to the proteins transferrin and hemopexin has also been reported, with both being  
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involved in iron/redox homeostasis (Yu et al., 2003). Peripheral redox proteomics remains in 
its infancy in AD research, but warrants further investigation in order for the role of 
oxidative metabolism in AD to be further understood. 
 
1.13 Aims and Overview of thesis 
The main aims of this thesis were to measure peripheral oxidative and nitrative stress of AD 
and more specifically identify plasma proteins which are specific targets for oxidative 
modification in AD. Broad measures of oxidative and nitrative stress were assessed and 
subjective and non-subjective experimental approaches used to determine the oxidative 
status of specific plasma proteins in AD. 
 
The value and importance of this work are as follows 1) existing studies which have assessed 
plasma protein carbonylation levels in AD present an unclear picture. Several studies report 
levels to be increased in AD compared to control subjects in contrast to others which observe 
no change. Therefore further studies are required to clarify plasma protein oxidation levels in 
these groups; 2) at the time of undertaking the work for this thesis investigation of plasma 
protein nitration in peripheral tissue was extremely limited. One study had assessed protein 
nitration levels in AD by Western blotting and reported an increase compared to controls. 
However, the data presented was minimal and no statistical analysis was provided for this 
reported finding. For this reason, studies which compare plasma protein nitration in AD and 
control subjects were required. The work in this thesis will firstly clarify protein nitration 
levels between disease and control and secondly further current understanding of peripheral 
nitrative stress in AD; and 3) only two studies have employed redox proteomics to 
investigate oxidized plasma proteins in AD. Therefore further investigation is required to add 
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to, and build on these studies to determine whether these particular proteins and others are 
oxidized in a different cohort of AD samples.  
 
Given the association of cardiovascular disease and atherosclerosis with AD, low density 
lipoprotein was a specifically chosen plasma protein whose oxidation status was determined. 
Additionally total levels of plasma protein oxidation and total antioxidant capacity were 
measured by ELISA and spectrophotometric assay respectively. This is described in 
Chapter 3. In light of the limited studies which have assessed nitrative stress in AD, a 
further outcome of this thesis was to develop and provide a quantitative measure for 3-
nitrotyrosine. The attempted use of HPLC-ECD and development of an in-house 3-
nitrotyrosine ELISA is described in Chapter 4. The validation of the Griess Assay to 
measure nitric oxide metabolites and the use of SDS-PAGE and Western blotting to provide 
a measure of total protein nitration, in addition to the identification of plasma proteins altered 
by nitration is the focus of Chapter 5. Gel based redox proteomics was undertaken in 
Chapter 6 to assess specific plasma proteins modified by oxidation in AD.  The use of a 
non-gel based proteomic method, which utilized isobaric labelling, was employed to explore 
plasma proteins modified by oxidation and nitration and is presented in Chapter 7. 
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2.1 Materials  
2.1.1 Chemicals and reagents 
Electrode wicks, Mineral oil, ReadyStripTM IPG strips, bio-lytes (100x), micro-spin® 6 
chromatography columns, Pre-cast Criterion™ gels, Kaleidoscope® pre-stained standards, 
ReadyprepTM TBP reducing agent, TGS, TG, thin blot filter paper and Aurum™ Affi-Gel® 
Blue columns was purchased from BioRad, UK. DestreakTM rehydration solution, 
HybondTM- P PVDF membrane, ECL + Western blotting detection system, AmershamTM 
tracker tape, and High performance chemiluminescent film Amersham hyperfilmTM was 
purchased from GE Healthcare, Amersham, UK. HPLC grade methanol, acetonitrile, 
acetone, ethanol, OSA acid, EDTA, sulphuric acid, sodium hydrogen carbonate was 
purchased from Fisher Scientific, UK. Dialysis membrane was purchased from Medicell 
International Limited, UK. Sequencing grade trypsin was purchased from Promega, USA. 
Rat anti-mouse IgE conjugated horseradish peroxidase antibody was purchased from AdB 
Serotec, UK. Goat anti-mouse IgG conjugated horseradish peroxidase was purchased from 
Cell Signalling, UK. Pronase from Streptomyces griseus was purchased from Biochemika. 
C18 ZipTipTM and mouse monoclonal anti-nitrotyrosine IgG antibody was purchased from 
Millipore, UK and mouse monoclonal α-2 macroglobulin and Complement 4A IgG 
antibodies waspurchased from AbCam Limited, Cambridge, UK.  Film developer and fixer 
were purchased from Ilford, UK. All other chemicals and reagents were purchased from 
Sigma Aldrich, UK. 
 
2.1.2 Plasma samples 
Samples collected for this thesis are part of an ongoing collaboration between Professor 
Patrizia Mecocci at the University hospital Perugia, Italy and Dr Sarah Aldred. Patients 
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attended the dementia clinic of the department of gerontology and geriatrics, University 
hospital Perugia, Italy in a fasted state and blood samples were collected. Ethical approval 
for sample collection and processing is held in Italy. 
 
All samples acquired conformed to the principles outlined in the Declaration of Helsinki. 
Patients with diagnosis of dementia made on the basis of scores obtained to a full battery of 
cognitive, functional and behavioural tests were divided into two groups according to 
NINDS-AIREN (Wetterling et al., 1996) and NINCDS-ADRDA (1985) criteria as follows: 
Neuropsychological and functional assessment tests were administered by a trained 
physician, who was blind to the operative procedure, in a quiet environment in the hospital. 
The battery of tests included the mini mental state examination (MMSE) as measure of 
global cognitive function and tests evaluating the following cognitive domains: a) memory: 
Babcock Story Recall test and Rey’s Auditory Verbal Learning test immediate (Rey-IR) and 
delayed recall (Rey-DR) to assess episodic memory, and verbal fluency with semantic cues 
(Category Naming Test, CNT) to estimate semantic abilities; b) attention and executive 
functions: Trail-Making test part A (TMT-A) and B (TMT-B) to evaluate selective and 
divided attention, respectively, and Controlled Oral Word Association test (COWA) to 
estimate executive functioning; c) visuospatial and constructional abilities: Copy Drawing 
test (CD). Details on administration procedures and Italian normative data for score 
adjustment for age and education, and normality cut-off scores (95% of the lower tolerance 
limit of the normal population distribution) were used for each test. Patients diagnosed as 
having AD were compared to healthy controls. After obtaining informed consent from 
subjects or their relatives, patients and controls underwent blood drawing. Blood was 
immediately centrifuged and plasma stored frozen at -80°C until analysis.  
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In this thesis it was necessary to use two separate sample sets of Alzheimer’s disease (AD) 
and age matched control plasma to investigate oxidative stress biomarkers in dementia.  
Plasma from an initial sample set, which consisted of 144 plasma samples (72 AD and 72 
aged matched controls), was used in chapters 3, 4 and 6 (see table 2.1).  
 
Subject Group Age (yrs) MMSE (mean ± SD) 
Alzheimer’s disease 80 ± 4 19 ± 4 
Control 75 ± 6 27 ± 2 
 
Table 2.1. Subject characteristics for first group of samples. 
 
A separate sample set of plasma was obtained (25 AD and 25 aged matched controls) and 
analysed in chapters 5 and 7 (see table 2.2).  
 
Subject Group Age (yrs) MMSE (mean ± SD) 
Alzheimer’s disease 74 ± 4 13 ± 10* 
Control 74 ± 6 28 ± 2** 
 
Table 2.2. Subject characteristics for second group of samples. *MMSE scores available 
for 17 out of 25 samples. **MMSE scores available for 18 out of 25 samples 
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2.2 Methods 
2.2.1 Bicinchoninic acid assay 
The bicinchoninic acid (BCA) assay based on method described by Smith et al. (1985) was 
used to assess plasma protein concentration. A stock solution of 1mg/ml Bovine Serum 
Albumin (BSA) was prepared and diluted to form a six point standard curve. Standards were 
kept at -80ºC until required. BCA working solution was prepared by adding 250 µl of copper 
sulphate solution (4% w/v) to 12.5 ml BCA solution (Sigma, UK). Standard (10 µl) or 
sample (10 µl) was added to 96 well microtitre plates and BCA working solution (200 µl) 
was added to each well for 30 minutes at 37ºC. Absorbance values were measured at 490 nm 
(Lab system Multiskan MS). Samples were assayed in triplicate and protein concentration 
expressed as mg/ml.  
 
2.2.2 Measurement of Protein oxidation using ELISA 
2.2.2.1 Preparing BSA standards 
Dialysis membrane was boiled in sodium bicarbonate (2%) and EDTA (1 mM, pH 8), 
washed thoroughly in distilled water and boiled for a further 10 minutes in EDTA (1 mM, 
pH 8). After cooling to room temperature, tubing was stored in ethanol at 4ºC. Before use, 
tubing was washed thoroughly in distilled water.  
 
Reduced and oxidized BSA was prepared as described by Carty et al. (2000). BSA, (10 
mg/ml) dissolved in TBS (Tris-HCl 6 g/l, 9 g/l NaCl, pH 7.4), was reduced with sodium 
borohydride (1 g) overnight at 4ºC. Excess foam was removed by the drop wise addition of 
100% acetone and the solution adjusted to a neutral pH using concentrated hydrochloric acid. 
BSA (10 mg/ml) was oxidized by exposure to 2, 2′-Azobis (2-methylpropionamidine) 
Chapter 2                                                                                                         General Methods 
38 
dihydrochloride (AAPH, 500 mM) for one hour at 37ºC, in a water bath. To remove residual 
oxidizing and reducing agents solutions were dialyzed against TBS, over a 24 hour period 
with six buffer changes. Reduced and oxidized BSA were adjusted to 2 mg/ml (Carty et al., 
2000), mixed at different oxidized ratios (0-100%) and stored at -80ºC until further use.  
 
The method used by Carty et al. (2000) to quantify the degree of protein oxidation to known 
BSA standards was undertaken. Standards (500 µl) were mixed with 2, 4 – DNPH (500 µl) 
and left at room temperature for one hour with gentle agitation. TCA (20% w/v; 500 µl) was 
added to each to precipitate protein solution and thoroughly mixed. Solutions were 
centrifuged for 3 minutes at 13,000 xg and protein pellets were washed vigorously three 
times with ethanol: ethyl acetate (ratio 1:1) and redissolved in 6 M guanidine hydrochloride 
(1 ml) for 30 minutes at 37ºC. Solutions were centrifuged at 13,000 xg for a further minute, 
the supernatant was removed and the absorbance of solutions was measured at 360 nm. 
Molarity of solutions was determined using a molar co-efficient value (ε360 = 22000 M-1cm-
1). Protein carbonylation levels were expressed as nmol/ per milligram of protein.  
 
2.2.2.2 Protein carbonyl ELISA 
Protein carbonyl ELISA was undertaken in accordance with Carty et al. (2000). Samples (50 
µl) diluted in coating buffer (50mM Sodium carbonate, pH 9.2) to a final concentration of 
0.05 mg/ml were applied to 96 well NUNC microtitre plates, for one hour at 37ºC. To each 
well 50µl of 2, 4-dinitrophenylhydrazine (DNPH) in 2 M HCl was added and left for one 
hour at room temperature. Wells were blocked with TBST (Tween 20, 0.1%) for 1 hour at 
37ºC and monoclonal mouse anti-DNP antibody diluted at 1:1000 was added for two hours 
at 37ºC. Wells were incubated with peroxidase conjugated rat anti-mouse IgE conjugated 
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HRP diluted at 1:5000 for 1 hour at 37ºC. Between each step wells were washed four times 
with TBS-Tween 20 (0.05%). Substrate (0.5 M Citrate phosphate buffer (10 mls), hydrogen 
peroxide (8 µl) and OPD tablet (2 mg); 50µl) was added to each well and the reaction was 
stopped after fifteen minutes with 2 M sulphuric acid. Absorbance values were measured at 
490 nm (Multiscan MS, Labsystems, Finland).  
 
2.2.3 Total antioxidant capacity  
Total antioxidant capacity was measured using a slight modification to the FRAP assay 
described by Benzie and Strain (1999) and McAnulty et al. (2005). Freshly prepared FRAP 
reagent (300 µl; 300 mM sodium acetate, pH 3.6, 10 mM 2, 4, 6-tris (2-pyridyl)-S-triazine in 
40 mM HCl and 20mM Ferric Chloride (FeCl3) in ddH2O in ratio 10:1:1) was added to 
plasma (10 µl) or standard samples (10 µl) in triplicate at room temperature. The absorbance 
was then measured at 650nm after an eight minute reaction period and FRAP values were 
expressed as FRAP (µM) as determined by linear regression using a range of ascorbic acid 
standards (0-1000 µM). An ascorbic acid standard of 1000 µM is equivalent to 2000 µM of 
antioxidant power as measured by FRAP. This is because the direct reaction of ascorbic acid 
gives a change in absorbance double that of Fe (II) (Benzie and Strain, 1999).  
 
2.2.4 Lipid peroxide assay 
A spectrophotometric assay based on that described by el-Saadani et al. (1989) was used for 
the measurement of lipid peroxide levels in plasma. Samples and a blank standard (10 µl) 
were assayed in duplicate or triplicate and added to a 96 well microtitre plate. Each well was 
incubated with 100 µl of reagent mix (see table 2.3) for 30 minutes at 25°C and protected 
from light. The plate was read at 340 nm (Multiscan MS, Labsystems, Finland). 
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Table 2.3. Reagent mix used for lipid peroxide assay 
 
The concentration of lipid peroxides in plasma was determined using the Beer- Lambert Law 
(extinction co-efficient ε340 = 24600 M-1cm-1). Values were expressed as µmol/l. 
 
2.2.5 One dimensional gel electrophoresis (1-DE) 
Plasma was added to an equal volume of Laemmli buffer (4% SDS, 20% glycerol, 10% 2-
mercaptoethanol, 0.004% bromophenol blue and 0.125 Tris HCl, pH 6.8) and boiled for 5 
minutes at 100°C. For separation, Pre-cast Criterion™ 4-15% gradient Tris-HCl gels and 
running buffer (25 mM Tris, 192 mM glycine and 0.1% SDS (w/v)) were used and plasma 
protein were run at 150 V (unlimited amps) for 85 minutes, or until dye front reached the 
bottom of the gel. Samples were assayed in duplicate or triplicate. Subsequently gels were 
Western blotted or silver stained. 
 
Reagent mix Concentration 
Potassium Phosphate 0.2 M, pH 6.2 
Potassium Iodide 0.12 M 
Sodium Azide 0.15 µM 
Triton X 2 g/l 
Alkylbenzyldimethylammonium Chloride 0.1 g/ml 
Ammonium Molybdate 10 µM 
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2.2.6 Two dimensional gel electrophoresis (2-DE) 
2.2.6.1 Isoelectric focussing 
Electrode wicks were soaked in an ample amount of ddH2O, blotted to remove excess liquid 
and then placed over electrode wires in an 11 cm IEF Protean tray (BioRad). Rehydration 
buffer and bio-lytes (0.5%) were added to plasma samples (100-150 µg). Samples (200 µl) 
were then applied to individual wells of IEF tray and 11 cm IPG ReadyStripTM strips 
inserted. The strips were covered with 2-3 mls mineral oil prior to isoelectric focussing to 
prevent dehydration during separation. Gels were focussed using a Protean IEF cell (BioRad) 
and were passively rehydrated for 12 hours at 20 ºC, they were subsequently run at 250 V for 
15 minutes, followed by linear ramp 250-8000 V for 3500 Vh and maintained at 8000 V for 
90 kVh. Gels were held at 500 V to prevent over focussing until stopped and stored at -20ºC.  
 
2.2.6.2 Gel electrophoresis 
Gels were equilibrated for 20 minutes in equilibration buffer (6 M Urea, 375 mM Tris HCl 
pH 8.8, 2% SDS, 20% Glycerol, Tributyl Phosphine (2mM) and a spatula tip of 
bromophenol blue) on a rotary mixer at room temperature prior to use. Individual IPG strips 
were inserted into wells of Pre-cast Criterion™ 4-15 % Tris-HCl gels and overlaid with hot 
agarose (1 %) to prevent movement when running. Once set the system was run at 150 V 
(unlimited amps) for 85 minutes, or until dye front reached the bottom of the gel. 
2.2.7 Western blotting 
Hybond-P™ membrane was equilibrated in 100% methanol for two minutes followed by 
transfer buffer (25 mM Tris, 192 mM glycine and 20% v/v methanol) for 10 minutes. 
Proteins were transferred from electrophoresis gels to Hybond-P™ membrane by applying 
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170 mA with unlimited voltage for two hours. After transfer of proteins Western blotting 
was undertaken as described in table 2.4. After the final washing step, signal was visualised  
using an ECL+ detection system and captured on ECL plus hyper film at various exposure 
times.  Film was developed using film developer and fixer. Blots were scanned using a GS-
800 densitometer (BioRad). 
 
Table 2.4. Outline of Western blotting protocol.  
 
 
2.2.8 Silver staining 
Silver staining was undertaken based on a method described by Yan et al. (2000). Gels were 
washed in acetic acid (10% v/w), methanol (40% v/w) for 15 minutes twice to fix proteins, 
and sensitized with methanol (30% v/w), sodium thiosulphate (0.2% v/w) and 0.83 M 
sodium acetate for 30 minutes. After three, five minute washes with HPLC grade water, gels 
were incubated for 20 minutes with silver nitrate (0.25% v/w). Gels were washed a further 
two times for five minutes and developed in freshly made sodium carbonate (0.24 M) and 
formaldehyde (0.04% v/v). To arrest reactions, gels were incubated with EDTA (0.05 M) for 
Step Solution Time 
Washing TBST (0.05%) Three ten minute washes 
Blocking Non fat milk (5%) in TBST (0.1%) 
 
Overnight at 4ºC 
Washing TBST (0.05%) Three ten minute washes 
Antibody incubation Primary antibody in TBST (0.1%) Two hours at room temperature 
Washing TBST (0.05%) Three ten minute washes 
Antibody incubation Secondary antibody in TBST (0.1%) One hour at room temperature 
Washing TBST (0.05%) Two ten minute washes 
Washing TBS with no Tween 20 Two ten minute washes 
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ten minutes and then washed in HPLC grade water. Gels were scanned using a GS-800 
densitometer (BioRad). 
 
2.2.9. Identification of plasma protein bands and spots 
2.2.9.1 In-gel digestion 
Destaining of samples was undertaken according to the method described by Gharahdaghi et 
al. (1999). Silver stained gel pieces of interest proteins were thawed and destained using 
potassium ferricyanide (30 mM) and sodium thiosulphate (100 mM) at a 1:1 ratio and rinsed 
three times with double distilled water (ddH2O). Destained gel pieces were then washed in 
ammonium bicarbonate (200 mM) for 20 minutes, rinsed with 3 changes of ddH2O and 
dehydrated repeatedly with acetonitrile. In gel digestion of samples was performed based on 
methods described by Rosenfield et al. (1992) and Hellman et al. (1995). Acetonitrile 
dehydrated gel pieces were rehydrated in a vacuum centrifuge for 5 minutes. The gel pieces 
were rehydrated with 10 mM DTT in 25 mM ammonium bicarbonate and incubated at 56ºC, 
for 45 minutes. DDT was removed and replaced with 55 mM iodoacetamide in 25 mM 
ammonium bicarbonate for 45 minutes at room temperature, samples were protected from 
light. The liquid was removed and gel pieces were incubated with shaking for 10 minutes in 
ammonium bicarbonate (25 mM) and twice with 50% acetonitrile in ammonium bicarbonate 
(25 mM). Destained gel pieces were then dehydrated in a vacuum centrifuge for 5 minutes. 
Gel pieces were covered with 12.5 ng/µl of trypsin in 25 mM ammonium bicarbonate, and 
rehydrated on ice for 10 minutes. Excess trypsin was removed, and gel pieces were covered 
in 25 mM ammonium bicarbonate and incubated at 37ºC overnight (~ 18 hours). Digest 
solutions were transferred to a fresh eppendorf tube (1.5 ml) and gel pieces covered with 
50% acetonitrile and 5% formic acid and vortexed for 30 minutes, this was repeated twice.  
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All digest solutions were pooled together and stored at -80ºC. Samples were desalted using a 
Michrom MacroTrap C8 cartridge and dried to 10 µl by vacuum centrifugation. 
 
2.2.9.2 LC-MS 
On-line liquid chromatography was performed by use of a Micro AS autosampler and 
Surveyor MS pump (Thermo Fisher Scientific, Bremen, Germany).  Peptides were loaded 
onto a 75 µm (internal diameter) Integrafrit (New Objective) C8 resolving column (length, 10 
cm) and separated over a 40 min gradient from 0 to 40% acetonitrile (J. T. Baker Inc.).  
Peptides eluted directly (~350 nl/min) via a Triversa nanospray source (Advion Biosciences) 
into a 7 Tesla LTQ FT mass spectrometer (Thermo Fisher Scientific) where they were 
subjected to data-dependent CID. 
 
2.2.9.3 Data-dependent CID 
The mass spectrometer alternated between a full FT-MS scan (m/z 400-1600) and subsequent 
CID MS/MS scans of the five most abundant ions above a threshold of 40,000.  Survey scans 
were acquired in the ICR cell with a resolution of 100,000 at m/z 400.  Precursor ions were 
isolated and subjected to CID in the linear ion trap in parallel with the completion of the full 
FT-MS scan.  The width of the precursor isolation window was m/z 3.  Only multiple 
charged precursor ions were selected for MS/MS.  CID was performed with helium gas at a 
normalized collision energy of 35%.  Automated gain control was used to accumulate 
sufficient precursor ions (target value, 5 × 104; maximum fill time, 0.2 s).  Precursor ions 
were activated for 30 ms.  Data acquisition was controlled by Xcalibur 2.0 and Tune 2.2 
software (Thermo Fisher Scientific). 
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2.2.9.4 Data Analysis 
DTA (data) files were created from the raw data using Bioworks 3.3.1 (Thermo Fisher 
Scientific).  The DTA files were searched directly using OMSSA Browser 2.1.1 against the 
human subset of the IPI database. N-terminus acetylation, Cysteine, Phenylalanine, 
Histidine, Methionine, Proline, Tryptophan and Tyrosine oxidation were specified as 
variable modifications, with carboxymethylation of cysteine as a static modification. The 
data were searched with a peptide m/z tolerance of ± 0.02 and a MS/MS m/z tolerance of ± 
0.8. The search results were scored and filtered with an E-value cut-off, so that the searches 
could be repeated exactly in the future (E-value cut-off is statistical confidence generated 
from the OSSMA algorithm when completing the search, and the value used is the suggested 
threshold). A probability score (p-Score) was generated (any p-Score > 0 was rejected) and 
OMSSA results were filtered to allow only the top scoring identification per DTA. 
 
2.2.10 General statistics  
For comparison of values between AD and control subjects, data from each group was 
checked for normality using the Shapiro-Wilk statistical test, and if this assumption was 
violated, log transformation was applied.  A parametric independent samples t-test, or a non 
parametric Mann Whitney U statistical test, was subsequently used on normally and non-
normally distributed data respectively. Significance was accepted if p < 0.05. 
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3.1 Abstract 
It is becoming increasingly clear that oxidative stress and vascular risk factors (e.g., 
atherosclerosis) play an important part in Alzheimer’s disease (AD) pathology. The 
established link between increased LDL oxidation and atherosclerosis, coupled to the 
demonstration, in AD peripheral tissue, that the rate of LDL oxidation is increased, may 
suggest a role for oxidized LDL in this neurodegenerative disease. This study assessed 
oxidative damage in total plasma proteins, and isolated LDL in AD patients and age matched 
controls. In addition total antioxidant capacity (TAC) and lipid peroxide levels were 
measured. Significantly higher LDL protein carbonylation was observed in AD compared to 
age matched controls (Control: 3.85 ± 0.86 Vs. AD: 4.17 ± 0.73 nmol/mg LDL; p = 0.05, 2 
tailed Mann-Whitney), in addition reduced TAC was found (Control: 1078.536 ± 252.633 
Vs. AD: 924.708 ± 174.429µM FRAP; p = 0.001, 2 tailed Mann-Whitney). No differences 
were seen in total plasma protein carbonyl content (Control: 3.98 ± 0.48 Vs. AD: 3.88 ± 
0.31nmol/mg protein, 2 tailed Mann-Whitney) or lipid peroxide levels (Control: 15.51 ± 
19.41 Vs. AD: 14.21 ± 15.06 nmol/mg protein, independent samples t-test).  These data 
further support the view that oxidation events in AD may be specific in nature, and represent 
functional changes to proteins, rather than random global events.  
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3.2 Introduction 
In recent years it has become clear that there are considerable overlaps between AD and 
vascular pathologies. Vascular dementia (VaD) is caused by damage to the vascular system 
leading to reduced supply of blood to the brain and loss of cognitive function (Roman, 
2003). The role that vascular diseases, and indeed that may play in AD has received an 
increasing amount of attention. VaD and AD have been considered two separate diseases, 
but it is now becoming increasingly clear that vascular factors are an important part of AD 
(Launer, 2002). A possible mechanism believed to contribute to both vascular pathologies 
and AD involves oxidative stress (for review see Bennett et al., 2009). Oxidative stress has 
been implicated in a number of diseases including Alzheimer’s disease, vascular dementia, 
cardiovascular disease, rheumatoid arthritis and diabetes (Telci et al., 2000; Markesbery, 
1997; Harrison et al., 2003; Casado et al., 2008; Taysi et al., 2002). 
 
ROS can increase to high levels in some disease processes or where there is antioxidant 
deficiency, and may react with cellular constituents to cause damage, disruption of function, 
or degradation. An increase in oxidation products has been identified in Alzheimer’s 
pathology including DNA damage seen as an increase in 8-oxo-dG in cortical tissue and 
lymphocytes (Mecocci et al., 2002). Markers of protein oxidation including protein carbonyl 
formation have been identified in AD brain tissue (Korolainen et al., 2002) and plasma 
proteins of Alzheimer’s sufferers have been identified as altered (Korolainen et al., 2007).  
 
Unfavourable lipoprotein profiles are associated with chronic vascular disease including 
heart disease and atherosclerosis, and are often associated with ageing. Decreased levels of 
high density lipoprotein (HDL) cholesterol and increased levels of low density lipoprotein 
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(LDL) cholesterol are strong markers for risk of disease (Fuster et al., 1992; Poulter, 2003). 
LDL transports cholesterol from the liver to the circulation, and is susceptible to oxidation 
by ROS. In addition, oxidative damage to LDL by ROS is a contributing factor in 
atherosclerosis (Raitakari et al., 1997). In LDL oxidation, damage is seen both to the lipid 
and to the protein moiety. A number of studies have suggested that protein oxidation of the 
lipoprotein molecule can occur as a direct result of free radical action and as a secondary 
result of the free radical cascade brought about by initial lipid peroxidation (Berlett and 
Stadtman, 1997). Although the majority of lipoprotein oxidation research has been done on 
the lipid moiety, protein oxidation has a number of functional consequences as 
Apolipoprotein B oxidation (the protein moiety associated with LDL) is pivotal to the 
modulation of LDL uptake and accumulation. Elevated levels of circulating oxidized LDL 
are reported in individuals suffering from cardiovascular disease (Holvoet et al., 2001; Kita 
et al., 2001), and, as previously mentioned, oxidative damage to LDL is a contributing factor 
in atherosclerosis (Raitakari et al., 1997). Atherosclerosis has also been linked to an 
increased incidence of AD and VaD (Hofman et al., 1997; van et al., 2007) and therefore risk 
factors for atherosclerosis may also represent risk factors for AD and VaD. Indeed, increased 
levels of LDL in AD serum (Kuo et al., 1998), in addition to an increased rate of lipoprotein 
oxidation in AD cerebrospinal fluid and plasma has been reported (Bassett et al., 1999; 
Schippling et al., 2000), which may suggest increased LDL oxidation is present in circulation 
of AD sufferers. However none of these studies actually assess levels of oxidized LDL in 
vivo. The primary aim of this study, therefore, was to identify increased oxidative damage to 
key plasma proteins in AD when compared to age matched controls; specifically LDL 
protein. 
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3.3 Methods 
 
3.3.1 Sample population 
AD samples and age matched control samples were obtained as described in general methods 
section 2.1.4. In total, 144 patients and control volunteers were recruited into the study (72 
in each group), dependent on availability of blood samples, and the success of LDL 
preparation subsets were used for endpoint analysis.   
 
3.3.2 BCA assay  
Total protein concentration was determined by the BCA assay as described in general 
methods section 2.2.1. 
 
3.3.3 Isolation of LDL 
LDL from all plasma samples was isolated by density gradient centrifugation in a Beckman 
TL-100 based on the method of Chung et al. (1980). Each plasma sample (1 ml) was 
adjusted to a three-step gradient using Sodium Chloride (0.04, 0.08 and 0.32 g/ml) and 
overlaid with isotonic saline (0.9% NaCl, B Braun, Sheffield, UK). Adjusted plasma was 
centrifuged for 4 hours, at 100,000 xg using a Beckman TL-100 ultracentrifuge and LDL 
was obtained and kept at –80°C until required. 
 
3.3.4 Protein carbonyl ELISA, FRAP and lipid peroxide assay 
Protein carbonyl ELISA, FRAP and lipid peroxide assays were undertaken as described in 
general methods section 2.2.2.2, 2.2.3 and 2.2.4. A subset of 50 AD and 59 control samples 
were used for lipid peroxide analysis and a subset of 47 AD and 56 control samples were 
used for FRAP analysis, this was based on sample availability. 
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3.3.5 Statistics 
Statistical analysis was undertaken as described in general methods section 2.2.10. 
Significance was accepted if p ≤ 0.05. 
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3.4 Results 
3.4.1 Subject Information 
The age ranges for both AD and control groups can be seen in table 2.1 (general methods), 
along with the average MMSE score for each group. At the time of this analysis, the mean 
time since diagnosis was 1.3 yrs +/- 0.8 in the AD group. Table 2.1 summarizes patient 
characteristics for the samples. They are not significantly different from each other in terms 
of age. 
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3.4.2 Protein oxidation 
As shown in figure 3.1, there was no observed difference in total plasma protein oxidation 
between the control and AD groups (Control 3.98 ± 0.48 nmol/mg Vs. AD: 3.88 ± 0.31 
nmol/mg; p = 0.197, 2 tailed Mann-Whitney). It is interesting to note that the spread of AD 
values compared to that of the controls is much greater.  
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Figure 3.1. Total plasma protein carbonyl levels. Protein oxidation was measured by 
carbonyl ELISA. Data (Control n = 72 and AD n = 72) are presented as a box plot. 
Percentiles are represented by the box (25th and 75th) and whisker (10th and 90th) with thick 
and thin lines corresponding to mean and median values respectively. Filled circles represent 
outliers. 
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3.4.3 LDL oxidation 
A significantly greater level of LDL oxidation was evident in AD compared to control 
subjects (Control 3.85 ± 0.86 nmol/mg Vs. AD: 4.17 ± 0.73 nmol/mg LDL; p = 0.05, 2 tailed 
Mann-Whitney), as shown in figure 3.2.  
 
 
 
Figure 3.2. LDL carbonylation levels. LDL oxidation was measured by carbonyl ELISA. 
Data (Control n = 70 and AD n = 69) are presented as a box plot. Percentiles are represented 
by the box (25th and 75th) and whisker (10th and 90th) with thick and thin lines corresponding 
to mean and median values respectively. *Significant difference between the control and AD 
group (*p = 0.05). Filled circles represent outliers. 
Control AD
LD
L 
c
ar
bo
n
yl
 
co
n
ce
n
tr
a
tio
n
 
(nm
o
l/m
g 
pr
o
te
in
)
2
3
4
5
6
7
*
Chapter 3                                Increased LDL oxidation, but not total plasma oxidation in AD 
55 
3.4.4 Total antioxidant capacity 
As evident in figure 3.3, there was a significant decrease in total antioxidant capacity, as 
measured by FRAP (section 3.3.4), in the AD group compared to the control group (Control: 
1078.536 ± 252. 633 Vs. AD: 924.708 ± 174.429 µM FRAP; p = 0.001, 2 tailed Mann-
Whitney).  
 
Figure 3.3. Total antioxidant capacity. TAC was measured by FRAP. Data (Control n = 59 
and AD = 50) are presented as a box plot. Percentiles are represented by the box (25th and 
75th) and whisker (10th and 90th) with thick and thin lines corresponding to mean and median 
values respectively. *Significant difference between the control and AD group (*p = 0.001). 
Filled circles represent outliers. 
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3.4.5 Plasma lipid peroxide levels 
One AD sample and 4 control samples were omitted from analysis as their lipid peroxide 
levels were below the limit of detection of this assay (1nmol/ml). As shown in figure 3.4, 
there was no change in levels of lipid peroxides between the control and AD group subjects 
(Control 15.51 ± 19.41 Vs. AD: 14.21 ± 15.06 nmol/ml lipid peroxides, p > 0.05; 
independent samples t-test).  
 
 
 
Figure 3.4. Lipid peroxide levels. Lipid peroxide levels were measured by lipid peroxide 
assay. Data (control n = 56 and AD n = 47) are presented as a box plot. Percentiles are 
represented by the box (25th and 75th) and whisker (10th and 90th) with thick and thin lines 
corresponding to mean and median values respectively. Filled circles represent outliers. 
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3.5 Discussion 
The study demonstrated increased LDL protein carbonylation in patients with AD. Studies 
suggest that levels of oxidative stress are elevated during the earliest stages of AD 
(Nunomura et al., 2001).  The demonstration in this work that LDL undergoes oxidation in 
AD, coupled to existing studies which have demonstrated that the rate of LDL oxidation 
increases with age and that this susceptibility to oxidation is elevated further in AD (Khalil et 
al., 1996; Schippling et al., 2000), may indicate that vascular change should considered as a 
relatively early event in AD pathology.  Indeed LDL oxidation is a pathological hallmark of 
atherosclerosis and atherosclerosis is an associated risk factor for AD.  
 
In contrast to LDL carbonylation, there was no difference in total plasma protein 
carbonylation between the AD and control groups. Existing studies assessing plasma protein 
oxidation in Alzheimer’s disease are equivocal, with several studies reporting no change but 
with others reporting increased levels in AD. For example, Greilberger et al. (2008) and 
Bermejo and colleagues (2008), in separate studies reported increased plasma protein 
oxidation in a group consisting of mild cognitive impairment (MCI) and AD patients. These 
studies are in contrast to no differences reported in mild to moderate and advanced AD 
(Zafrilla et al., 2006), or in mild AD patients (Baldeiras et al., 2008). All of the studies use 
similar spectrophotometric methodology to assess plasma protein oxidation so differences in 
methodology are unlikely to account for the disparity between studies. It is possible that the 
severity of the disease would influence protein oxidation levels, as it has been suggested 
oxidative stress is prevalent in the earliest stages of the disease (Nunomura et al., 2001); 
however, the studies mentioned above measure plasma protein oxidation in both MCI and 
early AD sufferers and in advanced AD.  
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There was also an appreciable variation in the degree of protein oxidation within the AD 
group of the present study. An explanation for the discrepancy in reported protein 
carbonylation and the observed range of values is the multi factorial nature of AD. For 
example, the rate of cognitive decline between individuals suffering from AD varies 
considerably. In some patients cognition deteriorates rapidly, where as in others very little 
change or no decline is experienced (Holmes and Lovestone, 2003). Differences in the rate 
of cognitive decline has been shown to influence peripheral proteins levels in AD subjects 
(Guntert et al., 2010). These subject characteristics may therefore contribute to the individual 
variation in protein oxidation levels seen in this study. Other subject characteristics (e.g., 
physical activity pattern, diet and vitamin use) may have also influenced some of the indices 
measured in this study. However these were not known, and as such are an acknowledged 
limitation of the presented work.  
 
Additionally, the absence of an increased plasma protein oxidation in AD in the current 
study may add to the evidence that suggests that oxidation events within AD are specific and 
critical events which take place to alter the function of certain proteins, and this may 
contribute to the pathology of AD, rather than oxidative damage occurring in a non specific 
and random manner. Previous studies assessing oxidative changes in AD brain have found 
similar specific protein oxidation events (Castegna et al., 2002a; Castegna et al., 2002b). 
 
In this study we observed a significant reduction in total antioxidant TAC in an AD group 
compared to a control group, as measured by FRAP. Various methodologies (e.g., and total 
antioxidant status (TAS)) have been employed to measure total antioxidant capacity (TAC) 
in AD compared to control plasma. Although these methods are not identical to each other, 
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they all provide a quantitative indication of the levels of total antioxidant components over 
time, or at a given time point in plasma. The results presented here are in agreement to a 
recent study by Sekler et al. (2008) who used the same methodology to measure TAC and 
reported a significant reduction of FRAP in an AD group compared to a control group, albeit 
only in the most severe cases (the authors also suggested that the stage of the disease may 
influence TAC). Indeed, further studies have demonstrated a significant decrease of total 
antioxidant status (TAS) in advanced AD, but not in moderate AD (Zafrilla et al., 2006) as 
well as a trend for decreased TAS in MCI and AD (Baldeiras et al., 2008). In addition,  a 
24% decrease in TAC in plasma from probable AD compared to controls (Repetto et al., 
1999) has been reported. Studies which assess levels of individual antioxidants in plasma 
from AD subjects report a depletion of several vitamins compared to control subjects 
(Bourdel-Marchasson et al., 2001; Rinaldi et al., 2003) and a reduction in an extensive range 
of vitamins and carotenoids has more recently been reported in AD and VaD patients 
(Polidori et al., 2004). It maybe that the vascular or degenerative severity of the disease 
accounts for the depletion of particular antioxidants, and thus contributes to the varied data 
reported by different groups regarding total antioxidant capacity in AD. 
 
The physiological levels of lipid peroxides reported in this work are in agreement with other 
studies.  For example in normal healthy individuals, levels are of low micromolar 
concentrations (Ferretti et al., 2008) and in patients with non-insulin dependent diabetes 
mellitus and metabolic disorders levels are increased to approximately 8 nmol/ml (Sodergren 
et al., 1998). However, no change in lipid peroxide levels was observed between control and 
AD subjects; this finding is in accordance with other groups who have reported no 
differences in MDA levels between these two groups (Polidori et al., 2004; Baldeiras et al., 
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2008). On the other hand, MDA and TBARS have been reported to be increased in AD 
serum and plasma  (Zafrilla et al., 2006; Martin-Aragon et al., 2009; Padurariu et al., 2009).   
 
It is becoming increasingly accepted that patients with AD, more often than not, will have a 
vascular element to their disease pathology (Launer, 2002). The observed higher LDL 
oxidation level in this study concurs with this perception. Almost all healthy elderly 
individuals will have atherosclerotic plaque formation, and associated increased circulating 
oxidized LDL, if compared to younger controls (Khalil et al., 1996). However, this study 
presented healthy aged individuals as controls, and thus the finding that LDL oxidation was 
significantly higher in AD, when compared to age matched controls, goes some way to 
demonstrating increased LDL oxidation is part of AD pathology.  
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4.1 Abstract 
The increased production of reactive oxygen and nitrogen species contributes to oxidative 
stress. The reaction between nitric oxide (NO•) and superoxide (O2•-) leads to the production 
of peroxynitrite (ONOO-), a highly reactive molecule which has the ability to oxidize and 
nitrate proteins. Protein nitration is important as it can impact protein function, and is 
therefore of particular interest in diseases associated with increased levels oxidative stress, 
such as Alzheimer’s disease (AD). NO• is clearly involved in vascular function and it is 
sensible to suggest that there may potential link between NO• and 3-nitrotyrosine levels in 
AD, given the reaction NO• and O2•- to form ONOO-. Plasma NO• levels have been 
successfully measured in AD. In contrast, although a wide range of studies have assessed 
protein nitration in AD brain tissue, limited studies exist which assess levels in plasma. 
There is a need to develop a high throughput method to measure 3-nitrotyrosine in AD 
plasma, to enable the potential link between NO• and 3-nitrotyrosine levels to be investigated 
in this disease. ELISA is one method which has been successfully employed to measure 
plasma 3-nitrotyrosine levels in individuals suffering from Diabetes Mellitus and Behçet 
disease, conditions both associated with increased oxidative stress. In contrast, at the time of 
undertaking this work, no study had previously reported the use of ELISA to measure plasma 
3-nitrotyrosine levels in AD. In the study presented here, attempts were made to develop an 
ELISA for the high throughput measurement of 3-nitrotyrosine in AD plasma, in order to 
investigate the potential link between NO• and 3-nitrotyrosine levels. Levels of 3-
nitrotyrosine levels could only be detected in a minority of plasma samples when employing 
ELISA, suggesting that currently ELISA is not sensitive enough to detect 3-nitrotyrosine in 
all AD and control plasma samples.  
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4.2 Introduction  
The increased production of reactive oxygen and nitrogen species (ROS/RNS) is a 
contributory factor of oxidative stress. Peroxynitrite (ONOO-), a RNS produced during the 
reaction between NO• and O2•- nitrates proteins in vivo. Protein nitration occurs when a nitro 
group (-NO2) is substituted for a hydrogen atom on the aromatic ring of a tyrosine residue at 
the 3 prime position; the adduct formed is named 3-nitrotyrosine (Souza et al., 2008). At 
physiological pH ONOO- is rapidly protonated to form peroxynitrous acid (ONOOH), which 
can be homolytically cleaved to form nitrogen dioxide (NO2•) and OH•. ONOOH may also 
react with CO2 to form NO2• and the carbonate radical (CO3•) (Halliwell, 2006; Souza et al., 
2008), with NO2• possessing the ability to react with and nitrate tyrosine residues. Additional 
nitrating agents which account for in vivo nitration include haemoperoxidases such as 
myeloperoxidase and eosinophil peroxidase (Souza et al., 2008). The predominant source of 
protein nitration in vivo is from ONOO-, and as such 3-nitrotyrosine is considered by many 
as an indirect marker for ONOO- (Beckman and Koppenol, 1996; Oldreive and Rice-Evans, 
2001). However, it is appreciated that other nitrating agents may also exist in vivo (Oldreive 
and Rice-Evans, 2001).  
 
Increased protein nitration is associated with AD brain pathology (Smith et al., 1997b; 
Hensley et al., 1998) and in addition, specific brain proteins have been shown to be nitrated 
in early AD and AD (Castegna et al., 2003; Reed et al., 2008). In contrast, limited studies 
have measured nitration in AD plasma. Calabrese and colleagues (2006) demonstrated that 
plasma proteins exhibited increased nitration in AD, however they only provided evidence 
for a minority of subjects using Western blotting and no statistical information was reported, 
hence further investigation is required. Limited information on nitration status is somewhat 
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surprising as a global measure of 3-nitrotyrosine in AD would be desirable for a number of 
reasons: firstly the current understanding of the role oxidative stress in the disease pathology 
would be furthered. For example there may be an additional link to vascular pathology (e.g., 
NO• is clearly involved in vascular function and hence it is sensible to suggest that NO• and 
O2•- may react); and secondly such studies would contribute to biomarker discovery.   
 
To date several methods have been used to quantify 3-nitrotyrosine levels in healthy human 
plasma. A number of methodologies have been mass spectrometry based, including GC-
tandem MS, GC-MS and LC-tandem MS. Non-mass spectrometry based techniques include 
various high performance liquid chromatography (HPLC) methods and ELISA (Tsikas and 
Caidahl, 2005). Reported levels of 3-nitrotyrosine from mass spectrometry based, and HPLC 
methods, range from approximately 1-60 nM (Tsikas and Caidahl, 2005). In addition, groups 
have attempted to develop a robust, reproducible and reliable 3-nitrotyrosine ELISA (see 
table 4.1), with the premise that it has a higher throughput, does not require specialist 
equipment and is less time consuming than other established techniques (i.e. GC-tandem 
MS, GC-MS and LC tandem MS and HPLC-ECD). There are a wide range of reported 
values from such assays, levels range between undetectable to 0.1 µM for healthy subjects, 
and are increased further in diseased subjects. These data also suggest that when assessing 3-
nitrotyrosine levels in plasma by ELISA, from diseased subjects, levels are elevated and 
typically of high nM or low µM concentrations. 
 
At the time of commencing this work, no studies had measured 3-nitrotyrosine in AD 
plasma, therefore the primary aim of this work was to attempt to develop an ELISA in order 
to measure total levels of 3-nitrotyrosine in AD.   
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4.3 Methods 
4.3.1 Sample Population 
Pooled AD and age matched control plasma from a subset of samples were obtained as 
described in general methods section 2.1.4, table 2.1.  Individual AD and age matched 
control samples from a second subset of samples were obtained as described in general 
methods section 2.1.4, table 2.2. 
 
4.3.2 BCA assay  
Total protein concentration was determined by the BCA assay as described in general 
methods section 2.2.1. 
 
4.3.3 HPLC-ECD 
4.3.3.1 Sample Preparation 
For measurement of total 3-nitrotyrosine samples were diluted to 1 mg/ml in Calcium 
Chloride (10 mM) and hydrolysed with Pronase (20 µg/ml) at 37ºC overnight and analysed 
by HPLC-ECD. For measurement of bound 3-nitrotyrosine samples (1 mg/ml) containing 
Pronase (20 µg/ml) and Calcium Chloride (10 mM) were incubated at 37ºC overnight. 
Samples were washed with ice cold methanol (300 µl), mixed thoroughly and centrifuged at 
3,500 xg for 10 minutes. The supernatant was discarded and this procedure was repeated. 
The resultant protein pellet was re-suspended in mobile phase (100 µl) and analysed by 
HPLC-ECD. Samples were assayed in duplicate or triplicate. 
 
 
 
Chapter 4                                                                    Development of a 3-nitrotyrosine ELISA 
67 
4.3.3.1 Detection and quantification of 3-nitrotyrosine 
A modified high performance liquid chromatography with electrochemical detection (HPLC-
ECD) method, from that described by Maruyama et al. (1996) was undertaken for the 
detection of plasma 3-nitrotyrosine and nitrated BSA. Synthetic 3-nitrotyrosine was used to 
calibrate the HPLC and produce a series of known standards for subsequent sample analysis 
(see figure 4.1). Samples were spiked with a known concentration of synthetic 3-
nitrotyrosine (10 µM) and loaded (10 µl) onto the column (Phenomenex, Luna 3 µM, C18 
(2) 100A, 150 x 4.60 mm). Mobile phase (Phosphoric Acid (50 mM), Citric Acid (50 mM, 
pH 5.0), EDTA (40 mg/l), Octane Sulphonic Acid (100 mg/l) and methanol (5%)) was set at 
a flow rate of 1.5 ml/min. An applied voltage was set at 990 mV as optimized from 
preliminary experiments (See Appendix I). Standard curves were constructed on a regular 
basis, and the limit of detection for this technique was consistently 1 µM. Levels of 3-
nitrotyrosine were calculated from a standard curve of peak areas (mV*min) from known 
concentrations of 3-nitrotyrosine using linear regression. The peak area of 3-nitrotyrosine (10 
µM) was taken away from peak areas measured for spiked samples prior to this calculation.  
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. 
Retention time 
mV 
Figure 4.1. Chromatogram of 3-nitrotyrosine synthetic standards. Peaks 
from top to bottom correspond to 20 µM, 10 µM, 5 µM, 2.5 µM and 1.25 µM. 
Area of chromatogram where 3-nitrotyrosine peaks reside is enlarged in 
boxed area. 
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4.3.4 Preparation of nitrated BSA using various reagents 
4.3.4.1 Sodium nitrite 
BSA (5 mg/ml) was dissolved in ddH2O and adjusted to pH 3.5 with glacial acetic acid. 
Sodium nitrite (200 mM) was then added to a final concentration of 1 mM (ter Steege et al., 
1998).  
 
4.3.4.2 Peroxynitrite 
Synthesis of peroxynitrite was based on a method described by Packer and Murphy (1994). 
Acidified hydrogen peroxide (0.6 M HCl + 0.7 M hydrogen peroxide) and sodium nitrite 
(0.6M) were mixed thoroughly and dropped into rapidly stirred sodium hydroxide (2 M) to 
arrest the reaction. Solutions of synthesised peroxynitrite were quantified using a molar 
absorbance co-efficient value (ε302 nm = 1670 M-1 cm-1(Packer and Murphy, 1994)) and were 
used immediately to nitrate BSA. BSA (1mg/ml) was dissolved in phosphate buffer (250 
mM K2HPO4-KH2PO4, pH 7.4) and exposed to peroxynitrite (1 mM). The solution was 
incubated for one hour in a water bath set at 37ºC and dialyzed against double distilled water 
for 24 hours, with six changes, to remove any nitrate or nitrate produced from peroxynitrite 
decomposition (Whiteman and Halliwell, 1999). 
 
4.3.5 1-DE, silver staining and Western blotting 
Nitrated BSA (5µg) was separated on a 1D gel, silver stained and blotted for 3-nitrotyrosine 
as described in general methods section 2.2.5, 2.2.7 and 2.2.8. For Western blotting, mouse 
monoclonal anti-nitrotyrosine antibody was used at 1:500 with an appropriate horseradish 
peroxidase conjugated secondary antibody (1: 2,000).  
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4.3.6 3-nitrotyrosine ELISA 
4.3.6.1 Preparation of 3-nitrotyrosine standards 
To prepare 3-nitrotyrosine standards for use in ELISA, serial dilutions of a known 
concentration of nitrated BSA stock (12.2 M) in coating buffer (50 mM Sodium carbonate, 
pH 9.2) was undertaken.  
 
4.3.6.2 ELISA 
A modified indirect ELISA protocol, based on that described by Ceriello et al. (2001) was 
undertaken. Samples (50 µl) diluted in coating buffer (50 mM Sodium carbonate, pH 9.2) 
were applied to a microtitre plate, for one hour at 37ºC. Wells were blocked overnight at 4ºC 
with 1% BSA in PBST (0.1%), incubated for 2 hours at 37ºC with mouse monoclonal anti-
nitrotyrosine antibody (1:500) and incubated with a horseradish peroxidase conjugated goat 
anti-mouse IgG secondary antibody (1:4000). The horseradish peroxidase reaction product 
was produced using citrate phosphate buffer 0.15 M (pH 5), O-phenylenediamine (2 mg) and 
hydrogen peroxide (1:125). The reaction was arrested with 2M H2SO4 and absorbance 
measured at 490nm using a microtitre plate reader. Background was accounted for by taking 
away blank absorbance values from all wells. The concentrations of nitrated proteins present 
in samples were compared to the standard curve nitrated BSA standards of known 
concentrations. They were expressed as µM BSA equivalents (i.e. an equivalent 
concentration of nitrotyrosine in BSA).  
 
4.3.7 In-solution digestion 
An in-solution digestion protocol based on that described by Kinter and Sherman (2000) was 
used to digest samples. Bovine serum albumin (BSA) was evaporated and re-suspended in 
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6M urea, 100mM Tris buffer to a concentration of 10mg/ml. Standards (100µl containing 
1mg of protein) were diluted with 775µl ddH2O (to reduce concentration of urea and retain 
trypsin activity).  Trypsin (20 ng/µl) was added to digested standards (1:100 substrate to 
protease ratio), and ddH2O was used as a substitute for controls, all standards were incubated 
overnight at 37ºC. Reactions were stopped by adjusting pH to < 6 with concentrated acetic 
acid. Standards were concentrated to approximately 100µl and total protein levels were 
determined using the BCA assay. Zip tips were used to remove urea from standards. They 
were prepared by wetting with 50% HPLC grade acetonitrile twice and then equilibrated 
with 0.1% trifluoroacetic acid twice. Digests were prepared by adding 1µl of 1% 
trifluoroacetic acid to 10µl of the digest. Once peptides were bound to the zip tip, they were 
washed with 0.1% trifluoroacetic acid twice and then eluted into 5µl of 50% acetonitrile 
solution. Acetonitrile was subsequently removed by vacuum centrifugation. Peptides were 
then resuspended in appropriate buffer for downstream applications.  
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4.4 Results  
4.4.1 Measurement of 3-nitrotyrosine using HPLC-ECD 
Quantification of plasma levels of 3-nitrotyrosine was undertaken in a small group of AD 
(n=4) and age-matched control plasma (n=3) in order to establish whether, 3-nitrotyrosine 
levels were detectable, and whether these levels were distinguishable between AD and 
control subjects. As shown in figure 4.2, levels of 3-nitrotyrosine in half of the samples 
analyzed are negligible and fall on or below the limit of detection. However, in three subjects 
3-nitrotyrosine was detected in the micromolar range (3 to 8 µM). Based on these results, in 
order to detect significant differences in 3-nitrotyrosine between AD and control samples, 
assessment of a large cohort would be necessary (sample size calculation estimated > 300). 
HPLC is an extremely time consuming and expensive technique and in order to assess 3-
nitrotyrosine in a large cohort of AD and age-matched control samples, ELISA was 
attempted. 
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Figure 4.2. Plasma levels of 3-nitrotyrosine from AD and controls 
using HPLC-ECD. Plasma from AD (n=4) and age-matched control 
subjects (n=3) was analysed for 3-nitrotyrosine using HPLC-ECD. Error 
bars represented as standard error of the mean and samples were assayed 
in duplicate. Limit of detection (1 µM) shown by dotted line. 
                 AD 1       AD 2     AD 3    AD 4   Con 1   Con 2   Con3 
Sample 
Chapter 4                                                                    Development of a 3-nitrotyrosine ELISA 
74 
4.4.2 Measurement of 3-nitrotyrosine using ELISA 
4.4.2.1 Preparation of nitrated standards using sodium nitrite 
For preparation of nitrated standards, BSA was nitrated with sodium nitrite (BSA-NaNO2). A 
noticeable colour change from colourless to yellow was observed after BSA solutions were 
incubated with sodium nitrite. This colour change may account for synthesis of ONOO-, but 
is likely to indicate the presence of 3-nitrotyrosine (ter Steege et al., 1998). Levels of nitrated 
BSA were calculated as 8.87 ± 1.95 µM by HPLC-ECD. However, as shown in figure 4.3, 
when levels of nitrated BSA were assessed by ELISA no signal was evident.  
 
 
 
 
Figure 4.3. ELISA to assess nitration to BSA using sodium nitrite. 
Samples (5 mg/ml) were assessed for nitration by ELISA (see section 4.3.4). 
Error bars are displayed as SEM. Samples were run in triplicate. 
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4.4.2.2 Western blotting to assess antibody binding 
The results of the ELISA suggested that nitration of BSA was unsuccessful. To confirm this 
Western blotting was undertaken. In addition, to confirm presence of BSA, 1-DE and silver 
staining was run in parallel. As shown in figure 4.4a (lanes 1 and 2), BSA and BSA-NaNO2 
are present on a 1D gel as evidenced by distinct bands at approximately 70 kDa.  In contrast, 
no band is present in the region of 70 kDa on a Western blot for nitrated BSA (Figure 4.4b, 
lane 2).  
 
To explain these disparities between quantification of 3-nitrotyrosine, using HPLC-ECD, and 
validation with 3-nitrotyrosine antibody, bound 3-nitrotyrosine was measured using HPLC-
ECD. Levels of ‘bound’ 3-nitrotyrosine were below the detection limit, and hence it was 
considered that free 3-nitrotyrosine was formed. Together these data suggested that nitration 
of BSA using this particular nitrating agent was ineffective.  
 
 87 kDa 
  1     2 
Figure 4.4. BSA nitration using sodium nitrite. Lane 1, BSA (5 µg); Lane 2, 
BSA treated with NaNO2 (5 µg). A) Silver stained 1D gel B) Western blot for 
3-nitrotyrosine.  
 
 87 kDa 
 B 
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4.4.2.3 Preparation of nitrated standards using peroxynitrite 
Peroxynitrite is a further agent commonly used to nitrate proteins. As a consequence 
peroxynitrite was employed as a nitrating agent as a consequence of the ineffective nitration 
of BSA using sodium nitrite. The concentration of prepared peroxynitrite solutions ranged 
between 20-30mM.  BSA treated with ONOO- was assayed for bound and total 3-
nitrotyrosine levels by HPLC-ECD.  Levels were found to be 2.56 ± 0.22 nmol/mg and 12.14 
± 0.77 µM respectively. From these data bound 3-nitrotyrosine is evident; suggesting that 
BSA nitration using peroxynitrite had been successful.  
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4.4.2.4 Confirmation of BSA nitration using ONOO- 
To confirm that BSA had been successfully nitrated, Western blotting was undertaken. In 
addition, to confirm presence of BSA, 1-DE and silver staining was run in parallel. As shown 
in figure 4.5a (lanes 1 and 2), BSA and BSA-ONOO- are present on a 1D gel as evidenced 
by distinct bands at approximately 70 kDa. In addition, the Western blot presented in figure 
4.5b demonstrates the successful nitration of BSA using peroxynitrite. This is demonstrated 
by the presence of a distinct band present at approximately 70 kDa for BSA treated with 
ONOO-, but not for BSA (Figure 4.5b, lanes 1 and 2).  
 
 
 
 
 
 1      2 
Figure 4.5. BSA nitration using peroxynitrite. Lane 1, BSA (5 µg); Lane 2, 
BSA treated with ONOO- (5 µg). A) Silver stained 1D gel B) Western blot for 
3-nitrotyrosine.  
 
 87 kDa  A 
 87 kDa  B 
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4.4.2.5 Construction of five point 3-nitrotyrosine standard curve for ELISA 
A standard curve of known nitrated BSA concentrations was constructed and assessed using 
ELISA (see methods section 4.3.6.1). As shown in Figure 4.6a, nitrated BSA concentrations 
ranging between 5 and 400 nM are detectable with the linear region of the standard curve 
evident between 5 and 100 nM nitrated BSA equivalents. A plateau at concentrations greater 
than approximately 150 nM nitrated BSA equivalents was observed. Figure 4.6b shows a 5 
point standard curve, for the linear region of the standard curve, for three separate 
experiments.  
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Figure 4.6. 3-nitrotyrosine standard curve. A) Levels of 3-nitrotyrosine 
plateau at approximately 150-200 nmol/l nitrated BSA B) A linear 5 point 
standard curve ranging from 5 (lowest detectable nitrated BSA standard) 
to 100 nmol/l nitrated BSA (n=3). Error bars displayed as SEM. 
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4.4.2.6 Levels of 3-nitrotyrosine in AD and age matched control plasma  
4.4.2.6.1 Pooled samples 
Due to the availability of AD and control plasma, initial experiments assessed 3-nitrotyrosine 
levels using pooled samples (n=3). Figure 4.7 shows that detectable levels of 3-nitrotyrosine 
were present in these pooled sample sets.   
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Figure 4.7. Pooled plasma 3-nitrotyrosine levels. Level of 
nitration expressed as nitrated BSA equivalents calculated by linear 
regression Pooled samples diluted 1 in 5 and error bars displayed as 
SEM. 
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4.4.2.6.2 Individual samples 
A small subset of samples (7 AD and 7 age matched control) from a second cohort were 
assayed for 3-nitrotyrosine at a 1 in 5 dilution. This was to confirm further that 3-
nitrotyrosine is detectable in individual plasma samples from this population, and to 
determine whether a difference is detectable using this methodology.  As shown in figure 
4.8a, detectable levels of nitration were variable between individual samples, with some 
samples above but others below the lowest detectable nitrotyrosine standard (5 nM nitrated 
BSA equivalent). Hence a larger subset of individual samples (12 AD and 12 control 
subjects) was assessed at a greater concentration. Samples were diluted 1 in 2. In agreement 
with the previous experiment, figure 4.8b demonstrates that a minority of samples are above 
the lowest detectable nitrotyrosine standard (5 nM nitrated BSA equivalent) with most below 
this point.   
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Figure 4.8. Plasma levels of 3-nitrotyrosine in AD and control samples.  
Levels 3-nitrotyrosine as determined by ELISA. A) Subset of 7 AD and 7 control 
plasma samples diluted 1 in 5. B) Subset of 12 AD and 12 control plasma samples 
diluted 1 in 2. The lowest detectable nitrated BSA standard for this assay was 5 
nM (Indicated by dotted line). Error bars represented as SEM and samples were 
assayed in triplicate. 
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4.4.2.7 Increasing detectable levels of 3-nitrotyrosine by trypsin digestion  
In order to improve the sensitivity of the ELISA, tryptic digestion of nitrated BSA to 
peptides was attempted. It was hypothesised that by cleaving proteins into smaller peptides 
nitrated tyrosine residues, that preferentially reside in the interior of proteins, would be 
exposed, and that this would allow binding of an antibody specific for the 3-nitrotyrosine 
adduct. 
 
BSA and BSA-ONOO- were compared to BSA and BSA-ONOO- digests using indirect 
ELISA. All samples were plated as the same protein concentration to ensure nitration levels 
were comparable. As shown in Figure 4.9, an expected increase in signal for BSA-ONOO- 
compared to BSA is apparent. Surprisingly, the BSA-ONOO- digest exhibits lower signal 
compared to BSA-ONOO-, and the same observation is evident for the BSA digest compared 
to BSA. These data showed that detectable levels of nitration are reduced using this 
approach. One possible reason for this observation may be that peptides do not adhere to, or 
are less likely to adhere to the microtitre plate when compared with proteins. The stringent 
washing steps employed during ELISA may also remove peptides from the surface of the 
microtitre plate. Peptides containing a 3-nitrotyrosine adduct may not therefore be 
recognized by an antibody specific for the 3-nitrotyrosine epitope. 
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Figure 4.9. In-solution trypsin digestion of BSA and BSA-ONOO- 
samples. Comparison of nitration levels between digested and non-
digested BSA samples and BSA-ONOO-. All samples plated at the same 
protein concentration (2.5 µg/ml), assayed in duplicate and values are 
represented as mean ± SEM. 
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4.5 Discussion 
It is firmly established that heightened levels of oxidative stress contribute to development 
and progression of Alzheimer’s disease (AD) (Markesbery, 1997). In regions of the brain 
most affected by AD pathologies increased levels of protein nitration are evident, suggesting 
a link between increased protein nitration and AD (Smith et al., 1997b; Hensley et al., 1998).  
Moreover, specific proteins in the IPL are targets of nitration and this modification may 
potentially alter their normal function, in AD (Castegna et al., 2003). Although markers of 
oxidative stress in plasma are increasingly being assessed for their application as a 
biomarker, and to contribute to current understanding as to their role in AD (Zafrilla et al., 
2006; Baldeiras et al., 2008), few studies have assessed global levels of protein nitration in 
peripheral tissues in AD (Calabrese et al., 2006; Korolainen and Pirttila, 2009). 
 
This work attempted to measure total levels of protein nitration in AD plasma. HPLC-ECD 
was initially used to measure 3-nitrotyrosine in AD plasma as it is considered one of the 
most sensitive and specific methods for 3-nitrotyrosine measurement in biological fluids 
(Hensley et al., 1999; Duncan, 2003).  After establishing the optimal applied voltage to use 
(see Appendix I), a detection limit of 1 µM was observed. In a small subset of AD and age 
matched control subjects analysed, levels of 3-nitrotyrosine were on or below the limit of 
detection. Hence, in order to gain a valid measure of 3-nitrotyrosine it was evident that a 
large sample set would be necessary. Thus attempts were made to develop an in-house 
ELISA. 
 
In order to prepare a series of known nitrated standards for use in ELISA initial experiments 
used sodium nitrite to nitrate BSA. Sodium nitrite was used as work by Onshima and 
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colleagues (1990) had previously demonstrated that approximately 2nmol of 3-nitroytrosine 
are produced per milligram of protein when exposed to this agent under acidic conditions. 
The phenolic hydroxyl group of protein bound tyrosine residues has a pKa of 10-10.3. Upon 
nitration this is lowered by three pH units to 7.2-7.5 and causes the phenolate ion to be 
formed at a lower pH (Souza et al., 2008). The phenolate ion produces an intense yellow 
colour indicating 3-nitrotyrosine formation (ter Steege et al., 1998). After initially observing 
a notable colour change in BSA treated with NaNO2 and detecting levels of total 3-
nitrotyrosine by HPLC, no signal was evident using ELISA or Western blotting. Having 
shown that levels of bound 3-nitrotyrosine were below the limit of detection it was 
considered that free 3-nitrotyrosine was potentially formed in solution when synthesising the 
nitrated protein.  
 
However, ONOO- is relatively stable in alkaline solution, but rapidly decomposes under 
acidic conditions (Beckman et al., 1994), and hence it was not known in this work whether 
ONOO- was actually formed during the sodium nitrite treatment. Additionally, it was not 
known whether Pronase successfully cleaved protein at every possible site, which may 
account for levels not being able to be detected. A further possibility is that other 
modifications to the may have occurred. For example, the modification 3-chlorotyrosine 
produces a peak at the same retention time as 3-nitrotyrosine using HPLC-ECD (Hensley et 
al., 1999). Although these two modifications are distinguishable by their electrical potential, 
in the work presented this was not investigated, and so this may have contributed to the 
peaks seen on chromatograms. Consequently peroxynitrite was used to nitrate BSA for 
preparation of standards for ELISA. This was successful and confirmed by HPLC-ECD and 
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Western blotting, Approximately 2.5nmol 3-nitrotyrosine per milligram of protein was found 
to be nitrated which is comparable to a study by Whiteman and Halliwell (1999). 
 
The resulting ELISA was able to detect 5nM BSA 3-nitrotyrosine (the lowest standard), with 
saturation of antibody binding at concentrations greater then approximately 150nM BSA 3-
nitrotyrosine. These observations are in agreement with other 3-nitrotyrosine ELISA’s 
presented in existing literature: Ceriello and colleagues (2001) reported that the limit of 
detection of their assay was 10 nM and that there was an evident flattening of the standard 
curve at concentrations greater than 400 nM. In addition, Sun et al. (2007) reported 
saturation of antibody binding at 3-nitrotyrosine concentrations exceeding 200 nM using a 
commercial competitive ELISA.  
 
Using a subset of pooled samples initial results suggested that a detectable difference in 3-
nitrotyrosine levels was evident between AD and control. However, when individual samples 
were assayed the majority fell below, or were near the limit of detection. These observations 
indicate that only a minority of plasma samples exhibit measurable levels of 3-nitrotyrosine 
when assessed by ELISA. The detectable levels evident in pooled samples presented in this 
study can be explained by at least one individual sample present in the pool having 
detectable levels of 3-nitrotyrosine, and substantiate this assumption. Moreover, these data 
are comparable to those reported in a recent study which used commercial ELISA to assess 
total levels of 3-nitrotyrosine in plasma from 17AD and 18 control subjects. Within this data 
set only three AD, and four control samples had measurable levels of 3-nitrotyrosine (above 
detection limit of the assay: 2 nM) (Korolainen and Pirttila, 2009).  
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It was hypothesised that the signal in these plasma samples could be increased by digesting 
plasma proteins into peptides. The rationale being that 3-nitrotyrosine adducts within the 
protein structure would be exposed and be recognized by an anti-nitrotyrosine antibody 
which would otherwise not be able to be detected.  It was observed that detectable signal was 
markedly reduced in standard samples which had been digested with trypsin. Potential 
reasons for these observations maybe that non-specific binding sites are removed, or peptides 
adhere less well to the microtitre surface as they are too small to bind sufficiently. 
Consequently peptides with the 3-nitrotyrosine adduct would not then be recognized by an 
antibody specific for this particular epitope. 
 
In conclusion, these data suggest that, the measurement of 3-nitrotyrosine in order to 
distinguish detectable differences between AD and age matched control is difficult using 
HPLC-ECD. It was observed that concentrations of 3-nitrotyrosine in AD samples were on 
the limit of detection of the HPLC-ECD system.  Secondly the measurement of 3-
nitrotyrosine using an indirect ELISA was found to be equally challenging. Increasing the 
sample size did not improve the ability to detect differences in 3-nitrotyrosine between AD 
and age matched controls. Although measurement of 3-nitrotyrosine using ELISA in this 
population is in its infancy, one may speculate that the current sensitivity of ELISA cannot 
cope with the individual variation of 3-nitrotyrosine levels within this sample population. 
Thirdly, the hypothesis that 3-nitrotyrosine signal could be increased by digesting proteins 
into peptides, thereby exposing 3-nitrotyrosine adducts and increasing antibody binding, is 
unproven. 
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5.1 Abstract 
It is well established that increased levels of oxidative and nitrative stress, in the brain, are 
part of Alzheimer’s disease (AD) pathology. In contrast, levels require further clarification in 
plasma. To extend previous work presented in Chapter 3, analysis of markers of oxidative 
stress were undertaken in a further AD (n=25) and control plasma (n=25) sample set. In 
addition, further measures to assess protein nitration and nitric oxide metabolites (NOx) were 
employed. No differences in total protein oxidation and antioxidant capacity (p > 0.05) were 
found. In contrast, plasma NO2-/ NO3- levels were significantly reduced (p < 0.001) and one 
plasma protein of approximately 170 kDa exhibited increased nitration in the AD group (p = 
0.001). When assessed by 1-DE, Western blotting and mass spectrometry (MS) this plasma 
protein was identified as alpha-2-macroglobulin (α-2M). 
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5.2 Introduction 
It is widely considered that increased oxidative stress, in the brain, is part of AD pathology. 
This view is based on extensive studies in brain tissue which have reported increased protein 
oxidation, lipid oxidation and protein nitration in AD (Smith et al., 1997b; Markesbery and 
Lovell, 1998; Aksenov et al., 2001; Butterfield et al., 2007). In contrast, levels of plasma 
protein nitration have been reported in only two studies involving AD sufferers (Calabrese et 
al., 2006; Korolainen and Pirttila, 2009), and levels of protein oxidation remain unclear in 
this tissue. 
 
Central to protein nitration in vivo is the nitrating agent peroxynitrite (ONOO-) (Souza et al., 
2008), produced during the reaction between nitric oxide (NO•) and superoxide (O2•-) (Souza 
et al., 2008). Therefore, NO• and O2•- can be considered as important molecules involved in 
the process of protein nitration. NO• possesses several important functions in the body. It is a 
potent vasodilator and regulates blood pressure, inhibits platelet and leukocyte adhesion, and 
thus has anti-atherosclerosis properties (Maxwell, 2002). In vivo NO• production is typically 
assessed by measurement of the stable end products of NO•, nitrite (NO2-) and nitrate (NO3-) 
(Moshage et al., 1995; Zahedi et al., 2008). NO• and O2•- are produced by several cells in the 
body and these include endothelial cells, macrophages and leukocytes, hence ONOO- 
production can occur within close proximity to these sites (Oldreive and Rice-Evans, 2001).  
 
In one study, plasma protein nitration levels were shown to be increased in AD by Western 
blotting (Calabrese et al., 2006). However, only one Western blot representing a few plasma 
samples was shown, and no protein band analysis or statistical data was reported. In studies 
where it has been assessed, NO• levels are reduced in AD serum and plasma (Selley, 2003; 
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Corzo et al., 2007). Given these observations, coupled to AD being a condition associated 
with increased oxidative stress, measurement of plasma protein nitration in AD is needed. 
Moreover, the relationship between plasma levels of NO• and protein nitration requires 
investigation in this disease.  
 
Plasma protein oxidation levels in AD compared to control patients have been investigated 
more extensively than protein nitration, but still require further clarification. The work 
presented in Chapter 3 of this thesis showed that plasma protein oxidation levels were 
comparable between AD and age-matched controls. These data are in agreement with some 
existing studies (Polidori et al., 2004; Zafrilla et al., 2006), but not with others (Greilberger 
et al., 2008; Baldeiras et al., 2008).  
 
Given the extremely limited studies which measure protein nitration in AD, the principle aim 
of this work was to compare levels of plasma protein nitration between a group of AD and 
control subjects using Western blotting, as well as investigate the relationship between 
plasma protein nitration and nitric oxide levels. In addition, a broad range of oxidative 
indices were measured in a different sample set to that used in Chapter 3. More specifically, 
levels of plasma protein carbonylation were measured in order to confirm the comparable 
levels reported between AD and control subjects in Chapter 3.  
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5.3 Methods 
5.3.1 Declaration of ownership 
In this Chapter the advice of Mr Andrew Jones was sought in order to undertake LC-MS/MS 
and CID. Responsibility for the choosing of filtering parameters for data analysis, and 
decisions on sample preparation were made by the author. The author was also present for 
the running of this analytical technique and was also responsible for all further data analysis.  
 
5.3.2 Sample Population 
AD samples and age matched control samples were obtained as described in general methods 
section 2.1.4. In total, 50 patients and control volunteers were used for this study (25 in each 
group).  
 
5.3.3 BCA assay  
Total protein concentration was determined by the BCA assay as described in general 
methods section 2.2.1. 
 
5.3.4 Measurement of total nitrite and nitrate levels in plasma 
5.3.4.1 Principle of the Griess Assay 
The Griess Assay was employed to assess total levels of the metabolites NO2- and NO3- in 
AD and control plasma samples. As shown in figure 5.1, plasma samples were deproteinized 
and the supernatant removed for analysis. Any NO3- present in the supernatant was reduced 
to NO2- by the addition of vanadium (III) chloride. Griess Reagent was subsequently added 
and a colour change which is directly proportional to the level of NO2- was observed.  This 
colour change can be measured by a spectrophotometer set at 540 nm and the amount of 
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nitrite in samples can then be determined by comparison to a standard curve of known nitrite 
concentrations. Total nitrite and nitrate levels were represented as total nitric oxide 
metabolites (NOx) and measurement of NOx is considered a direct marker of  in vivo NO• 
production (Moshage et al., 1995; Miranda et al., 2001). 
 
5.3.4.2 Measurement of NOx using the Griess Assay 
Measurement of NOx was undertaken as described by Zahedi et al. (2008). Plasma samples 
(100 µl) were diluted fourfold with HPLC grade water (375 µl) and 25 µl zinc sulphate (300 
mg/ml) added to give a final concentration of 15mg/ml (Moshage et al., 1995). Samples were 
centrifuged at 10,000 g for 10 minutes (Miranda et al., 2001; Zahedi et al., 2008) and 
supernatants (100 µl) were applied to a 96 well microtitre plate. To each well 100 µl 
vanadium (III) chloride (8mg/ml) was added and then. 50 µl sulphanilamide (2%) and 50 µl 
N-(1-naphthyl) ethylendiamine dihydrochloride (0.1%) was added immediately. Plates were 
incubated at 370C for 30 minutes and absorbance read at 540 nm (Multiscan MS, 
Labsystems, Finland ) (Zahedi et al., 2008). Total nitric oxide metabolites were calculated 
from the linear standard curve of known nitrite concentrations ranging from 0-100 µM 
(Zahedi et al., 2008). All samples were assayed in triplicate.  
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Figure 5.1.  Determination of total nitrite and nitrate levels in plasma.  Plasma 
samples are firstly deproteinized by the addition of zinc sulphate and centrifugation at 
10,000 g for 10 minutes. The supernatants are then added to wells of a microtitre 
plate. Vanadium chloride is added to each well to reduce all NO3- to NO2- and then 
Griess Reagent is immediately added. A colour change which is directly proportional 
to the amount of NO2- present in the sample is observed after 30 minutes incubation, 
and can be measured at 540 nm using a spectrophotometer. The amount of nitrite 
present in the sample can be determined by comparison with a standard curve of 
known nitrite concentrations. The total amount of nitrite and nitrate levels is 
represented as total nitric oxide metabolites (NOx). 
x 
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5.3.5 Measurement of protein nitration  
To evaluate nitration to plasma proteins, samples (30 µg) were separated by 1D 
electrophoresis and protein expression and nitration were assessed by silver staining and 
Western blotting as described in general methods sections 2.2.5, 2.2.7 and 2.2.8. For 
Western blotting, mouse monoclonal anti-nitrotyrosine antibody was used at 1:500 with an 
appropriate horseradish peroxidase conjugated secondary antibody (1: 2,000). The optical 
densities of bands present on 1D gels and/or Western blots corresponding to nitrated plasma 
proteins and plasma proteins respectively, were evaluated using Quantity One™ software 
(BioRad) by user defined volume integration. An equal number of control and AD samples 
were assessed on each 1D gels and/or Western blot to ensure that ECL and silver stain 
development were identical between the two groups. Optical densities for protein nitration 
values were normalised against optical densities for total protein values. Blots with samples 
considered of poor quality were repeated. Samples were run in duplicate. 
 
5.3.6 Broad measures of oxidative stress 
Plasma protein oxidation, total antioxidant capacity (TAC) and lipid peroxides were carried 
out as stated in the general methods sections 2.2.2, 2.2.3 and 2.2.4.  
 
5.3.7 Mass Spectrometry analysis 
Protein band excision, LC-MS/MS, data dependent CID and analysis were undertaken as 
described in general methods (general methods section 2.2.9.2). 
 
5.3.8 Statistics 
Statistical analysis was undertaken as described in general methods section 2.2.10. 
Chapter 5                                        Peripheral markers of nitrative and oxidative stress in AD 
97 
5.4 Results 
5.4.1 Nitric oxide metabolites 
As shown in figure 5.2, plasma NOx levels as measured by the Griess Assay were 
significantly reduced in the AD group compared to age matched control subjects (Control: 
60.50 ± 25.00 µM Vs. AD: 30.34 ± 29.88 µM; p < 0.001, Mann-Whitney U test). 
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Figure 5.2. Total nitric oxide metabolite levels. Data (n=25; AD and control) are presented 
as a box plot. Nitric oxide metabolites were measured by Griess Assay (section 
5.3.4).Percentiles are represented by the box (25th and 75th) and whisker (10th and 90th) with 
thick and thin lines corresponding to mean and median values respectively. Outliers are 
shown as filled circles. ***p < 0.001 Vs Control.  
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5.4.2 Plasma protein nitration 
5.4.2.1 Optimization of antibody conditions  
In order to identify nitrated plasma protein bands it was necessary to use relatively 
concentrated primary and secondary antibody solutions. As shown in Figure 5.3, for plasma 
proteins (30 µg) there are a greater amount of visible nitrated protein bands using mouse 
peroxidase conjugated goat anti-mouse secondary antibody at 1:2000, compared to 1:4000, 
when using mouse monoclonal anti-nitrotyrosine primary antibody at 1:500. 
 
 1        2 
250 kDa 
150 kDa 
100 kDa 
50 kDa 
25 kDa 
Figure 5.3. Optimizing antibody conditions. Mouse monoclonal anti-
nitrotyrosine antibody used at 1:500 dilutions with peroxidase 
conjugated secondary antibody used at 1:2000 (lane 1) and 1:4000 (lane 
2).  
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5.4.2.2 Specificity of peroxidase conjugated goat anti- mouse IgG antibody 
The specificity of secondary antibody for the mouse monoclonal primary antibody was 
investigated. Due to the high concentration of secondary antibody required in order to detect 
nitrated plasma protein bands, some non-specific binding was expected and as demonstrated 
in figure 5.4, a degree of non-specific binding is evident. The non-specificity is likely to be 
cross reactivity to human immunoglobulin G which comprises of heavy chain (~150,000 Da) 
and light chains (~50,000 and 22,500 Da). The non-specific binding using the Sigma 
(A4416) antibody is more severe than the Cell Signalling antibody (#7076), however the 
intensity of bands which correspond to nitrated proteins are more visible and thus easier to 
quantify using a densitometer. Several protein bands corresponding to nitrated plasma 
proteins are present: bands are evident at approximately 250, 170, 120 and 80 kDa. 
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  1        2                      3        4 
250 kDa 
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25 kDa 
Figure 5.4. Assessing non-specificity of secondary antibody. Two secondary 
antibodies were used to assess specificity. Lane 1: Mouse monoclonal anti-
nitrotyrosine antibody (1:500) with peroxidase conjugated goat anti-mouse 
secondary antibody (Sigma A4416) at 1:2000 dilution; lane 2: Peroxidase 
conjugated goat anti-mouse secondary antibody (Sigma A4416) at 1:2000 
dilution; lane 3: Mouse monoclonal anti-nitrotyrosine antibody (1:500) with 
peroxidase conjugated goat anti-mouse secondary antibody (Cell Signalling 
#7076) at 1:2000 dilution; and lane 4: Peroxidase conjugated goat anti-mouse 
secondary antibody (Cell Signalling #7076) at 1:2000 dilution. 
Human 
Ig 
Human 
Ig 
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5.4.3 Plasma protein nitration 
Bands corresponding to plasma protein nitration and protein expression were quantified by 
Quantity one software (BioRad) as shown in Figure 5.5. The prominent nitrated bands at 
approximately 170 kDa and 80 kDa, labelled as U7-10 and U31-34 (U refers to user defined 
parameters), were detectable and quantifiable in all plasma samples; the very faint nitrated 
band at approximately 250 kDa although visible to the naked eye, was not accurately 
quantifiable using a densitometer in all plasma samples; and the nitrated band at 
approximately 120 kDa was detectable and accurately quantifiable, but only in a minority of 
plasma samples.  
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250 kDa 
150 kDa 
100 kDa 
50 kDa 
25 kDa 
Figure 5.5. Quantification of protein expression and protein nitration. 
Quantity one® software (BioRad) was used to calculate optical density of 
three individual bands at approximately 170, 120 and 80 kDa using user 
defined volume integration (Boxed and labelled accordingly). For equivalent 
bands (U7-U10, U4 & U5; U19-22, U16 & U17; and U31-34, U28 and U29) 
analysed on Western blots and silver stained gels, user defined volumes were 
kept consistent and an equal amount of control and AD samples were 
assayed: Lane 1, Western blot for control sample assayed in duplicate; Lane 
2, Western blot for AD sample assayed in duplicate; Lane 3, silver stained 
control; and Lane 4, silver stained AD sample.  
  1             2                3    4 
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5.4.3.1 Protein band exhibits increased nitration in AD plasma 
As demonstrated in figure 5.6 the band at approximately 170 kDa exhibits significantly 
greater signal after normalisation against total protein levels (Control: 0.95 ± 0.45 OD units 
Vs. AD: 1.36 ± 0.62 OD units; p = 0.001, Mann-Whitney U test), suggesting its nitration 
status is increased in AD compared to control. No difference in signal and thus nitration 
status was observed for the band at approximately 80 kDa (Control: 0.97 ± 0.38 OD units 
Vs. AD: 1.12 ± 0.52 OD units; p = 0.27, independent samples t-test).  
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Figure 5.6. Increased nitration for unknown plasma protein band at ~170 kDa. 
Data (n=25; AD and control) are presented as a box plot. Percentiles are represented 
by the box (25th and 75th) and whisker (10th and 90th) with thick and thin lines 
corresponding to mean and median values respectively. Outliers are shown as filled 
circles. *p = 0.001 Vs. Control.  
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5.4.3.2 Identification of excised plasma protein band 
In an attempt to identify the protein corresponding to the 170 kDa band, the protein band was 
excised from a silver stained gel. This particular band was very prominent on the Western 
blot and silver stained gel enabling its accurate excision. The protein band was digested and 
subjected to LC-MS and data dependent CID (as described in general methods 2.2.9). Data 
files created from the raw data produced by LC-MS and data-dependent CID for the excised 
gel band was searched against the human subset of the international protein index (IPI) 
database. As shown in table 5.1 a confident match for α-2 macroglobulin (α-2M) was 
obtained. The top match based on protein score had total peptide coverage of 28.29% (see 
figure 5.7). 
 
Table 5.1. Protein identification for excised protein band using OSSMA. For positive 
identifications, the peptides are initially scored and filtered with an E-value threshold (this 
value is the statistical confidence generated from the OMSSA algorithm when running a 
search), and the value used is the suggested threshold. The peptide scores are then compared 
according to random chance using a second probability equation, and a Protein Score (p-
Score) is calculated. Any p-Score >0 is discarded as a false identification. The lower the 
protein score the more confident the protein identification The greatest protein match from 
IPI database for excised protein band corresponded to α-2-macroglobulin with a highly 
confident p-Score of -837.53. *** A further protein match for α-2-macroglobulin from 
database search. 
Protein 
Band 
Accession number/gi Protein 
Score 
Coverage 
(%) 
Description MW 
 
~170kDa  
 
P01023/112911 
Q5R4NB/75054706 
Q5NVH5/75054626 
P08603/159517847 
P04264/238054406 
A5A6M6/215275331 
Q28522/2492797 
A2V9Z4/190358749 
P027069/1351907 
P01024/119370332 
***P06238/119370261 
 
-837.53 
-791.50 
-586.60 
-371.29 
-315.40 
-314.37 
-296.91 
-296.58 
-286.73 
-280.10 
-81.01 
 
28.29 
26.80 
45.32 
21.36 
27.64 
26.37 
25.33 
25.00 
24.55 
10.82 
5.03 
 
α-2-macroglobulin 
α-2-macroglobulin 
Serum albumin 
Complement Factor H 
Keratin, Type II 
Keratin, Type II  
Serum albumin 
Serum albumin 
Serum albumin 
Complement C3 
α-2-macroglobulin   
 
163.3 
163.3 
69.4 
139.1 
66.0 
65.5 
67.9 
68.9 
69.3 
187.1 
163.8 
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1 MGKNKLLHPS  LVLLLLVLLP  TDASVSGKPQ  YMVLVPSLLH 
41 TETTEKGCVL  LSYLNETVTV  SASLESVRGN  RSLFTDLEAE 
81 NDVLHCVAFA  VPKSSSNEEV  MFLTVQVKGP  TQEFKKRTTV 
121 MVKNEDSLVF  VQTDKSIYKP  GQTVKFRVVS  MDENFHPLNE 
161 LIPLVYIQDP  KGNRIAQWQS  FQLEGGLKQF  SFPLSSEPFQ 
201 GSYKVVVQKK  SGGRTEHPFT  VEEFVLPKFE  VQVTVPKIIT 
241 ILEEEMNVSV  CGLYTYGKPV  PGHVTVSICR  KYSDASDCHG 
281 EDSQAFCEKF  SGQLNSHGCF  YQQVKTKVFQ  LKRKEYEMKL 
321 HTEAQIQEEG  TVVELTGRQS  SEITRTITKL  SFVKVDSHFR 
361 QGIPFFGQVR  LVDGKGVPIP  NKVIFIRGNE  ANYYSNATTD 
401 EHGLVQFSIN  TTNVMGTSLT  VRVNYKDRSP  CYGYQWVSEE 
441 HEEAHHTAYL  VFSPSKSFVH  LEPMSHELPC  GHTQTVQAHY 
481 ILNGGTLLGL  KKLSFYYLIM  AKGGIVRTGT  HGLLVKQEDM 
521 KGHFSISIPV  KSDIAPVARL  LIYAVLPTGD  VIGDSAKYDV 
561 ENCLANKVDL  SFSPSQSLPA  SHAHLRVTAA  PQSVCALRAV 
601 DQSVLLMKPD  AELSASSVYN  LLPEKDLTGF  PGPLNDQDDE 
641 DCINRHNVYI  NGITYTPVSS  TNEKDMYSFL  EDMGLKAFTN 
681 SKIRKPKMCP  QLQQYEMHGP  EGLRVGFYES  DVMGRGHARL 
721 VHVEEPHTET  VRKYFPETWI  WDLVVVNSAG  VAEVGVTVPD 
761 TITEWKAGAF  CLSEDAGLGI  SSTASLRAFQ  PFFVELTMPY 
801 SVIRGEAFTL  KATVLNYLPK  CIRVSVQLEA  SPAFLAVPVE 
841 KEQAPHCICA  NGRQTVSWAV  TPKSLGNVNF  TVSAEALESQ 
881 ELCGTEVPSV  PEHGRKDTVI  KPLLVEPEGL  EKETTFNSLL 
921 CPSGGEVSEE  LSLKLPPNVV  EESARASVSV  LGDILGSAMQ 
961 NTQNLLQMPY  GCGEQNMVLF  APNIYVLDYL  NETQQLTPEV 
1001 KSKAIGYLNT  GYQRQLNYKH  YDGSYSTFGE  RYGRNQGNTW 
1041 LTAFVLKTFA  QARAYIFIDE  AHITQALIWL  SQRQKDNGCF 
1081 RSSGSLLNNA  IKGGVEDEVT  LSAYITIALL  EIPLTVTHPV 
1121 VRNALFCLES  AWKTAQEGDH  GSHVYTKALL  AYAFALAGNQ 
1161 DKRKEVLKSL  NEEAVKKDNS  VHWERPQKPK  APVGHFYEPQ 
1201 APSAEVEMTS  YVLLAYLTAQ  PAPTSEDLTS  ATNIVKWITK 
1241 QQNAQGGFSS  TQDTVVALHA  LSKYGAATFT  RTGKAAQVTI 
1281 QSSGTFSSKF  QVDNNNRLLL  QQVSLPELPG  EYSMKVTGEG 
1321 CVYLQTSLKY  NILPEKEEFP  FALGVQTLPQ  TCDEPKAHTS 
1361 FQISLSVSYT  GSRSASNMAI  VDVKMVSGFI  PLKPTVKMLE 
1401 RSNHVSRTEV  SSNHVLIYLD  KVSNQTLSLF  FTVLQDVPVR 
                1441    DLKPAIVKVY  DYYETDEFAI  AEYNAPCSKD  LGNA 
Figure 5.7. Peptide coverage for α-2-macroglobulin (P01023/112911). The 
sequence information for α-2-macroglobulin is shown. Matched residues are 
highlighted in grey. A total peptide coverage of 28.29% (417 out of 1474) for this 
sequence was observed. 
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Three further possible matches for, serum albumin, complement and keratin type II proteins 
are also evident. When the molecular weights of each individual protein are taken into 
account the likely identity of the excised plasma protein is α-2 macroglobulin (α-2M). 
Multiple proteins present during 1-DG separation may explain the reason for several 
identifications. Although the protein was confidently identified as α-2M, no evidence that 
this plasma protein is actually nitrated was found. As shown in Figure 5.8, LC-MS/MS 
spectra for the three highest scoring peptide matches for the α-2M sequence demonstrate that 
no tyrosine residues present are nitrated.  
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Figure 5.8. Mass spectra of top three peptide hits for α-2M sequence. The top three 
peptide matches for the α-2M sequence demonstrate that no tyrosine residues present are 
nitrated. Total amino acid coverage for each peptide is greater than 92.9%. 
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5.4.4 Protein oxidation 
As shown in figure 5.9 no differences in total levels of protein carbonylation between AD 
and age matched control subjects, from the particular sample set used in this chapter 
(Control: 2.91 ± 0.26 nmol/mg Vs. AD: 2.89 ± 0.26 nmol/mg protein, p = 0.8 independent 
samples t-test).  
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Figure 5.9. Total protein oxidation. Protein oxidation was measured by carbonyl ELISA. 
Data (n=25; AD and control) are presented as a box plot. Percentiles are represented by the 
box (25th and 75th) and whisker (10th and 90th) with thick and thin lines corresponding to 
mean and median values respectively. Filled circles represent outliers. 
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5.4.5 Total antioxidant capacity 
No change in total antioxidant capacity was observed (figure 5.10), as measured by FRAP, 
between AD and age matched control subjects, from the particular sample set used in this 
chapter (Control: 910.800 ± 208.927µM Vs. AD: 992.933 ± 331.012µM, p = 0.4 
independent samples t-test). 
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Figure 5.10. Total Antioxidant Capacity. TAC was measured by FRAP. Data (n=25; AD 
and control) are presented as a box plot. Percentiles are represented by the box (25th and 75th) 
and whisker (10th and 90th) with thick and thin lines corresponding to mean and median 
values respectively. Filled circles represent outliers. 
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5.4.6 Lipid peroxide levels 
As shown in figure 5.11 no changes in lipid peroxide levels were observed in AD compared 
and age matched control samples, from the particular sample set used in this chapter 
(Control: 6.53 ± 5.23nmol/ml, Vs. AD: 10.26 ± 14.17nmol/ml, p = 0.4 independent samples 
t-test). Six AD and fourteen control samples were below the limit of detection of this assay 
(1nmol/ml).  
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Figure 5.11. Lipid peroxide levels. Lipid peroxide levels were measured by lipid peroxide 
assay. Data (n=25; AD and control) are presented as a box plot. Percentiles are represented 
by the box (25th and 75th) and whisker (10th and 90th) with thick and thin lines corresponding 
to mean and median values respectively. Filled circles represent outliers. 
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5.5 Discussion 
In view of the growing evidence supporting a role for nitrative stress in AD, this study aimed 
to evaluate NO• and protein nitration levels in AD plasma in addition to other markers of 
oxidative stress. NO• and levels of 3-nitrotyrosine were assessed as measurements which 
reflect nitrative stress. 
 
It is widely accepted that levels of plasma NO2-/NO3- reflect in vivo production of NO• 
(Moshage et al., 1995; Zahedi et al., 2008). In this study a remarkable decrease in NOx levels 
was observed in AD compared to control subjects, a finding which is in agreement with 
existing studies in AD patients (Selley, 2003; Corzo et al., 2007). It is appreciated that diet 
can influence plasma NO2- and NO3- levels as certain foods (e.g., spinach, kale) are high in 
these metabolites (Dusse et al., 2005). With this in mind, it has been suggested that subjects 
should be fasted and their diet restricted two days prior to blood drawing (Dusse et al., 
2005), however such measures are difficult to control for in this specific population. 
Therefore, caution is required when interpreting the results presented in this work.  
 
Although it was not possible to accurately assess total protein nitration by Western blotting 
due to non-specific antibody binding, one specific plasma protein was successfully found to 
exhibit increased nitration in the AD group. Given this finding, one may suggest that 
decreased plasma NOx levels maybe a result of their reaction and subsequent removal by  
O2•-. Production of ONOO- may then subsequently nitrate specific plasma proteins. On the 
other hand, as suggested by Selley (2003) the reduction in NO• maybe due to increased levels 
of homocysteine and asymmetric dimethylarginine and subsequent inhibition of the NO• 
producing enzyme nitric oxide synthase. 
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In this study no difference in total protein oxidation or lipid peroxides was observed. These 
data are in agreement with results presented in Chapter 3, which were undertaken on a 
different set of plasma samples. In contrast, the reduction in TAC reported in AD compared 
to control subjects in Chapter 3 was not replicated in the sample set analysed in this study. It 
has been suggested that disease severity (e.g., mild, moderate or severe AD) may affect 
peripheral levels of antioxidants (Sekler et al., 2008) and hence using samples which include 
individuals across the full spectrum of AD severity may represent a reason for TAC levels to 
remain unchanged between the AD and control groups in this study. However, a significant 
reduction in TAC was demonstrated in Chapter 3 without different stages of the disease 
being taken into consideration. Moreover, there is also a study which reports of no 
correlation between the degree of cognitive impairment as quantified by MMSE, and TAC as 
measured by FRAP, when using large cohorts (Guidi et al., 2006).  Interestingly the same 
study found a slight negative correlation between TAC, as measured by FRAP, and the 
duration of the disease (Guidi et al., 2006) suggesting that disease duration may affect TAC. 
The APOE genotype of AD subjects may also have an effect on TAC levels as measured by 
FRAP. A study undertaken by Pulido and colleagues (2005) reported that only AD subjects 
classified as APO 4/4 had a significant reduction in antioxidant capacity. A further factor 
which may contribute to the equivalent TAC demonstrated in this work is the number of 
subjects that were analysed. As with this study, groups who report no change in TAC 
between AD and control subjects typically assess a relatively small number of subjects (20 to 
25 AD samples) (Sinclair et al., 1998; Pulido et al., 2005). Although not known, subject 
characteristics such as vitamin use, physical activity pattern and diet may have also 
influenced this measurement, and hence are a limitation of this work. Taken together these 
data may suggest that the conflicting TAC data presented in this study, and in Chapter 3, 
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may be in part due to subject APOE genotype, the duration of disease or the relatively small 
cohort of samples analysed.  
 
The observation that total protein carbonylation remained unchanged between AD and 
control subjects is in agreement with other studies (Polidori et al., 2004; Zafrilla et al., 2006). 
Further, a recent study which assessed total levels of oxidized and nitrated proteins in 
various peripheral tissues, which included plasma, found no difference in levels between AD 
and controls (Korolainen and Pirttila, 2009). Based on these data the authors suggest that 
oxidative metabolism related to AD pathogenesis cannot be detected. One may suggest that 
as shown with previous studies in AD brain and plasma (Castegna et al., 2002a; Castegna et 
al., 2002b; Castegna et al., 2003; Choi et al., 2002), specific proteins which may be involved 
in disease pathology are targets of oxidative modification, rather than these events being a 
random, more global process.  
 
Indeed, data presented in this chapter identified α-2M as one plasma protein that exhibited 
increased nitration in AD compared to age matched control subjects. These observations are 
also in agreement with a study by Mitrogianni et al. (2004); this group used the same 
methodology to identify specific proteins that exhibited increased plasma protein nitration in 
haemodialysis patients, a condition also associated with increased oxidative stress. α-2M was 
identified by its approximate molecular weight on a Western blot and by mass spectrometry 
and sequence data of the excised protein band.  
 
One limitation of using 1-DE to evaluate plasma protein nitration is that given the vast 
dynamic range of plasma proteins (i.e. magnitude of different concentrations of proteins) 
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other proteins of similar molecular weights, which may account for the nitrated protein, may 
be masked by α-2M as it is highly abundant in plasma. However, nitration is selective and 1 
to 10 residues of tyrosine per 100,000 are nitrated in conditions associated with inflammation 
and cardiovascular disease (Souza et al., 2008). Therefore it is very likely that only nitrated 
proteins which are highly abundant (e.g. α-2M) will be detected when employing 1-DE and 
Western blotting.  
 
From the mass spectrometry data there was no evidence that α-2M was actually nitrated. 
Tyrosine and Tryptophan amino acid residues are targets for nitration by reactive oxygen 
species (Berlett and Stadtman, 1997; Souza et al., 2008), and of the peptides which 
accounted for 28.29% of the α-2M protein sequence, none of these residues were found to be 
nitrated. However, nitration of α-2M cannot be ruled out based on this assumption alone, as a 
further 72.71% of the protein sequence was not matched and therefore may well have 
contained nitrated tyrosine and tryptophan residues. Although likely to be modified, from the 
mass spectrometry data presented here α-2M cannot be confirmed as the nitrated plasma 
protein. 
 
In AD altered levels of α-2M have been described previously. Its expression is increased in 
senile plaques and plasma from AD sufferers (Bauer et al., 1991; Hye et al., 2006). There is a 
selective and specific interaction between α-2M and the Aβ peptide and α-2M inhibits the 
fibrillization of Aβ peptide. Based on these observations it has been suggested α-2M may 
sequester and bind the Aβ peptide to provide its clearance from tissues brain (Du et al., 1997; 
Hughes et al., 1998). Increased nitration to α-2M as tentatively shown in this work may 
compromise this suggested function and thus result in greater Aβ load evident in the AD 
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brain. In addition this interaction may indicate that this particular protein is targeted for 
oxidative damage, more so than others. Moreover, the balance between proteases and 
protease inhibitors plays an important role in mediating inflammation associated tissue 
damage. As previously mentioned, α-2M is a protease inhibitor, and its modification by 
oxidation or nitration may impact on its function and thus play an important role during the 
inflammation process. For example, Wu et al. (1998) demonstrated that oxidation to α-2M 
affects its ability to bind cytokines and growth factors and thus proposed that such 
modification may act as a switch mechanism to help regulate acute inflammation and tissue 
repair. Further work by the same group reported that oxidized α-2M is greater in synovial 
fluid from Rheumatoid Arthritis patients when compared to control plasma, and that the 
degree of oxidation correlates to the observed reduction in its activity (Wu and Pizzo, 2001). 
One may speculate that nitration to α-2M would exert a similar effect and thus contribute to 
inflammatory processes associated with AD (Akiyama et al., 2000). 
 
In summary, this study tentatively identified α-2M as a plasma protein which exhibits 
increased nitration in AD. Further work is required to definitively show and confirm this 
finding. In addition, no difference in total plasma protein oxidation between AD and control 
subjects was observed, providing further evidence that oxidative events in AD are specific, 
rather than global events. Further studies in a larger cohort of samples are required to further 
confirm these findings.  
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6.1 Abstract 
The recent emergence of ‘redox’ proteomics has allowed for the identification of proteins 
altered by oxidative modifications. Such investigations in Alzheimer’s disease (AD) brain 
have advanced the existing understanding into the oxidative mechanisms which underlie the 
disease. Plasma is representative of processes and events which occur in the body and 
coupled to its easy accessibility and practicality provides an ideal source to monitor 
oxidative changes to proteins which may occur during AD. In this study, non-depleted 
pooled AD and pooled control plasma (n=25) were subjected to 2-DE with Western blotting 
for the detection of proteins which were specifically oxidized. One protein was shown to 
exhibit increased oxidation in AD. The use of narrow range IPG gels and excision of altered 
plasma proteins from multiple gels was undertaken to overcome encountered difficulties 
when attempting to obtain protein identification.  
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6.2 Introduction  
Proteomics is the study of a group of proteins expressed at a particular snapshot in time (e.g., 
a disease state). In addition, proteomics can be used to assess post translational modifications 
(PTM) to proteins which may include phosphorylation, sulphation and glycosylation. These 
are important as they can determine activity, turnover and stability of a protein, which 
governs its function (Pandey and Mann, 2000). It has been assumed that oxidative events are 
damaging and harmful since early exercise studies in the late 1970’s and early 1980’s 
(Dillard et al., 1978; Davies et al., 1982). More recently, the notion that these events may 
actually be important regulatory PTMs is gaining credibility (Spickett et al., 2006).  
 
Impairment of protein function and reduced activity are recognized consequences of protein 
oxidation (Friguet, 2006), and therefore proteins which are targets of such events are of 
particular interest.  The emergence of a recent new division of proteomics named ‘redox 
proteomics,’ allows the identification of specific proteins modified by oxidation. By using 2-
DE coupled with immunoblotting, oxidative modifications to proteins (e.g., oxidation, 
nitration, advanced glycation end products, advanced lipid end products) can be assessed. 
This has allowed the molecular mechanisms of diseases associated with oxidative stress, 
such as AD, to be further understood (Butterfield et al., 2006). 
 
Increasingly, the focus of AD research has been to come up with approaches to slow or 
prevent the development of AD. As a consequence, recent redox proteomic studies have 
switched their focus to oxidative modifications that occur as AD progresses, by either 
comparing brain tissue from mild cognitive impairment (MCI) and early AD subjects, or by 
examining brain regions, such as the entorhinal cortex, which are affected at the earliest 
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stage of AD (Braak and Braak, 1995; Terni et al., 2009; Sultana et al., 2010). For example, 
Terni et al (2009) demonstrated that mitochondrial ATP synthase exhibited increased 
lipooxidation at the first stage of AD, when no clinical symptoms are evident.  
 
Perhaps the largest drawback of such work is that brain tissue can only be obtained post 
mortem. Even though these aforementioned redox proteomic studies are vitally important in 
characterising oxidative changes which occur when AD progresses, brain tissue does not 
reveal specific peripheral oxidative changes that maybe significant in AD, and cannot be 
used as a biomarker in a living person to monitor interventions or therapies. Although AD 
originates in the brain, blood plasma does contain brain derived proteins (Aluise et al., 
2008); and oxidative changes (e.g., protein carbonylation) in plasma provide a good 
indication of oxidative status in the body (Veskoukis et al., 2009). Studies which have 
investigated plasma protein oxidation in AD present an unclear picture, some have 
demonstrated increased plasma protein oxidation in AD, where as others have reported no 
change (Bermejo et al., 2008; Zafrilla et al., 2006).  In agreement with studies undertaken by 
Zafrilla et al. (2006) and Balderias et al. (2008), results from Chapter 3 demonstrated that 
plasma protein oxidation levels are equivalent between AD and controls. However, TAC 
levels were shown to be reduced, and a specific plasma protein which was oxidized was also 
identified. These observations may suggest that oxidation to specific plasma proteins are 
more important than a global oxidative change, when investigating peripheral oxidative 
stress in AD.  
 
To date, limited ‘redox’ proteomic AD research has been undertaken in plasma in order to 
identify proteins altered by oxidation, and only a few oxidized plasma proteins have so far 
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been identified.  Conrad et al. (2000) used Western blotting to demonstrate that a 78 kDa 
plasma protein exhibited increased oxidation in AD compared to control patients. In two 
later studies specific plasma proteins and glycoproteins were shown to be targets of 
oxidation in AD (Choi et al., 2002; Yu et al., 2003). In this study 2-DE with Western blotting 
was undertaken to identify specific plasma proteins which undergo oxidation in AD 
compared to age-matched controls.  
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6.3 Methods 
6.3.1 Declaration of Ownership  
In this Chapter the advice of Mr Andrew Jones was sought in order to undertake LC-MS/MS 
and CID. Responsibility for the choosing of filtering parameters for data analysis, and 
decisions on sample preparation were made by the author. The author was also present for 
the running of this analytical technique and was responsible for all further data analysis.  
 
6.3.2 Sample selection 
A subset of 50 samples (25 AD and 25 control patients) were selected from the original 144 
sample set (see section 2.1.4 in general methods) based on the availability of plasma.  
 
6.3.3 Desalting plasma samples 
Twenty five control and AD samples were pooled together and desalted using Micro Bio-
Spin™ 6 chromatography columns. Total protein concentration of the desalted samples was 
measured using the BCA assay (see general methods section 2.2.1).  
 
6.3.4 IEF, 2-DE, silver staining and derivatization of protein carbonyls,  
Desalted pooled plasma samples (100-150 µg) were separated by IEF and 2-DE (see general 
methods 2.2.6).  Total protein content was visualised by silver staining (general methods 
2.2.8) and protein carbonylation was determined by an anti-DNP Western blot. For anti-DNP 
Western blots plasma protein transfer was undertaken as described in general methods 
section 2.2.7. Hybond-P™ membrane (GE Healthcare, UK) was subsequently derivatized 
with 2, 4-DNPH (1mM 2, 4-DNPH in 2M HCl), washed three times in TBST (0.05%) for 10 
minutes and then incubated with mouse monoclonal anti-DNP (1:200) for 2 hours at room 
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temperature. Hybond-P™ membrane (GE Healthcare, UK) was washed a further three times 
in TBST (0.05%) for 10 minutes, and then incubated with an appropriate horseradish 
peroxidase conjugated secondary antibody (1: 2,000) for 1 hour at room temperature. 
Oxidized protein spots were visualized using a chemiluminescent detection system (see 
general methods section 2.2.7). Modified protein spots were excised from silver stained gels 
under aseptic conditions with a sterile scalpel, placed into clean eppendorf tubes and kept 
overnight at -20ºC.  
 
6.3.5 Plasma protein oxidation analysis and statistics 
Pooled AD and control plasma samples were run concurrently to ensure that any detectable 
differences seen were truly representative of the disease state. Gaussian modelled protein 
spots were matched and their optical densities assessed using PD Quest image analysis 
software™ (BioRad).  As employed in existing proteomic studies protein spots which 
exhibited a difference in signal intensity of ≥ 3-fold, with a p value of < 0.05 (independent 
samples t-test) was considered significant (Castegna et al., 2002b; Butterfield et al., 2006b).  
Protein expression of spots was accounted for by normalisation against total protein content.  
 
6.3.6 Immunoprecipitation of oxidized proteins 
Preparation of magnetic Dynabeads® (Invitrogen, UK), Dynabead- antibody binding and 
immunoprecipitation of target proteins was undertaken as described in the manufacturer’s 
guidelines. Dynabeads® (Invitrogen, UK) were re-suspended by gentle inversion and 
washed three times with citrate phosphate buffer (pH 5). Mouse monoclonal anti-DNP 
antibody was diluted in citrate phosphate buffer, added to Dynabeads® at the desired ratio 
(Dynabeads: Antibody; 75:1) and rotated for 40 minutes, at 4ºC. Dynabead®-antibody 
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complexes were washed three times with citrate phosphate buffer (pH 5). Samples were 
diluted to desired concentration (Dynabead-Antibody complex: antigen; 1:10) in citrate 
phosphate buffer (pH 5) and incubated with Dynabead®-antibody complexes for one hour at 
4ºC. For 2-DE gels immuno-precipitates were resuspended in rehydration buffer, boiled for 5 
minutes and kept at -20ºC until they were analyzed. Optimal amounts of oxidized plasma 
proteins to use were deduced from preliminary experiments using oxidized BSA. The 
amount of plasma proteins used was governed by antibody availability. 
 
6.3.7 Mass Spectrometry analysis 
Protein spot excision, LC-MS/MS, data dependent CID and analysis were undertaken as 
described in general methods (section 2.2.9.2). 
  
Chapter 6                                                                                        Gel based redox proteomics 
124 
6.4 Results 
6.4.1 Two dimensional gel electrophoresis and Western blotting for protein oxidation 
Representative blots of a pooled AD and pooled control plasma sample assayed concurrently 
are shown in figure 6.1. As visualized on the Western blot there are numerous plasma 
proteins which are carbonylated within the 4-8 pH range in both the pooled AD and control 
samples. This is accompanied by minimal background signal. 
 
 
Figure 6.1. Protein oxidation in Pooled AD and Pooled Control sample. 
Plasma protein oxidation was assessed by an anti-DNP Western blot (see section 
6.6.4). A representative blot for a pooled AD and pooled control plasma sample 
run concurrently is shown. (A) Pooled Control (100 µg) and (B) Pooled AD 
(100 µg). 
pH 3 10 
75kDa 
37kDa 
25kDa 
75kDa 
37kDa 
25kDa 
B 
A 
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6.4.2 Matching oxidized plasma proteins between groups  
Forty seven carbonylated plasma proteins were successfully matched between all replicate 
Western blots (Pooled AD and control blots run in triplicate). Figure 6.2 shows an example 
of protein matching in pooled AD and control samples run in parallel for protein 
carbonylation using PD Quest™ software. The triangles represent landmark plasma protein 
spots which are well resolved and present in all replicate gels. These landmarks are used for 
gel alignment and accurate protein spot matching. 
 
      
 
Figure 6.2. Protein spot matching using PD Quest software™. Representative blots for 
pooled control and pooled AD samples are shown. Blots were assayed in parallel to ensure 
identical experimental and developmental conditions. A reference blot (master) is created 
which contains protein spots from all pooled control and pooled AD blots; from this protein 
spots can be matched between all replicate blots and differences identified between control 
and AD groups.  
 
Master AD Control 
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6.4.3 Oxidation differences between AD and control subjects  
Of all of the matched proteins, only one protein was identified as exhibiting increased 
oxidation AD compared to control subjects when ≥ 3 fold change was applied. Following 
normalisation for total protein concentration, this difference was still observed (Figure 6.3).   
 
Parallel silver stained gels of the same samples were used for total protein content. Figure 
6.3A shows the region of interest on a silver stained gel and Western blot.  The protein 
exhibiting increased oxidation is circled. Figure 6.3B shows the optical densities for total 
protein content, amount of oxidation and degree of protein oxidation when AD and control 
samples were compared. The degree of protein oxidation was calculated by dividing the 
optical density of the amount of oxidation by total protein content.  
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6.4.4 The use of immunoprecipitation and verification of antibody suitability  
Due to the low abundant nature of the oxidized plasma protein it was necessary to undertake 
immunoprecipitation (IP) in order to try to increase the chances of gaining a protein identity 
by mass spectrometry. Downstream applications of IP (e.g., SDS-PAGE and 2-DE) can 
result in co-elution of antibody and target protein due to the use of the reducing agents (e.g., 
2-mercapthoethanol and destreak™). Therefore a preliminary experiment to ensure that the 
antibody used for IP was not of the same molecular weight and isoelectric point as the 
plasma protein of interest was undertaken.  As shown in figure 6.4B (circled), the pooled AD 
plasma sample derivatized with 2, 4-DNPH and spiked with rat anti mouse IgE secondary 
antibody is accompanied with minimal streaking compared to the non-spiked pooled AD 
plasma sample in the gel region of interest (circled in figure 6.4A).  
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32.5 kDa 
216 kDa 
18.4 kDa 
A 
B 
3 10 pH 
Figure 6.4. Characteristics of primary antibodies used for 
immunoprecipitation using 2-DE. (A) Silver stain of pooled AD plasma 
(100 µg); (B) derivatized with 2, 4 – DNPH and spiked with mouse 
monoclonal anti-DNP IgE (10 µg). 
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6.4.5 IP of oxidized proteins 
6.4.5.1 Optimal antigen concentration  
To ensure that optimal conditions were employed for IP of oxidized plasma proteins (e.g., 
Dynabead-antibody complexes were not over saturated with antigen) preliminary 
experiments were undertaking using oxidized BSA (see methods section for 2.2.2.1 for 
preparation). Figure 6.5 demonstrates that the optimal amount of antigen added to Dynabead-
antibody complexes without over saturation was approximately 10-20 µg per 150 µg 
Dynabead-antibody complexes. 
 
 
 
 
 
 
 
 
58 kDa 
Figure 6.5.  Optimization of amount of bead-antibody complex and antigen, 
using oxidized BSA. Dynabead® protein G, mouse monoclonal anti-DNP and 
various concentrations of oxidized BSA, derivatized with 2, 4 – DNPH. 
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6.4.5.2 IP of oxidized plasma proteins 
IP of oxidized plasma proteins resulted in reduced background when they were separated by 
2-DE and silver stained (figure 6.6A and 6.6B). The resolution of several highly abundant 
plasma proteins was also improved (See figures 6.6A and 6.6B).  However the plasma 
protein spot of interest was barely visible and could not be detected by densitometry and the 
resolution was of poorer quality than the non IP sample (Figure 6.6, circled). This technique 
was considered a non-viable approach and not used further due to the antibody investment 
and cost. 
 
 
 
 
Figure 6.6.  Comparison of oxidized plasma proteins and precipitated oxidized 
plasma proteins by silver staining. (A) Plasma proteins (200 µg) and (B) 
oxidized plasma proteins (225 µg). Part of gel which contains proteins of interest 
are boxed to the right of the gel. 
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6.4.6 Excision of protein spot from single and multiple 2D gels 
Following unsuccessful use of IP, attempts were made to gain protein identification by 
simply excising the modified protein spot. LC-MS/MS and data dependent CID was used to 
gain protein identification. Figure 6.7 shows a representative gel of the plasma protein spot 
location and its excision.  
 
 
 
 
 
 
 
Oxidized Spot 
38.2kDa 
87.7kDa 
Figure 6.7. Excision of single plasma protein spot from a representative 
silver stained gel. Plasma proteins (100 µg) separated by 2DGE; Isoelectric 
focussing undertaken using pH 3-10 Readystrips™, SDS-PAGE was undertaken 
using 4-15% Tris-HCl criterion gels. Plasma proteins were visualised using silver 
staining.  The oxidized protein is boxed.  
7 9 
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Following MS analysis, the top two most confident matches comprised of trypsin and 
anionic trypsin (see Appendix III for data). Low protein concentration due to low protein 
abundance was considered the limiting factor of successful protein identification, potentially 
due to self digestion of trypsin precursor protein. Therefore the plasma protein spot was 
excised from two gels, in order to gain more protein quantity and pooled together. As shown 
in Table 6.1 (see Appendix III for full data), trypsin was the most confident match, with the 
greatest protein score and peptide coverage, for each sample. A further match included actin; 
however the molecular weight and isoelectric point for actin is not consistent with the region 
of the 2D gel from which the protein spot was excised.  
 
 
 
 
 Accession number/gi Protein 
Score 
Coverage 
(%) 
Description MW *pI 
Unknown 
oxidized 
protein 
P00761/136429 
P10981/113258 
P84183/113258 
 
-129.62 
-82.03 
-82.03 
 
17.32 
11.97 
11.97 
 
Trypsin 
Actin-87E 
Actin, cytoplasmic 
 
24.4 
41.8 
41.8 
 
7.00 
5.30 
5.30 
 
Table 6.1. Data for protein identification from LC-MS/MS for excision of two spots.  
Top protein hits listed for excised spots from silverstained 2D gels. *pI was predicted 
using ExPASY proteomics server from protein sequence data. 
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6.4.7 Identification of a highly abundant plasma protein 
In order to confirm that the excision of protein spots and their subsequent identification was 
possible under these experimental conditions a very abundant protein spot in the neutral 
region of the 2D gel was excised as a control.  The location of this plasma protein spot is 
displayed in figure 6.8. The protein spot was identified as Transthyretin as there are two hits 
in the top four matches and of these (see Appendix III for full data), there is a high protein 
score and high coverage for this particular protein. In addition the isoelectric point and 
molecular weight of this protein corresponds to the location of the protein spot on a 2D gel. 
These data confirmed that the excision of protein spots, their digestion and identification had 
been undertaken successfully, and that previous unsuccessful protein identification was due 
to low abundance. 
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 B 
 
Figure 6.8. Excision and identification of highly abundant protein. (A) Plasma proteins 
(100 µg) separated by 2-DE; Isoelectric focussing undertaken using pH 3-10 Readystrips , 
SDS-PAGE was undertaken using 4-15% Tris-HCl criterion gels. Plasma proteins were 
visualised using silver staining.  High abundant protein (circled) excised from gel. (B) Top 
four protein hits listed for excised spot from silver stained gel. *pI was predicted using 
ExPASY proteomics server from protein sequence data. 
 
 
 
 
 Accession number/gi Protein 
Score 
Coverage 
(%) 
Description MW *pI 
 
Control 
spot 
P02766/136464 
P04264/238054406 
A5A6M6/215275331 
Q5NVS2/75040810 
 
-461.67 
-278.59 
-263.85 
-211.81 
48.98 
25.00 
23.70 
30.00 
Transthyretin 
Keratin 
Keratin 
Transthyretin 
 
15.9 
66.0 
65.0 
15.8 
5.52 
8.15 
7.61 
5.38 
5 9 
18.4kDa 
7.6kDa 
78kDa 
45.7kDa 
A 
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6.4.8 Protein identification by pooling multiple spots from narrow range gels 
To overcome the low levels of protein which had prevented protein identification in previous 
experiments application of more plasma protein to the IPG strip was necessary. However, the 
large range IPG strips previously used, clearly shows congestion and poor resolution of some 
proteins. The use of narrow range IPG strips allows a greater concentration of protein to be 
focussed, while maintaining good protein resolution and avoiding excessive spot congestion 
in the second dimension of separation (Yan et al., 2000) and thus was employed for further 
experiments. Figure 6.9 illustrates that protein spots were less congested on the gel and were 
better resolved, more intensely stained and visually more prominent having employed this 
approach (compare to figure 6.7). In addition this allowed greater accuracy when excising 
the modified plasma protein.  
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198.4KDa 
7 10 
pH 
38.2KDa 
87.7KDa 
126.3KDa 
Figure 6.9. Representative narrow range gel of pooled AD plasma sample.  
Pooled AD plasma proteins (150 µg) focused in 1st dimension using narrow 
range pH 7-10 IPG Readystrip™ (BioRad) and separated in 2nd dimension 
using Tris-HCl Criterion 4-15% gels (BioRad). A) Silver stained gel. B) location 
of excised spot. 
A 
B 
Chapter 6                                                                                        Gel based redox proteomics 
138 
Following mass spectrometric analysis of the excised protein from the narrow range IPG 
strip experiment, protein identification for the plasma protein which exhibited increased 
oxidation in AD was still unsuccessful. As demonstrated in table 6.2 (see Appendix III) 
serum albumin precursor proteins accounted for five out of the six top matches for this 
unknown protein spot, but their isoelectric point and molecular weight was calculated to be 
approximately 5.9 and 69 kDa respectively, which is evidently inaccurate as the pI of the 
excised spot was estimated to be nearer 8 from its location on a 2D gel. Therefore serum 
albumin precursor protein cannot be the true identity of this particular excised spot.  
 
Table 6.2. Protein identification for oxidized plasma protein spot. Proteins listed in 
descending order according to best protein match. *pI was determined using pI/MW 
prediction software available on ExPASY proteomics server.  
 Accession number/gi Protein 
Score 
Coverage (%) Description MW *pI 
 
Unknown 
oxidized 
protein 
spot  
 
 
 
 
Q5NVH5/75054626 
Q28522/2492797 
A2V9Z4/190358749 
P08835/71152981 
P00761/436129 
P49065/44889024 
 
-288.31 
-145.26 
-145.24 
-138.33 
-103.18 
-49.51 
 
 
 
12.81 
4.67 
4.61 
2.14 
8.66 
1.97 
 
 
Serum Albumin 
Serum Albumin 
Serum Albumin 
Serum Albumin 
Trypsin 
Serum Albumin 
 
69.4 
67.9 
68.9 
69.7 
24.4 
68.9 
 
 
5.92 
5.85 
5.91 
6.08 
7.00 
5.85 
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6.5 Discussion 
Two-dimensional gel electrophoresis coupled to Western blotting highlighted one plasma 
protein which exhibited increased oxidation in AD compared to age matched control plasma. 
Numerous attempts, employing different gel techniques, to identify this protein by mass 
spectrometry failed. Protein identification could not be achieved because the sample was 
contaminated with albumin and the only hit obtained was to albumin. This identity was 
incorrect as the molecular weight and isoelectric point did not correspond to the location of 
the excised spot, as visualised on a 2-DG.   
 
There are a number of gel based proteomic studies which combine 2-DE and Western 
blotting that have been successfully used to analyse protein modifications in AD brain 
(Korolainen et al., 2002; Castegna et al., 2002a; Castegna et al., 2002b; Castegna et al., 
2003; Pamplona et al., 2005; Terni et al., 2009; Sultana et al., 2010). For example 
Korolainen and colleagues (2002) demonstrated that protein carbonylation status is altered in 
several proteins from the frontal cortex region of AD brain tissue and Castegna et al. (2002a) 
revealed creatine kinase BB, glutamine synthase and ubiquitin carboxy-terminal hydrolase 
L-1 as proteins, present in the inferior lobule region, which exhibit increased oxidation.  
 
While in brain 2-DE and MS are enough to gain protein identification from an excised gel 
spot, it appears from data presented in this work and reports by others (Korolainen et al., 
2007) that it is not sufficient when attempting to identify the low abundant peripheral 
proteins. Such proteomic work in AD plasma is very limited; to date only two studies have 
used this technique. Choi et al. (2002) showed that the fibrinogen γ-chain and α-1-antitrypsin 
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precursor protein are oxidized in AD plasma and Yu and colleagues (2003) reported a few 
plasma glycoproteins to be oxidized in AD. 
 
Redox proteomic studies which have investigated protein modifications between AD and 
controls samples calculate the signal ratio between individual protein spots, and then look at 
differences above a particular threshold (Choi et al., 2002; Butterfield et al., 2006; Castegna 
et al., 2002b). In this study the same approach was employed to identify one altered plasma 
protein; a stringent 3 fold change was applied, and changes with a p-value < 0.05 were 
considered significant. A recognized limitation of this methodology is that the variability of 
each individual protein is not taken into account as the researcher is only looking at an 
average change, and hence any differences seen can only be assumed to be representative of 
a particular population. However, this approach does have a potential role in preliminary 
analysis, enabling altered proteins to be identified for further investigation (Karp and Lilley, 
2007).  
 
Albumin makes up a large proportion of the plasma proteome and has transport functions in 
human blood plasma, it binds to a wide range of compounds including lipoproteins, 
cytokines and hormones (Adkins et al., 2002). Its capacity to stick to a variety of compounds 
in human blood plasma may provide one possible explanation for its identification in the 
work presented here. Additionally, the presence of a prominent region of proteins 
representing albumin as visualised on a 2-DG (Anderson and Anderson, 1977), coupled to 
evidence of streaking, suggested that the identification of serum albumin could be artefactual 
and not the real identity of the oxidized protein.  A large group of human plasma proteins 
corresponding to fibrinogen γ-chain fragments are located in the gel region where the protein 
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spot was excised from (Anderson and Anderson, 1977), and are therefore more likely to 
represent the  protein spot identity, rather than human serum albumin. 
 
The high abundance of albumin in plasma is a recognized problem in such work, and with 
this in mind one approach is to deplete plasma of albumin prior to analysis, to uncover the 
‘deeper’ proteome (Righetti et al., 2005). Conversely, interesting proteins that may have 
been altered due the disease or condition may be depleted or excluded if depletion is 
employed (Hye et al., 2006), and there is always the possibility that serum albumin may be a 
disease altered protein. For example, in a recent study by Greilberger and colleagues (2008) 
the disulphide form of albumin was shown to be increased in plasma from individuals with 
neurodegenerative disorders; where cysteine 34 residue was oxidized compared to its native 
form. Additionally, plasma albumin is the predominant target of oxidation in other 
conditions associated with increased oxidative stress, such as Uraemia (Himmelfarb and 
McMonagle, 2001).  
 
A further decision faced when employing gel-based proteomics in plasma, is whether to use 
individual samples or to pool samples together prior to analysis. Each approach has its merits 
and disadvantages. Availability of material to the researcher, and time and cost which may 
limit the amount of gels that can be processed, are acknowledged disadvantages of using 
individual samples (Horgan, 2007). Moreover, the efficiency of protein spot matching is 
reduced when analysing a large number of individual gels (Voss and Haberl, 2000).  
 
Sample pooling is attractive as it can overcome these aforementioned limitations. The 
approach also reduces biological variation by forming an average sample (Karp et al., 2005), 
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which may allow differences and similarities between individual groups to be more easily 
identified. It may also prevent inaccurate conclusions based on information obtained from a 
limited number of individual samples. On the other hand, by forming an average protein 
distribution the pooling process may lead to the loss of information; individual proteins 
which are not present in all of the sample pool will go undetected (Zolg, 2006). In a recent 
study Diz et al. (2009) reported that volumes of protein spots in a sample pool matched that 
of the majority of individual samples for that particular pool. In addition the study found 
sample pooling led to a reduction in biological variation, thus providing reassuring evidence 
for some key aspects of the sample pooling approach. The use of multiple individual gels and 
sample pooling have been successfully implemented in studies which use gel based 
proteomics for biomarker discovery (Huang et al. 2006; Hye et al. 2006; Taneja et al. 2009). 
In this study the decision was made to pool individual samples together for proteomic 
analysis.  
 
IP is a technique that can be used to concentrate a particular target protein from a biological 
sample. In this work it was initially employed to concentrate plasma proteins modified by 
oxidation to enhance the chances of obtaining positive protein identification. This was 
necessary because the modified plasma protein of interest was of low abundance, however 
this approach provided no improvement compared to a normally processed plasma sample. 
Initial mass spectrometry data for the excised plasma protein spot from single and multiple 
gels revealed high protein scores and peptide coverage for trypsin precursor protein.  This 
observation suggested that self digestion of trypsin may have occurred, and hence that it was 
likely that low plasma protein concentration was a limiting factor. Indeed difficulty in 
detecting low abundant proteins has previously been reported in a study by Korolainen and 
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colleagues (2007) who were unable to identify such proteins by pooling spots from several 
gels. Moreover, at present there is no definitive answer as to how many low abundant protein 
spots from replicate gels should be pooled together to gain a positive protein identification. 
The use of narrow range IPG strips allowing for more plasma proteins to be focussed, 
improved spot clarity and reduced spot congestion in this study, but did not overcome this 
encountered problem.   
 
In summary, one plasma protein was found to have altered oxidative status in AD compared 
to control. A positive identification for this protein could not be obtained because the sample 
was contaminated with albumin.  The decision was taken, following unsuccessful use of IP 
and narrow range IPG strips, not to pursue the identity of this protein using gel based 
methods. If future studies were to employ 2-DG, a larger sample should be used with narrow 
range IPG strips to confirm and add to these findings. The use of non-gel based proteomic 
methods may complement gel based approaches, and may be more successful in identifying 
proteins altered due to disease.   
Chapter 7                                                                                           Non-gel based proteomics 
144 
 
 
 
Chapter 7 
 
Non-gel based proteomics for the study of 
Alzheimer’s disease 
Chapter 7                                                                                           Non-gel based proteomics 
145 
7.1 Abstract 
The specific location and nature of oxidative modifications to proteins are of particular 
importance as they may impact on protein structure and function. The introduction of 
isobaric tagging for absolute and relative quantification (iTRAQ) has allowed for the 
comparison of protein expression levels between various sample populations. This technique, 
coupled to improvements in high resolution mass spectrometry may provide the potential for 
protein modification analysis. iTRAQ analysis was undertaken and identified eleven peptides 
which were altered in expression in plasma samples from AD sufferers when compared to 
control. Five peptides containing a nitration adduct were identified, with four displaying 
increased expression and one displaying decreased expression in AD compared to control 
samples. In addition, eleven peptides containing oxidized adducts were identified with ten 
showing increased expression and one showing decreased expression in AD compared to 
control samples. Furthermore, eleven plasma proteins were found to be differentially 
expressed between pooled AD and control plasma samples, which were considered of 
possible significance. The identity of alpha-2-Macroglobulin (α-2M) and Complement 4a 
protein (C4a) were validated by Western blotting. The modification data require further 
investigation but suggest that peptides are differentially oxidized and nitrated between AD 
and control subjects. Of particular interest are the presence of oxidation adducts to serum 
transferrin and haptoglobin, given their role in iron homeostasis and ability to sequester 
haemoglobin respectively and thus prevention of radical generation in plasma. 
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7.2 Introduction 
The importance of oxidative modifications in relation to disease pathology has been 
elegantly demonstrated in studies assessing AD brain. Sultana and colleagues (2006a) 
conducted a study in AD and control hippocampus tissue and reported that the chaperone 
enzyme Pin1 exhibited increased oxidation and was down regulated in parallel with a 
reduction in habitual activity in AD. The authors suggested that as Pin1 binds to tau, a 
protein involved in microtubule assembly which is central to the formation of neurofibrillary 
tangle pathologies, one could speculate that such changes maybe involved in AD 
development.  
  
Identifying the nature and location of post-translational modifications (PTMs), is potentially 
more important than assessing the global status of a protein. Oxidation and nitration events 
may now be thought of as PTMs in their own right (Spickett et al., 2006) and the location of 
specific oxidative modifications on the protein may aid understanding of how oxidative 
modifications lead to the altered function of a protein. A study undertaken by Ishii et al. 
(2003) is supportive of this concept. The group showed that incubation of the enzyme 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) with HNE, resulted in 60% of amino 
acid bound HNE being in the form of Michael adducts, which possess carbonyl functionality. 
This was concurrent with a decrease in enzyme activity due to selective modification of 
amino acids located at the molecules surface. Moreover, Ji, Neverova and colleagues (2006) 
reported that in rat, peroxynitrite activation of microsomal glutathione S-transferase 1 is 
mediated by the nitration of a tyrosine residue located at position 92. From this observation 
the authors suggested that this activation is an important mechanism for cellular protection 
against nitrosative stress.  
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Classically, two dimensional gel electrophoresis (2-DE) based redox proteomic research has 
been used to identify specific proteins which are modified by oxidation in disease. In AD 
several proteins have been reported to be modified by oxidation or nitration in the inferior 
parietal lobule and hippocampus regions of the brain (Castegna et al., 2002a; Castegna et al., 
2002b; Castegna et al., 2003; Sultana et al., 2006a). In contrast, very few studies have 
identified specific plasma proteins modified by oxidation (Choi et al., 2002; Yu et al., 2003), 
and no study has investigated nitration to specific plasma proteins in AD. In addition to this, 
in all of these aforementioned studies the location and nature of these oxidative 
modifications were not reported.  One reason may be that more protein sample is required to 
determine specific sites of modification, rather than just obtaining a protein identity (Pandey 
and Mann, 2000). Moreover, previous experiments reported in Chapter 5 of this thesis 
(Bennett et al. unpublished) highlighted the difficulty in obtaining even a protein identity for 
a low abundant protein when using 2-DE, and in these experiments locating the site of 
modification was impossible. This limitation has also been reported in a recent study by 
Korolainen et al. (2007) when the authors attempted to identify modified cerebrospinal fluid 
(CSF) proteins from AD patients using 2-DE. 
 
An innovative approach using iTRAQ (isobaric tagging for absolute and relative 
quantification) reagents coupled to mass spectrometry (MS), for quantitative measurement of 
protein expression levels in complex protein mixtures was first described in Saccharomyces 
cerevisiae by Ross and colleagues (2004). There are eight forms of iTRAQ reagent currently 
available with each reagent comprising of a reporter group, a balance group and an amine 
specific peptide reactive group. The reporter groups (114.1, 115.1, 116.1, 117.1, 118.1, 
119.1, 120.1 and 121.1 Da) are balanced with a neutral group (31, 30, 29, 28, 27, 26, 25 and 
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24Da) such that after reacting with primary amino group of peptides they are isobaric (total 
mass of 145.1Da). When undertaking this methodology samples are labelled with one of the 
iTRAQ reagents and then mixed before MS analysis. In all samples, identical peptides will 
be visualised as one distinct peak on a mass spectrum, as they will be labelled with a 
different isobaric tag, and will therefore have the same mass and be chemically 
indistinguishable from each other. Upon fragmentation the neutral balance group is lost and 
the reporter groups can then be detected on the MS/MS spectrum (Ross et al., 2004; 
Chiappetta et al., 2009). Peptides can be identified by their fragmentation sequence, and the 
relative abundance of reporter group ions allows for the accurate comparison of a particular 
peptide between two or more experimental conditions (see figure 7.1). Since this landmark 
study by Ross and colleagues (2004) the technique has been successfully used to identify 
protein expression level differences, in peripheral tissue from AD patients (Abdi et al., 2006; 
Guntert et al., 2010). 
 
More recently Amoresano and co-workers (2009) demonstrated that the iTRAQ labelling 
strategy could be used for the analysis of PTMs. The group coupled MS analysis with 
selective labelling of ortho-nitrotyrosine residues using iTRAQ reagents, and reported that 
the number and position of modified tyrosine residues in plasma from haemodialysis patients 
could be identified. Furthermore, given the recent introduction of the next generation ion trap 
Orbitrap instrument described by Olsen et al. (2009), possible improvements to PTM’s 
analysis maybe possible due to greater resolution and accuracy provided by using this system 
(Olsen et al., 2009; Chiappetta et al., 2009) 
 
Chapter 7                                                                                           Non-gel based proteomics 
149 
In this study, iTRAQ labelling coupled to mass spectrometry using a LTQ Orbitrap Velos 
system was undertaken in order to identify plasma proteins altered by expression and more 
importantly proteins which were modified by oxidation or nitration in AD. At the time of 
undertaking this research, no previous study had investigated specific plasma proteins altered 
by nitration in AD. Moreover, plasma protein expression and the identification of specific 
sites of oxidative modifications in AD had not been explored using this non-gel based 
methodology.    
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Figure 7.1. iTRAQ labelling and mass spectrometry. Diagram based on that of Ross et 
al. (2004). A) Isobaric tag consisting of a reporter ion, neutral group and a reactive amine 
group. Overall mass of reporter ion and balance group kept the same using 13C, 15N and 
18O atoms. AD and control samples are labelled with different iTRAQ tags and mixed. B) 
AD and control peptides are chemically indistinguishable on mass spectra and are 
visualised by one peak as have the same m/z. C) During MS/MS labelled peptides are 
fragmented; peptides are deduced from fragmentation data and relative amount of 
reporter ions allow the relative amounts of peptides to be determined. 
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7.3 Methods 
7.3.1 Declaration of ownership 
In this Chapter the expertise and advice of Dr Andrew Creese was sought in order to 
undertake the running of SCX chromatography and LC-MS/MS. Responsibility for the 
choosing of filtering parameters for data analysis, and decisions on pooling of fractionated 
samples and their depletion were made by the author. The author was also present for the 
running of these analytical techniques and was responsible for all further data analysis.  
 
7.3.2 Sample selection 
Twenty five control and twenty five AD plasma samples were pooled together for the 
experiment (see general methods section 2.1.4).  
 
7.3.3 Albumin depletion 
To increase the number of low abundant plasma proteins detected, pooled samples were 
depleted of the most abundant plasma protein (albumin) with an Aurum Affi-gel blue mini 
kit. Protein concentrations were determined by BCA assay (see general methods section 
2.2.1). For assessment of albumin depletion, depleted and non depleted pooled plasma 
protein samples (50µg) were separated by 1-DE and visualized by silver staining (see general 
methods, section 2.2.5 and 2.2.7).  
 
7.3.4 iTRAQ labelling  
Two pooled samples were digested in parallel with trypsin and used for iTRAQ experiments. 
Samples (50 µl, 1 mg/ml) were diluted with ammonium bicarbonate (150 µl, 200 mM) and 
dithiothreitol (40 µl, 50 mM) was added and incubated at 60oC for 45 minutes. The samples 
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were returned to room temperature before iodoacetamide (200 µl, 22 mM) was added and the 
samples incubated at room temperature for 25 minutes. To consume any remaining 
iodoacetamide, dithiothreitol (56 µl, 5 mM) was added and samples incubated for 15 
minutes. The samples were digested overnight with sequencing grade modified trypsin (2 
µg) at 37oC. The samples were vacuum centrifuged to dryness, resuspended in trifluoroacetic 
acid (TFA, 0.5%, 200 µl) and desalted using a Michrom desalting Macrotrap (Michrom, 
USA). The trap was wetted using acetonitrile:water (50:50, 300 µl) and washed with TFA 
(0.1%, 200 µl). The sample was loaded onto the trap and washed with TFA (0.1%, 200 µl) 
and eluted in acetonitrile:water (70:30, 200 µl). Samples were vacuum centrifuged to 
dryness.  
 
Samples were resuspended in dissolution buffer (0.5 M triethylammonium bicarbonate, 30 
µl). Half the sample was taken forward for labelling and two samples were labelled in total, 
as follows. The iTRAQ 8-plex labels (Applied Biosystems, USA) were resuspended in 
isopropanol (50 µl), added to the 2 samples as below, vortexed for 1 minute and incubated at 
room temperature for 2 hours. The labels were applied in the following order (condition, 
sample ID): Control, 115; Alzheimer’s disease, 117. The two labelled samples were 
combined and vacuum centrifuged dry. The pooled sample was desalted as above and 
resuspended in mobile phase A (see below, 200 µl).  
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7.3.5 Strong cation HPLC 
The dynamic range of plasma protein concentrations are in the region of nine to ten orders of 
magnitude, resulting in more abundant proteins masking proteins of lower abundance during 
proteomic analysis (Righetti et al., 2005). Therefore, the sample was separated using strong 
cation exchange high performance liquid chromatography (SCX-HPLC) and fractions 
collected in order to obtain a more detailed proteomic analysis. The chromatography was 
performed on an Ettan LC (GE Healthcare Life Science, UK) with a Frac-950 fraction 
collection system. The sample was separated on a polysulfoethyl A column (100 mm x 2.1 
mm, 5 µm particle size, 200 Å pore size. PolyLC, USA) with a javelin guard cartridge (10 
mm x 2.1 mm, 5 um particle size, 200 Å pore size. PolyLC, USA). Mobile phase A was 
potassium dihydrogen orthophosphate (10 mM, pH 3) dissolved in water:acetonitrile (80:20). 
Mobile phase B was potassium dihydrogen orthophosphate (10 mM), potassium chloride 
(500 mM, pH 3) dissolved in water:acetonitrile (80:20). The LC gradient ran from 0 to 80% 
mobile phase B over 73 minutes. Half of the sample was loaded into column and eighteen 
fractions were collected in eppendorf tubes (1.5 ml). Fractions were combined to give a total 
of 5 fractions (fractions 5, 16 and 17 were combined; 6, 14 and 15 combined; 3, 7 and 13 
combined; 4, 8 and 12 combined; 9, 10 and 11 combined). The combinations gave rise to a 
minimum number of fractions with similar peptide quantities. The five fractions were 
vacuum centrifuged to dryness and desalted as above. The fractions were resuspended in 
formic acid (0.1%, 50 µl). Each sample was analysed in triplicate with 5 µl used for mass 
spectrometric analysis. 
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7.3.6 LC-MS/MS 
On-line liquid chromatography was performed by use of a Dionex Ultimate 3000 
autosampler and Surveyor MS pump (Thermo Fisher Scientific, Bremen, Germany).  
Peptides were loaded onto a 75 µm (internal diameter) Integrafrit (New Objective, USA) 
C18 resolving column (length 10 cm) and separated over a 30 minute gradient from 3.2% to 
40% acetonitrile (Baker, Holland). Peptides were eluted directly (≈350 nL/min) via a 
Triversa nanospray source (Advion Biosciences, NY, USA) into a LTQ Orbitrap Velos ETD 
mass spectrometer (Thermo Fisher Scientific), where they were subjected to data-dependent 
MS/MS. 
 
7.3.7 Data-dependent MS/MS 
The mass spectrometer alternated between a full FT-MS scan (m/z 380-1600) and 
subsequent higher collision dissociation (HCD) and CID MS/MS scans of the three most 
abundant ions above a threshold of 5,000. HCD was used solely for quantification and CID 
for identification. Survey scans were acquired in the Orbitrap with a resolution of 60,000 at 
m/z 400. Precursor ions were subjected to HCD in the HCD collision cell. The width of the 
precursor isolation window was 3 m/z. Only multiply-charged precursor ions were selected 
for MS/MS. HCD was performed with nitrogen gas at a normalized collision energy of 55% 
and activation time 100 ms. Automated gain control was used to accumulate sufficient 
precursor ions (target value 10x105, maximum fill time 100 ms). Precursor ions were 
subjected to CID in the linear ion trap. The width of the precursor isolation window was 2 
m/z. CID was performed with helium gas at a normalized collision energy of 35%, activation 
Q 0.25 and activation time 10 ms. Automated gain control was used to accumulate sufficient 
precursor ions (target value 10x105, maximum fill time 50 ms).  
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Dynamic exclusion was used with a repeat count of 1 and exclusion duration of 180 s. Data 
acquisition was controlled by Xcalibur software V2.1.0 (Thermo Fisher Scientific Inc.). 
 
7.3.8 Data analysis 
The MS/MS spectra were searched against a concatenated forward and reverse IPI human 
database v3.72 (173046 entries) using the SEQUEST algorithm in Proteome Discoverer sp 
1.0 (Thermo Fisher Scientific). iTRAQ labels, tyrosine and tryptophan nitration and 
methionine oxidation were specified as variable modifications, with 
carboxyamidomethylation of cysteine as a static modification. The data were searched with a 
precursor mass error of 10 ppm and a fragment mass error of 0.5 Da. The search results were 
filtered using XCorr vs charge state (peptides reporting XCorr values <2.5 for 2+ ions, <3.0 
for 3+ ions and <3.5 for 4+ or greater ions are rejected) resulting in a false discovery rate of 
2 protein in 49 proteins identified (See figure 7.2 for overview of iTRAQ procedure). 
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115 (□) 
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Quantify differences relative to AD group by iTRAQ ratio (A117/ A115) 
Fractionate by SCX Chromatography 
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MS/MS Spectra for a peptide Reporter ions from MS/MS Spectra 
Mix labelled peptides together 
Figure 7.2. Overview of iTRAQ experiment. Further detail provided in methods 
section. 
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7.3.9 Quantification of protein expression differences between groups 
Protein quantification was achieved by averaging the iTRAQ ratio of individual peptides for 
a particular protein; ratios were obtained for individual peptides by dividing the intensity 
count of the iTRAQ label 117 (Pooled AD sample) by label 115 (Pooled Control sample). 
After iTRAQ ratios were calculated, normalisation against the mean value of all iTRAQ 
ratios, when all peptides were considered, was enforced, such that the data was normally 
distributed with the mean and median values equal to 1.  A slight modification to the 
approach used by Abdi et al. (2006) to define changes in protein expression was employed; 
changes of more than 50% were considered significant. Changes which were <15% and 
≥15% were defined as having unlikely and uncertain significance respectively. 
 
7.3.10 Western blot analysis and statistics 
Western blotting was undertaken as described in section 2.2.7. Mouse monoclonal anti-α-2M 
(AbCam Ltd, Cambridge, UK) was used at 1:10,000 with an appropriate horseradish 
peroxidase conjugated secondary antibody (1: 50,000). Mouse monoclonal anti-C4a antibody 
(AbCam Ltd, Cambridge, UK) was used at 1:200 with an appropriate horseradish peroxidase 
conjugated secondary antibody (1: 2,000). Pooled AD and control samples (10 µg) were 
assayed in duplicate or triplicate. Optical densities of bands were analysed by user defined 
volume integration using Quantity One software™ (BioRad). Statistical analysis was 
undertaken as described in section 2.2.10. 
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7.4 Results 
7.4.1 Albumin depletion  
Figure 7.3 shows pooled control and AD plasma samples were successfully depleted of 
albumin using Aurum™ Affi-Gel® Blue columns. A very prominent protein band at 
approximately 66 kDa is present in non-depleted pooled control plasma as visualised on a 
silver stained gel (Figure 3a, lanes 1 and 2). This band corresponds to Human Serum 
Albumin.  The intensity and size of this band is decreased in the depleted pooled control 
plasma sample (Figure 3a, lanes 3 and 4). This difference is also observed between non-
depleted and depleted pooled AD plasma (Figure 3b, lanes 1 to 4). 
 
 
75 kDa 
50 kDa 
75 kDa 
50 kDa 
A 
B 
   1        2   3         4 
Figure 7.3. Albumin depletion of Pooled plasma samples. A) Non-depleted pooled 
control sample (lanes 1 and 2) and depleted pooled control sample (lanes 3 and 4). B) 
Non-depleted pooled AD sample (lanes 1 and 2) and depleted pooled AD sample 
(lanes 3 and 4). All plasma samples (20 µg) were loaded in duplicate. 
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7.4.2 Fractionation of peptides by SCX-HPLC 
Figure 7.4 shows the iTRAQ labelled sample was separated into several fractions (A1-B15) 
using SCX-chromatography. The line with several peaks represents absorption of UV at 
214nm for the sample as it passes through the column. The initial peak corresponds to the 
solvent front, which represents any chemicals which do not bind to the column; subsequent 
peaks correspond to peptides in the sample. Further peaks correspond to the amount of 
peptides present; peaks visible later on the chromatogram correspond to peptides which have 
a higher affinity for the column and bind for longer based on their charge. As demonstrated 
in figure 7.4 a large quantity of peptides are present in fractions A4 and A5 in contrast to 
fractions A15 and B15 which have little peptide abundance. Conductance increased linearly 
as the sample was passed through the column suggesting the gradient had been successful 
(diagonal line).  
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Figure 7.4. SCX chromatogram for iTRAQ labelled sample. SCX elution profile of 
sample: UV absorption at 214nm is represented by line with several peaks, fractions are 
represented along the x-axis (Labelled A1-B15) and conductance demonstrating a successful 
linear gradient is shown by the diagonal line running from bottom left to top right of 
chromatogram.   
 
 
ml 
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7.4.3 Protein expression differences between AD and Control 
Forty nine proteins present in both AD and control groups were successfully detected using 
iTRAQ and LC-MS/MS. Of this initial group of proteins two were reverse sequences and six 
were keratin type precursor proteins. Thirty six of the remaining 41 proteins had > 2 unique 
peptides and were taken forward for analysis. It was also noted that there was some 
redundant data. For example 245 peptides were identified for serum albumin precursor 
protein, of which several different peptides were detected multiple times. As shown in Table 
7.1, proteins exhibited variable protein expression between the AD and control group. More 
specifically no proteins were identified as having significantly altered expression between 
the two groups. Eleven proteins were found to have altered expression which was considered 
to be of possible significance; 6 proteins were increased and 5 were decreased in the AD 
group compared to the control group. Protein expression differences in the remaining twenty 
five proteins were considered unlikely to be significant.  
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7.4.4 Validation of protein expression data 
Plasma proteins α-2M and C4a protein were chosen to validate protein expression data 
acquired from LC-MS/MS. α-2M was used as a control (i.e. no change in protein expression 
between groups) and C4a was used as a positive control as it was one of six proteins found to 
be increased in AD with possible significance.  
 
7.4.4.1 α-2-Macroglobulin  
When visualised on a Western blot α-2M forms a band at 173kDa. As shown in figure 7.5, in 
both pooled AD and control samples there is a distinct band at approximately 170 kDa which 
corresponds to α-2M.   Consistent with LC-MS/MS data (section 7.4.3, table 7.1) there is no 
difference (Control: 170.76 ± 38.47 OD Vs AD: 188.54 ± 1.79 OD units; p = 0.63, 
independent samples t-test) in α-2-Macroglobulin levels as assessed by Western blotting.  
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Figure 7.5. α-2M protein expression in control and AD subjects. A band at 
approximately 170 kDa corresponding to α-2M is evident on a Western blot for control 
and AD plasma samples. Primary mouse monoclonal anti-α-2M (1:10,000; AbCam, 
Cambridge, UK) antibody and an appropriate peroxidase conjugated goat anti-mouse 
secondary (1:50,000; Sigma, UK) were used. 
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7.4.4.2 Complement 4a protein  
Complement 4 is an inflammatory protein which is broken down to form C4a protein which 
has a molecular weight of 193 kDa. As shown in figure 7.6, a band is present in both pooled 
AD and control samples at approximately 190 kDa. Consistent with LC-MS/MS data 
(section 7.4.3, table 7.1) there was a significant increase in C4a protein expression in the 
pooled AD compared to pooled control sample when assessed by densitometry (Control: 
43.78 ± 3.62 OD Vs AD: 69.46 ± 10.21 OD units; p = 0.02, independent samples t-test). 
 
 
  CON                    AD 
190kDa 
Arbitrary value 
(OD units) 
0
40
80
120
CON AD
* 
Figure 7.6. C4a protein expression in control and AD subjects. A band at 
approximately 190 kDa corresponding to C4a protein is evident on a Western blot for 
control and AD plasma samples. Primary mouse monoclonal anti-C4a (1:250; AbCam, 
Cambridge, UK) antibody and an appropriate peroxidase conjugated goat anti-mouse 
secondary (1:2000; Sigma, UK) were used. * p = 0.02. 
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7.4.5 Modified peptides in AD and control plasma 
Forty four peptides were identified as exhibiting an oxidative modification, with twelve of 
these representing reverse sequences. As shown in Table 7.2, five peptides present in both 
AD and control plasma were found to contain nitrated tyrosine or tryptophan residues (a 
schematic diagram of nitrated tyrosine and tryptophan residues are shown in figure 7.7). 
These peptides correspond to Alkaline Phosphatase, Dynein heavy chain 1 and 11, 
Glycolipid transfer protein and Thyroid Receptor Interacting Protein 11. In addition, several 
peptides were shown to be oxidized in both AD and control plasma populations. These 
peptides are named in Table 7.2, and include Serotransferrin, Fibrinogen β-chain, Isoforms 1, 
2 of fibrinogen α-chain, α-2M, Vitronectin, DNA mismatch repair protein, Serum amyloid 
A-4 protein, serum albumin (Isoforms 1 and 2) and Haptoglobin. They all contained oxidized 
adducts.  
 
 
Figure 7.7. Nitrated Tryptophan and Tyrosine residues. 3-nitrotyrosine (A) is formed 
by the reaction of RNS and tyrosine residues in proteins. Tryptophan has several sites 
which can be nitrated or oxidized. These include ring positions 2,4,5,7 and the indole 
imino group (dotted line). 6-NO2Trp (B)  is the most abundant nitrated product formed by 
the reaction of RNS and tryptophan in proteins (B), although 4-NO2Trp and 5-NO2Trp has 
also been reported (Yamakura and Ikeda, 2006). 
NO2 
CH2 
C CO NH 
H 
CH2 C 
CO 
NH 
NO2 
N 
H 
H 
B A 
1 
2 
3 
4 
5 
6 
4 
7 
6 
5 
1 
3 
2 
Chapter 7                                                                                           Non-gel based proteomics 
169 
 
X
C
o
rr
 
Sc
o
re
 
2.
55
 
2.
71
 
2.
58
 
3.
04
 
2.
80
 
4.
99
 
4.
57
 
3.
00
 
3.
29
 
3.
89
 
3.
36
 
2.
72
 
11
7/
11
5 
R
a
tio
 
↓
 
↑
 
↑
 
↑
 
↑
 
↑
 
↑
 
↑
 
↑
 
↑
 
↑
 
O
x
id
a
tiv
e 
M
o
di
fic
a
tio
n
 
Y
10
 
[N
] 
 
W
2 
[N
] 
 
Y
3[
N
]  
 
Y
2[
N
]  
 
W
8[
N
] 
 
M
9[
O
]  
C1
2 
[C
ar
bo
m
id
o
m
et
hy
l] 
 
M
9[
O
] 
 
M
9[
O
] 
 
M
7[
O
]  
M
6[
O
] 
 
M
7[
O
] 
 
M
3[
O
] 
 
A
m
in
o
 
a
ci
d 
se
qu
en
ce
 
 
(p
ep
tid
e) 
V
QH
A
SP
A
G
A
yA
H
TV
N
R
 
Ew
M
K
G
IP
ER
LV
G
LE
ER
 
 
A
M
yS
A
EL
EK
QK
 
 
K
yH
G
W
IV
QK
 
 
A
SS
IT
EI
w
SL
N
K
 
 
IE
SD
V
SA
Qm
EY
cR
 
 
V
G
FY
ES
D
V
m
G
R
 
  
EA
LQ
G
V
G
D
m
G
R
 
K
D
SG
FQ
m
N
QL
R
 
D
SG
FQ
m
N
QL
R
 
 
Y
V
TS
A
Pm
PE
PQ
A
PG
R
 
 
IL
m
TV
ES
A
K
 
 
Pr
o
te
in
 
A
lk
al
in
e 
Ph
o
sp
ha
ta
se
 
D
yn
ei
n
 
he
av
y 
ch
ai
n
 
Th
yr
o
id
 
re
ce
pt
o
r 
in
te
ra
ct
in
g 
pr
o
te
in
 
11
 
 
G
ly
co
lip
id
 
tr
an
sf
er
 
pr
o
te
in
 
D
yn
ei
n
 
he
av
y 
ch
ai
n
 
11
 
Fi
br
in
o
ge
n
 
β
-
ch
ai
n
 
α
-
2-
M
ac
ro
gl
o
bu
lin
 
Se
ru
m
 
am
yl
o
id
 
A
-
4 
pr
o
te
in
 
Se
ru
m
 
Tr
an
sf
er
rin
 
(S
er
o
tr
an
sf
er
rin
) 
54
,
 
52
,
 
66
,
 
53
 
kD
a 
pr
o
te
in
 
 
U
n
kn
o
w
n
 
pr
o
te
in
 
Chapter 7                                                                                           Non-gel based proteomics 
170 
 
 
 
X
C
o
rr
 
Sc
o
re
 
3.
09
 
3.
71
 
3.
00
 
5.
25
 
3.
93
 
2.
60
 
11
7/
11
5 
R
a
tio
 
↑
 
↑
 
↑
 
↓
 
↑
 
↑
 
O
x
id
a
tiv
e 
M
o
di
fic
a
tio
n
 
M
13
[O
] 
 
M
10
 
[O
] 
 
M
6[
O
], 
C9
,
C1
0[
Ca
rb
am
id
o
m
et
hy
l] 
 
M
3[
O
], 
C1
2[
Ca
rb
am
id
o
m
et
hy
l] 
 
M
3[
O
] 
 
M
2[
O
] 
 
A
m
in
o
 
a
ci
d 
se
qu
en
ce
 
(p
ep
tid
e) 
D
W
H
G
V
PG
QV
D
A
A
m
A
G
R
 
 
D
SH
SL
TT
N
Im
EI
LR
 
ET
Y
G
Em
A
D
cc
A
K
 
 
Y
V
m
LP
V
A
D
QD
Qc
IR
 
 
A
V
m
D
D
FA
A
FV
EK
 
 
R
m
V
TG
N
G
SL
K
R
 
 
Pr
o
te
in
 
V
itr
o
n
ec
tin
 
 
Fi
br
in
o
ge
n
 
α
-
ch
ai
n
 
Is
o
fo
rm
 
1 
o
f s
er
u
m
 
al
bu
m
in
 
H
ap
to
gl
o
bi
n
 
 
Is
o
fo
rm
 
2 
o
f s
er
u
m
 
al
bu
m
in
 
D
N
A
 
m
ism
at
ch
 
re
pa
ir 
M
sh
6 
pr
o
te
in
 
Ta
bl
e 
7.
2.
 
Le
v
el
s 
o
f p
ep
tid
es
 
co
n
ta
in
in
g 
o
x
id
a
tiv
el
y 
m
o
di
fie
d 
re
sid
u
es
 
in
 
A
D
 
a
n
d 
a
ge
-
m
a
tc
he
d 
co
n
tr
o
l p
la
sm
a
.
 
M
o
di
fie
d 
pe
pt
id
es
 
w
er
e 
pr
es
en
t 
in
 
bo
th
 
A
D
 
an
d 
co
n
tr
o
l p
la
sm
a 
pr
o
te
in
,
 
as
 
as
se
ss
ed
 
by
 
iT
R
A
Q 
an
d 
LC
-
M
S/
M
S.
 
Le
v
el
s 
o
f 
m
o
di
fie
d 
pe
pt
id
es
 
w
er
e 
al
te
re
d 
be
tw
ee
n
 
gr
o
u
ps
 
an
d 
ar
e 
in
di
ca
te
d 
by
 
ar
ro
w
s 
re
la
tiv
e 
to
 
A
D
.
 
Th
e 
le
tte
rs
 
in
 
th
e 
m
o
di
fic
at
io
n
 
co
lu
m
n
 
re
fe
r 
to
 
th
e 
am
in
o
 
ac
id
 
w
hi
ch
 
is 
m
o
di
fie
d 
an
d 
[N
] o
r 
[O
] r
ef
er
s 
to
 
w
he
th
er
 
th
ey
 
ar
e 
m
o
di
fie
d 
by
 
n
itr
at
io
n
 
o
r 
o
x
id
at
io
n
 
re
sp
ec
tiv
el
y.
 
Chapter 7                                                                                           Non-gel based proteomics 
171 
 
 
 
 
Number Acid 
B 
[M+H]+ 
  
Y 
[M+H]+ 
  Number 
         
1 V ---   ---   16 
2 Q 228.134   1624.76   15 
3 H 365.193 365.18 1496.7   14 
4 A 436.23 436.25 1359.64 1359.56 13 
5 S 523.262 523.2 1288.6 1288.64 12 
6 P 620.315 620.31 1201.57 1201.53 11 
7 A 691.352 691.38 1104.52 1104.54 10 
8 G 748.374   1033.48 1033.39 9 
9 A 819.411 819.39 976.46   8 
10 Y(Nitration) 1027.46 1027.65 905.422 905.41 7 
11 A 1098.5   697.374 697.85 6 
12 H 1235.56   626.337 626.4 5 
13 T 1336.6   489.278 489.01 4 
14 V 1435.67 1435.99 388.23 388.25 3 
15 N 1549.71 1549.65 289.162 289.36 2 
16 R ---   175.119   1 
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Number Acid 
B 
[M+H]+ 
  
Y 
[M+H]+ 
  Number 
         
1 E ---   ---   16 
2 W(Nitration) 361.109 361.28 1857.96   15 
3 M 492.15 492.33 1626.9   14 
4 K 620.245   1495.86 1495.6 13 
5 G 677.266   1367.76   12 
6 I 790.35 790.56 1310.74 1310.7 11 
7 P 887.403   1197.66 1197.59 10 
8 E 1016.45   1100.61   9 
9 R 1172.55 1172.45 971.563 971.9 8 
10 L 1285.63 1285.56 815.462   7 
11 V 1384.7 1384.7 702.378 702.42 6 
12 G 1441.72 1441.62 603.31 603.32 5 
13 L 1554.8 1554.87 546.288 546.44 4 
14 E 1683.85 1685.72 433.204 433.26 3 
15 E 1812.89 1812.85 304.162   2 
16 R ---   175.119   1 
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Number Acid 
B 
[M+H]+   
Y 
[M+H]+   Number 
         
  iTRAQ8plex           
1 A 376.2497 376.39 1646.836 1646.81 11 
2 M 507.2902   1575.799 1575.8 10 
3 Y(Nitration) 715.3386 715.5 1444.759 1444.86 9 
4 S 802.3707 802.53 1236.71 1236.65 8 
5 A 873.4078   1149.678 1149.49 7 
6 E 1002.45 1002.45 1078.641 1078.38 6 
7 L 1115.534 1115.66 949.5984 949.52 5 
8 E 1244.577 1244.71 836.5143 836.51 4 
9 K 1372.672 1372.66 707.4717 707.41 3 
10 Q 1500.731 1500.68 579.3767 579.41 2 
11 K(iTRAQ8plex) ---   451.3182 451.41 1 
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Number Acid 
B 
[M+H]+   
Y 
[M+H]+   Number 
         
  
iTRAQ8plex 
          
1 K 433.308 432.94 1507.83   9 
2 Y(NITRO) 641.356   1379.74 1378.72 8 
3 H 778.415 778.74 1171.69 1171.56 7 
4 G 835.436 835.59 1034.63 1034.58 6 
5 W 1021.52   977.609 978.5 5 
6 I 1134.6 1134.54 791.529 791.45 4 
7 V 1233.67 1233.62 678.445 678.49 3 
8 Q 1361.73 1362.19 579.377 579.37 2 
9 K(iTRAQ8plex) ---    451.318 451.5 1 
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Number Acid 
B 
[M+H]+   
Y 
[M+H]+   Number 
         
 
1 
 
iTRAQ8plex 
A 376.25 376.34 -   12 
2 S 463.28 463.21 1322.66 1322.58 11 
3 S 550.31 550.28 1235.63 1235.61 10 
4 I 663.4 663.46 1148.59 1148.62 9 
5 T 764.45 764.45 1035.51 1035.55 8 
6 E 893.49 893.56 934.46 934.52 7 
7 I 1006.57   805.42 805.42 6 
8 W(Nitration) 1237.64 1237.63 692.34 692.32 5 
9 S 1324.67 1324.52 461.27   4 
10 L 1437.75   374.24 374.27 3 
11 N 1551.8   261.16 261.2 2 
12 K -   147.11   1 
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Number Acid 
B 
[M+H]+   
Y 
[M+H]+   Number 
         
  iTRAQ8plex           
1 I 418.297 418.44 1603.67 1603.72 13 
2 E 547.339 547.35 1490.59   12 
3 S 634.371   1361.55 1361.43 11 
4 D 749.398 749.45 1274.51 1274.47 10 
5 V 848.467 848.5 1159.49 1159.26 9 
6 S 935.499 935.49 1060.42 1060.38 8 
7 A 1006.54 1006.52 973.387 973.33 7 
8 Q 1134.59 1134.53 902.35 902.37 6 
9 M(Oxidation) 1281.63 1281.61 774.291 774.34 5 
10 E 1410.67 1410.69 627.256 627.29 4 
11 Y 1573.74 1573.67 498.213 498.27 3 
12 C(Carbamidomethyl) 1733.77   335.15 335.39 2 
13 R ---   175.119   1 
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Number Acid 
B 
[M+H]+   
Y 
[M+H]+   Number 
              
  
iTRAQ8plex 
          
1 V 404.281 404.42 1275.57 1275.81 11 
2 G 461.303 461.41 1176.5 1176.65 10 
3 F 608.371 608.39 1119.48 1119.77 9 
4 Y 771.434 771.3 972.409 972.42 8 
5 E 900.477 900.5 809.346 809.37 7 
6 S 987.509 987.59 680.303 680.32 6 
7 D 1102.54 1102.45 593.271 593.29 5 
8 V 1201.6 1201.56 478.244 478.32 4 
9 M(Oxidation) 1348.64   379.176 379.38 3 
10 G 1405.66   232.14 232.24 2 
11 R ---   175.119 175.15 1 
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Number Acid 
B 
[M+H]+   
Y 
[M+H]+   Number 
         
  
iTRAQ8plex 
          
1 D 420.24 420.47 1211.55   10 
2 S 507.272 507.41 1096.52   9 
3 G 564.293 564.33 1009.49 1009.4 8 
4 F 711.362 711.43 952.467 952.64 7 
5 Q 839.42 839.46 805.399 805.4 6 
6 M(Oxidation) 986.456 986.42 677.34 677.46 5 
7 N 1100.5 1100.56 530.305 530.36 4 
8 Q 1228.56 1228.48 416.262 416.47 3 
9 L 1341.64   288.203 288.48 2 
10 R ---   175.119 175.31 1 
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Number Acid 
B 
[M+H]+ 
  
Y 
[M+H]+ 
  Number 
         
   iTRAQ8plex           
1 D 420.24 420.54 -   14 
2 S 507.28 507.43 1530.79   13 
3 H 644.34 644.49 1443.76   12 
4 S 731.37 731.48 1306.7 1306.62 11 
5 L 844.45 844.55 1219.67 1219.6 10 
6 T 945.5 945.55 1106.59 1106.57 9 
7 T 1046.55 1046.61 1005.54 1005.54 8 
8 N 1160.59 1160.56 904.49 904.61 7 
9 I 1273.67 1273.58 790.45 790.58 6 
10 M(Oxidation) 1420.71   677.37 677.51 5 
11 E 1549.75   530.33 530.5 4 
12 I 1662.84   401.29 401.73 3 
13 L 1775.92   288.2 288.7 2 
14 R -   175.12   1 
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Number Acid B [M+H]+   Y [M+H]+   Number 
         
              
1 Y ---    ---    14 
2 V 263.139 263.27 1560.75   13 
3 M(Oxidation) 410.174 410.29 1461.68 1461.59 12 
4 L 523.259 523.2 1314.65 1314.57 11 
5 P 620.311 620.32 1201.56 1201.53 10 
6 V 719.38 719.4 1104.51 1104.52 9 
7 A 790.417 790.5 1005.44 1005.48 8 
8 D 905.444 905.47 934.405 934.46 7 
9 Q 1033.5 1033.55 819.378 819.43 6 
10 D 1148.53 1148.47 691.319 691.39 5 
11 Q 1276.59 1276.49 576.292 576.31 4 
12 C(Carbamidomethyl) 1436.62 1436.53 448.234 448.31 3 
13 I 1549.7 1549.59 288.203 288.34 2 
14 R ---    175.119   1 
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Figure 7.8. Raw MS sequencing data for oxidative modifications. Representative raw MS 
spectra are displayed for tryptophan and tyrosine nitration, and oxidized methionine 
modifications. The peptide sequence and ‘b’ and ‘y’ ion fragmentation are shown for each 
individual chromatogram (relative abundance and m/z values on y and x-axis respectively). 
Representative raw MS chromatograms for: A) Alkaline phosphatase; C) Thyroid receptor 
interacting protein 11; and D) Glycolipid transfer protein represent examples of tyrosine 
nitration. Representative raw MS chromatograms for: B) Dynein heavy chain; and E) Dynein 
heavy chain 11 represent examples of tryptophan nitration. Representative raw MS 
chromatograms for: F) Fibrinogen β-chain; G) Alpha 2-Macroglobulin; H) Serotransferrin; 
I) Fibrinogen α-chain; and J) Haptoglobin represent examples of methionine oxidation.  
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7.5 Discussion 
The main outcome of this study was the identification of a small number of peptides which 
were observed to carry either carbonylation or nitration adducts in disease and control 
samples. In addition several plasma proteins were identified as having altered expression in 
AD compared to controls.  It is not practical to discuss exhaustively all of the altered proteins 
in detail; thus the discussion will focus on peptides demonstrated to contain oxidized 
adducts, considered to be particularly interesting in relation to AD. Moreover, discussion of 
protein expression changes from the presented iTRAQ work will be limited to those proteins 
validated by Western blotting.  
 
Transition metals have the capacity to undergo reduction and oxidation reactions and as such 
have the potential to be involved in free radical reactions. The most abundant transition 
metal in the body is iron (Fe). Fe always exists in a bound state, normally with a protein, and 
when stored or transported is chelated by the specific iron binding proteins ferritin and 
transferrin (Tf) respectively (McCord, 2004). In AD brain it has been shown that iron and 
iron binding proteins are altered, with accumulation of iron in AD hippocampal tissue a 
source of free radicals which likely contributes towards oxidative damage evident in this 
disease (Connor et al., 1992; Smith et al., 1997a). In addition it has also been suggested that 
changes to iron binding protein levels in serum may indicate that these changes manifest 
themselves as peripheral markers (Smith et al., 1997a).  
 
In this work it was observed that there was a greater amount of individual peptides in AD 
plasma compared to control subjects corresponding to Serotransferrin (serum Tf) which 
contained an oxidized methionine. This finding is of particular interest as a previous study by 
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Yu and colleagues (2003) also identified that serum Tf exhibits increased oxidation in AD 
compared to control patients. One may speculate that such modifications to serum Tf may 
alter iron homeostasis and thereby play a role in AD by increasing FR induced bio molecular 
damage (e.g., lipid peroxidation). However, whether oxidative modification to serum Tf 
contributes to AD development, or is a secondary event of this disease remains unclear.   
 
A further finding of the work presented in this chapter was the identification of a peptide 
altered by oxidation which corresponded to Haptoglobin (Hp). Hp is a glycoprotein present 
in human plasma which functions to sequester free-haemoglobin (Hb) released from 
erythrocytes into the blood. Due to the oxidative nature of the iron containing heme group 
present in Free-Hb, free radicals can be readily formed. Consequently, Hp is considered to 
provide a crucial protective effect against oxidant damage induced by Hb (Kato, 2009). In a 
recent study Tseng et al. (2004) demonstrated that Hp was a potent antioxidant in LDL 
oxidation. This result coupled to previous experiments by the group which showed that the 
antioxidant potency of Hp exceeded that of Probucol (a drug commonly used to treat 
atherosclerosis), led the authors to suggest that theoretically, at the cellular level, Hp could 
play an important role as a natural antioxidant in protection against atherosclerosis (Tseng et 
al., 2004). Protein oxidation can alter how a protein functions; the altered levels of peptides 
containing oxidation adducts identified in this work may therefore potentially impact on the 
natural antioxidant function of Hp. Although further investigation is warranted to confirm 
this finding, altered antioxidant function of Hp may have implications in AD, given its strong 
association with vascular disease (Hofman et al., 1997; Ott et al., 1996). 
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The thyroid hormone receptor (TR) belongs to the nuclear receptor superfamily and is a 
ligand activated transcription factor that controls multiple biological functions. The main 
ligand for TR is 3, 5, 3’-triiodothyronine (T3), which results from the deiodination of 
thyroxine (T4) (Flamant et al., 2006). Upon binding, T3 induces a conformational change to 
TR which results in transcriptional activation of the receptor, by allowing and preventing 
coactivator and corepressor interactions respectively (Flamant et al., 2006). In this study 
thyroid receptor interacting protein 11 (TRIP11) was found to contain a nitrated tyrosine 
residue, of which there was a greater amount present in AD compared to control plasma. 
Although there appears to be no direct literature concerning TRIP11, the role of a 230 KDa 
protein named TRIP230, which corresponds to the C-terminal region of TRIP11, has been 
investigated (Chang et al., 1997). TRIP230 is a coactivator which binds the thyroid receptor 
in a T3 dependent manner and enhances transcription of the activated receptor (Chang et al., 
1997). Although its biological function has yet to be fully elucidated, it has been suggested 
that it may have coactivator functions related to the cell cycle and be regulated at the post-
translational level (Chen et al., 1999). A link between thyroid hormones and AD 
neuropathology does exist, with high levels of these demonstrated to regulate gene 
expression and decrease APP expression in adult mouse brain (O'Barr et al., 2006). One may 
speculate that the presence of a nitration adduct, as identified here, may have implications for 
such processes in AD. For example the nitration of TRIP11 may alter its interaction with the 
TR and prevent transcription of specific target genes.  
 
These specific modifications to the aforementioned plasma proteins provide an initial point 
of interest that warrants further investigation. First, they require validation by a different 
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technique and secondly functional tests should be employed to determine their biological 
relevance.  
 
iTRAQ coupled to MS analysis identified several plasma proteins that were differentially 
expressed between AD and control samples, as assessed by iTRAQ coupled to MS analysis. 
In order to validate these protein expression data two plasma proteins were selected for 
Western blotting; α-2M was chosen as its expression, as measured by iTRAQ remained 
unchanged, and C4a protein was chosen as its expression, as measured by iTRAQ was 
increased by 15% in the pooled AD sample compared to the pooled control sample. Western 
blotting studies validated and verified these findings. 
 
This work demonstrated that plasma α-2M levels are equivalent between AD and control 
samples which is in agreement with a number of previous studies in peripheral tissue 
(Blennow et al., 2000; Scacchi et al., 2002). The finding is however, in contrast to one recent 
study by Hye et al. (2006) who reported increased α-2M plasma levels in AD compared to 
controls patients using 2-DE, which was validated by Western blotting using a separate 
cohort of samples. A further result of this work was the demonstration that α-2M contained 
an oxidized adduct in AD and control plasma. It has been shown that oxidation at 
physiologically relevant concentrations can inactivate α-2M (Wu and Pizzo, 1999). 
Moreover, in Rheumatoid Arthritis, an inflammatory disease associated with increased tissue 
destruction, levels of oxidized α-2M are increased (Wu and Pizzo, 2001). The authors of 
both of these studies suggested that oxidative modification to α-2M may affect its binding 
affinity for inflammatory proteins and enhance tissue damage during inflammation (Wu and 
Pizzo, 2001; Wu and Pizzo, 1999).  
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Although the oxidative modification data for α-2M requires further investigation, in the 
context of AD this finding is of particular interest. One may speculate that oxidation to this 
specific plasma protein (e.g., α-2M) in AD may partially contribute to the disease by 
enhancing tissue damage and stimulating inflammation (Akiyama et al., 2000). In addition, 
this work builds on that presented in Chapter 5, where α-2M was tentatively shown to be 
nitrated in AD, validating that nitration was increased and not protein expression.  
 
This study also showed increased C4a protein expression in AD compared to control plasma 
by LC-MS/MS analysis, which was further validated by Western blotting. C4a acts as a weak 
mediator of inflammation and is produced on cleavage of Complement 4 protein. Indeed a 
strong link between inflammation and the functional changes evident in AD has been made, 
which has been discussed comprehensively in a review by Akiyama et al. (2000). In brain 
tissue a role for the complement 4 proteins in AD has been suggested. In early studies 
Complement 4 and its cleavage products were reported to be present in close proximity to 
senile plaques and neurofibrillary tangles (Eikelenboom and Stam, 1982; McGeer et al., 
1989). In addition, the expression of five plasma proteins was shown to be reduced in AD, 
with these changes being of possible significance. The data presented in this study showed 
that α-1-glycoprotein plasma protein expression was markedly reduced; interestingly its 
expression has also been shown to be decreased in CSF from AD patients (Puchades et al., 
2003), although its biological function remains unknown.  
 
One important issue that requires discussion is the consideration of sample preparation when 
undertaking proteomic analysis. In this work the decision was made to use pooled samples 
instead of individual samples, which may be considered a limitation. This decision was 
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based on two recent studies which suggested that the use of pooled samples, rather than 
individual samples, was more productive when employing proteomics to analyse the AD 
CSF proteome (Zhang et al., 2005; Abdi et al., 2006). The main disadvantage of using 
individual samples is the inability to distinguish whether a change observed in a sample is 
due to the nature of that particular individual or the disease itself (Zhang et al., 2005; Abdi et 
al., 2006). The use of pooled samples removes this problem and effectively creates a 
representative disease sample. A further consideration when undertaking proteomic analysis 
in plasma is the presence of highly abundant proteins such as albumin. These proteins may 
cloud or mask the presence of low abundant proteins (Righetti et al., 2005). As a 
consequence pooled samples were depleted of albumin and then fractionated to enable a 
more detailed analysis of the AD and control plasma proteomes. 
 
In summary this study successfully used iTRAQ coupled to MS/MS analysis to identify   
peptides which contained nitration and oxidation adducts in AD and control plasma. These 
initial data require further investigation by firstly selecting and validating proteins of interest 
and then determining the effect of oxidative modifications at these particular sites on their 
function.  
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8.1 Introduction 
The main aim of the studies presented in this thesis was to evaluate oxidative stress in 
Alzheimer’s disease (AD) plasma and more specifically to assess oxidative modifications to 
individual plasma proteins. It is widely accepted that oxidative stress increases with ageing, 
and in recent years it has become apparent that in age-related diseases such as AD, these 
levels are further increased above what is considered normal healthy ageing (Markesbery, 
1997). Oxidative damage to proteins (e.g., carbonylation, nitration) maybe of particular 
importance as it impacts upon how a protein functions (Friguet, 2006). In AD this may be of 
particular relevance when considering disease pathology, for example glycolytic enzymes, 
modified by oxidation, may be linked to the decreased glucose metabolism associated with 
AD (Castegna et al., 2002b; Costantini et al., 2008). In this work it was hypothesised that 
specific plasma proteins, likely to be vascular, would be targets for oxidative modification in 
AD, and that such changes would be potentially important when considering and 
understanding peripheral oxidative stress in AD. 
 
Within AD research, studies using brain tissue are still of primary importance when 
assessing disease pathology, however one drawback is that these studies are conducted post-
mortem. As a consequence, determining oxidative changes during the progression of the 
disease is near impossible using such methodologies. Further, the monitoring of 
interventions such as antioxidant supplementation is not possible. Peripheral tissues such as 
plasma and cerebrospinal fluid (CSF) provide a means of undertaking such work. The 
acquisition of plasma is less invasive than CSF collection (Hye et al., 2006) and contains 
proteins reflective of processes which occur in the body (Veskoukis et al., 2009). In addition, 
500mls of CSF, which is in direct contact with the brain and is reflective of processes which 
Chapter 8                                                                                                     General Discussion 
190 
occur in the brain, is turned over into plasma each day (Davidsson and Sjogren, 2006; Hye et 
al., 2006). Therefore changes in plasma represent global and vascular changes in oxidative 
stress which occur in AD, and may also present potential biomarkers for this disease. The 
results presented here suggest that overall plasma protein oxidation levels are not different 
when AD and normally aged individuals are compared, and that individual plasma proteins 
are specific targets for oxidative modification in AD. This thesis explores different 
methodologies to assess oxidative changes in AD. Importantly, it highlights some of the 
difficulties encountered when attempting to identify particular modified proteins using 
classical gel based proteomics. In addition it demonstrates that emerging novel and powerful 
mass spectrometry techniques can be employed to identify several proteins modified by 
oxidation, providing an initial starting point for further investigation. 
 
8.2 Main findings 
In Chapter 3 broad based oxidative stress markers were evaluated in addition to the 
oxidation status of low density lipoprotein (LDL). Due to the strong association between 
atherosclerosis and AD from population based studies (Hofman et al., 1997), coupled with 
the demonstration that the susceptibility of LDL to oxidation in plasma and CSF is increased 
in AD (Bassett et al., 1999; Schippling et al., 2000), it was hypothesised that plasma LDL 
oxidation would be increased in AD. The results from this study demonstrated that oxidized 
LDL was increased in AD and confirmed this hypothesis. This observation suggests that 
vascular changes such as oxidized LDL may partly contribute to AD pathology as the 
increased levels were significantly higher in AD sufferers, over and above the normal 
increased levels of oxidized LDL expected with age. Indeed, although patients with 
cardiovascular disease were excluded from this work, all subjects are still likely to have a 
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degree of atherosclerosis, given that hardening of arteries is an early event in life which 
progresses with age. To see levels of oxidized LDL in AD over and above that of controls, 
suggested that this change was related to disease. 
  
Total levels of plasma lipid peroxides and plasma protein oxidation were unchanged in AD 
compared to control subjects. These results support the majority of reports in the current 
literature. One possible argument is that severity of the disease may influence protein 
oxidation levels (Bermejo et al., 2008; Ansari and Scheff, 2010) and therefore no significant 
difference in levels may be evident when comparing AD and control subjects which involve 
sufferers of differing disease severity. Results presented in Chapter 3 support substantial 
evidence which suggests that specific plasma proteins are targets of oxidation (e.g., LDL). A 
global change in protein oxidation may therefore not be the important issue that requires 
investigation. Moreover, establishing a group of proteins that are altered, in the quest to 
further understand peripheral oxidative changes and develop a biomarker, is of more 
importance. 
 
A high throughput measure of protein nitration is of particular interest as it may represent a 
footprint of the potent peroxynitrite radical (ONOO-), and may contribute to further 
understanding disease pathology. On this premise the main focus of Chapter 4 was to 
develop an ELISA for the semi-quantification of total protein nitration. This approach had 
been previously used successfully in other diseases associated with oxidative stress (Ceriello 
et al., 2001; Bekpinar et al., 2005). However, the data presented in this thesis suggests that 
most samples were below the detection limit of HPLC-ECD (1 µM) and an indirect ELISA 
(5 nM), and therefore that this approach lacked the sensitivity required for this measurement. 
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In a comprehensive study recently undertaken by Korolainen and Pirttilä (Korolainen and 
Pirttila, 2009) 3-nitrotyrosine levels in AD CSF, plasma and serum were assessed by 
commercial ELISA. In agreement with the findings produced in this thesis, levels of nitration 
from samples analysed in this aforementioned study were below the detection limit of the 
assay (2 nmol/l).   
 
Following on from work in Chapter 4, a different strategy was employed in Chapter 5 in an 
attempt to obtain a semi-quantitative measure of protein nitration. The Griess Assay and 1-
DE coupled to Western blotting were employed to measure nitric oxide (NO•) levels and 
plasma protein nitration respectively. Results showed that plasma nitric oxide metabolites 
(NO2-/ NO3-) were reduced in AD, which is in agreement with several recent studies and 
adds weight to the observation that endothelial dysfunction is a characteristic of AD 
pathology (Selley, 2003). From the outset this work aimed to look at the association of nitric 
oxide levels and total plasma protein nitration, and it was proposed that 3-nitrotyrosine may 
be increased concurrently with a decrease in nitric oxide levels. This was based on the 
concept that NO• would react with superoxide anions to form ONOO- and nitration of 
proteins. However, the results were inconclusive as problems with antibody non-specificity 
prevented accurate quantification of total nitration levels. That said, several nitrated proteins 
were observed and one of these, which corresponded to α-2 Macroglobulin (α-2M), was 
increased in AD compared to control subjects. Although one cannot rule out a change in 
global levels of nitration from these data, it does demonstrate that a specific protein is a 
target for oxidative modification (e.g., nitration) which is in agreement with the observations 
from Chapter 3. Moreover total protein carbonylation levels were consistent between groups 
confirming initial data from Chapter 3 in a separate cohort of plasma samples. 
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The use of redox proteomics to identify specific plasma proteins which undergo oxidation 
was the main focus of Chapter 6. One plasma protein was found to undergo oxidation in AD 
compared to control subjects, although accurate identification of this protein could not be 
achieved due to low abundance, despite efforts using further techniques to do so. Work in 
this chapter used non-depleted samples which may be considered a limitation due to 
presence of high abundant proteins.  
 
Following the inability to gain a protein identity in Chapter 6, non-gel based proteomics 
was employed to assess protein expression and modification in AD compared to control. The 
use of non-gel based proteomics is emerging as a powerful technique which can be utilized 
to discovery plasma based biomarkers and complement existing 2-DE based methods. The 
results presented in Chapter 7 show several site specific oxidative modifications to proteins 
in both AD and control plasma. These oxidative modifications presented in both populations 
warrant further investigation. In addition the altered expression of several plasma proteins 
which were of possible significance was investigated. The expression of one of these plasma 
proteins, Complement 4a, was shown to be significantly increased in AD compared to 
control subjects. In contrast, the expression levels of α-2M were shown to be equivalent 
between AD and control subjects. Taken together, the results presented in Chapter 5 and 
Chapter 7 suggest that α-2M plasma protein expression remains unchanged, but that its 
nitration status is increased in AD. 
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8.3 Findings in context of existing literature 
8.3.1 Equivalent plasma protein oxidation 
When considering all broad measurements of oxidative stress presented in this thesis, it is 
apparent that total protein oxidation levels are unchanged in AD compared to control 
subjects. Despite some conflicting reports, this is in agreement with the majority of recent 
studies which assess this generic marker of oxidative stress (Baldeiras et al., 2008; Polidori 
et al., 2004; Pulido et al., 2005; Zafrilla et al., 2006). A potential explanation for equivalent 
protein oxidation levels is that disease severity may affect oxidative stress levels. There are 
studies which agree (Bermejo et al., 2008; Ansari and Scheff, 2010) and disagree (Zafrilla et 
al., 2006) with this idea as previously discussed.  
 
The data from this thesis demonstrate that at least two plasma proteins (i.e. LDL and an 
unknown plasma protein) exhibit increased oxidation in AD, but that total protein oxidation 
remains equivalent when assessing total protein carbonylation (Aldred et al., 2009). As the 
plasma proteome is composed of thousands of proteins at any one given time, the oxidation 
of a few specific proteins may not be enough to cause a global change.  This would support 
studies in AD brain tissue, where specific proteins have been shown to be oxidized, nitrated 
and lipoxidized (Castegna et al., 2002b; Castegna et al., 2003; Pamplona et al., 2005). It may 
well be the case that investigating particular plasma proteins which are targets of oxidative 
modification may provide more information on disease process, rather than a measurement 
of oxidative stress in whole plasma in AD.  
 
 
 
Chapter 8                                                                                                     General Discussion 
195 
8.3.2 Complementing gel based proteomics with non-gel based proteomics 
Classically gel-based proteomics has been used to assess protein expression changes to the 
plasma proteome in disease states, and to a lesser extent oxidative modifications which 
occur. However more recently it appears that proteomics is moving away from classical gel-
based methods to non-gel based methods when assessing the plasma proteome for protein 
expression changes in AD (Abdi et al., 2006; Choe et al., 2007). For example Lovestone and 
co-workers have used gel based methods to successfully identify plasma proteins which are 
altered in expression in AD (Hye et al., 2006), but have more recently used iTRAQ labelling 
coupled to mass spectrometry to complement this early work and discover several more 
proteins which have altered expression (Guntert et al., 2010). Given the recent improvement 
of isobaric labelling strategies coupled to mass spectrometry (Chiappetta et al., 2009) a non 
gel-based redox proteomic approach may also complement gel based redox proteomics. 
Work presented in this thesis suggests such an approach can be undertaken as non-gel based 
proteomics was employed to successfully identify specific sites of oxidative modification to 
plasma proteins in AD and control subjects. Where the technology perhaps still lacks, is in 
identifying modifications which are unique to the disease process.  
 
8.3.3 Measurement of plasma 3-nitrotyrosine in AD 
In this thesis two analytical techniques were employed to analyse 3-nitrotyrosine levels in 
biological fluids which included HPLC-ECD and antibody based methods. The actual 
physiological levels of 3-nitrotyrosine in normal and diseased subject’s plasma remain open 
for debate, with conflicting data available in the literature. Basal levels of 3-nitrotyrosine 
using all of the analytical techniques mentioned are quite varied and range from undetectable 
to between 1 and 64 nM (Tsikas and Caidahl, 2005). The general consensus is that under 
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normal conditions, levels of free and bound 3-nitrotyrosine are low, but levels become 
elevated in conditions associated with increased oxidative stress (Souza et al., 2008). 
 
In this work ELISA with a detection limit of 5 nM was used in order to provide a high 
throughput semi-quantitative measure of 3-nitrotyrosine in AD and age-matched control 
plasma. Levels of 3-nitrotyrosine were only detectable in a minority of plasma samples by 
HPLC-ECD (detection limit 1 µM) and only two out of 24 plasma samples were detectable 
by ELISA (detection limit 5 nM). Indeed in a recent study Korolainen and Pirttilä (2009) 
were unable to detect nitration using a commercial ELISA with a detection limit of 1nM in 
the majority of large cohort of AD CSF and plasma samples. In AD peripheral tissue 3-
nitrotyrosine levels have been reported as 0.44 ± 0.031 nM and 11.4 ± 5.4 nM in studies by 
two separate groups using HPLC with electrochemical detection and gas chromatography-
tandem mass spectrometry (Tohgi et al., 1999; Ryberg et al., 2004). From the data presented 
in this thesis and the aforementioned studies it is highly likely that plasma levels of 3-
nitrotyrosine in AD are in the low nanomolar range. Therefore more sensitive analytical 
techniques need to be used to detect this analyte and determine whether total levels of free 
and bound 3-nitrotyrosine are actually altered in AD plasma.   
 
8.4 Future directions 
8.4.1 Oxidative stress in vascular dementia  
There is a requirement to distinguish between different types of dementia to enable more 
suitable and directed therapies. Understanding the role of oxidative stress in different types 
of dementia will enable further characterisation of dementia and may contribute to biomarker 
discovery. Although several studies have compared markers of oxidative stress between Mild 
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Cognitive Impairment and AD, limited work has focussed on oxidative changes between 
vascular dementia (VaD) and AD. A link does exist between oxidative stress and VaD given 
that increased free radical production is associated with cerebral ischemia (Zini et al., 1992), 
a risk factor for vascular type dementias.  
 
There are studies supporting a role for oxidative stress in VaD, with most to date 
investigating the lipid peroxidation product MDA. For example, MDA levels have been 
shown to be increased in AD and VaD patients over the ages of 65 (Casado et al., 2008), and 
in a very recent study Gustaw-Rothenberg et al. (2010) reported MDA levels to be increased 
in VaD and AD compared to controls. Interestingly this study highlighted a significant 3.4 
fold increase in levels in VaD compared to AD. Notably there are only limited or in fact no 
measurements of protein carbonylation and nitration in VaD and AD comparison studies 
(Polidori et al., 2004). 
 
Further investigations which compare a wide range of oxidative stress measurements are 
warranted in order to clarify the role of oxidative stress in VaD, and more specifically 
oxidative differences between AD and VaD. An extension of existing studies may be to 
undertake redox proteomic research to identify specific plasma proteins which are 
differentially altered between these two types of dementia. 
 
8.4.2 Exercise as a therapeutic intervention for AD 
A future direction and an extension of the work presented in this thesis would be to evaluate 
the effect of exercise on markers of oxidative stress in AD, with plasma being an ideal 
source due to the non-invasive nature of its collection. The benefits of exercise in AD are 
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well documented: Larson et al. (2006) reported that regular exercise is associated with 
delayed the onset of Alzheimer’s type dementia. Further studies have shown exercise 
training resulted in improved cognition in fifteen patients with senile dementia (Palleschi et 
al., 1996); and improved capacity to perform everyday tasks in addition to improving muscle 
strength and flexibility in AD patients (Santana-Sosa et al., 2008). Given the recent 
demonstration by Donnelly and co-workers (2008) that cardiovascular fitness is comparable 
between demented and non-demented patients, in addition to oxidative stress being an early 
event in AD (Nunomura et al., 2001), a walking exercise test in this elderly population in the 
earliest stages of this disease is most definitely plausible. 
 
When considering oxidative stress as an AD pathology, then exercise may be used to explore 
the AD disease process. Oxidative stress and free radical production during exercise has been 
well studied.  Early work by Davies et al. (1982) suggested that exercise may be detrimental 
as it was demonstrated that free radicals were produced in rat skeletal muscle after running to 
exhaustion, and more recently increased free radical generation in rat skeletal muscle, after 
an acute bout of exhaustive exercise, was shown to be accompanied by increased oxidative 
stress (Bejma and Ji, 1999). However, Vina and co-workers (2000) found that oxidative 
stress occurred during exercise, but only when it was exhaustive. 
 
Additionally, more recent research has shown exercise induced radical production to be 
essential for adaptation and signalling processes, thus suggesting that the production of ROS, 
during moderate intensity exercise, may be beneficial. Work by Navarro et al. (2004) 
demonstrated that moderate exercise in ageing mice reduced markers of oxidative damage 
(e.g., protein carbonyls and TBARS) in the sub mitochondrial fractions from organs 
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including the brain. Exercise also increased the activities of antioxidant enzymes (e.g., Mn-
SOD, Cu, Zn-SOD and catalase) in these organs (Navarro et al., 2004; Boveris and Navarro, 
2008), and this was paralleled with improvements in behavioural tests. A more recent study 
by Gomez-Cabrera et al. (2005) showed that ROS generated during exercise activates NFκB, 
which results in increased expression of important antioxidant enzymes such as Mn-SOD 
and GPx.  This study highlights the importance of ROS produced during exercise for their 
role in cellular adaptations. Such studies have led to a growing opinion amongst exercise 
physiologists that moderate intensity exercise may itself be an antioxidant (Gomez-Cabrera 
et al., 2008).  
 
In AD specifically, animal studies have shown that exercise can reduce Aβ42 peptide and 
improve behavioural function in transgenic mice (Um et al., 2008). Moreover, increases in 
neurotrophins (e.g., BDNF), heat shock protein 70 and antioxidant enzymes (e.g., SOD-1 
and catalase) were also observed in exercised compared to sedentary transgenic mice (Um et 
al., 2008). These data support a role for exercise as a therapeutic strategy for the treatment of 
AD (Um et al., 2008) and may suggest that an improvement to the antioxidant defence 
system is one underlying mechanism by which exercise may exert its effect. 
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8.5 Conclusions 
In conclusion, the series of studies conducted throughout this thesis suggest that particular 
plasma proteins are targets for oxidation, rather than oxidation events being random in 
nature. When considering LDL, it is likely that it is specifically oxidized in AD plasma as a 
result of its intimate involvement in the development of atherosclerosis, an established risk 
factor for this disease, instead of occurring as a consequence of AD. In contrast, other plasma 
proteins such as α-2M, which was found to exhibit an oxidized adduct, may be specifically 
targeted for oxidation due to the impact this modification has on their function. It has been 
proposed that oxidation to α-2M acts as a switch mechanism by down regulating acute 
inflammation and up-regulating tissue repair by sequestering cytokines and releasing growth 
factors respectively. This may be relevant in AD, a condition which is strongly linked with 
inflammation.  
 
In addition, questions still remain as to whether free or bound 3-nitrotyrosine plasma levels 
are altered in AD, given the difficulties encountered during this thesis when assessing plasma 
protein nitration. Further experiments are therefore required which use analytical methods 
sensitive enough to accurately measure global 3-nitrotyrosine in plasma.  Finally, the use of 
gel based and non-gel based proteomics identified plasma proteins which are targets for 
oxidative modification. This work requires further exploration to identify significant 
modifications which may be implicit in AD pathology.  
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APPENDIX I 
Optimizing applied voltage for HPLC-ECD; Thesis Chapter 4.  
For detection of 3-nitrotyrosine in plasma from Alzheimer’s disease (AD) and age-matched 
control subjects the present study used a modified HPLC-ECD method from that described 
by Maruyama et al. (1996). Method development was necessary to establish the optimum 
applied voltage required to provide the greatest 3-nitrotyrosine signal. A known 
concentration of synthetic 3-nitrotyrosine (10µM) was manually loaded onto the column and 
the applied voltage was adjusted by 10mV increments ranging between 900mV and 
1040mV. All other conditions were kept standard and each sample was assayed in duplicate. 
The optimal applied voltage was evident at 990mV.   
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APPENDIX II 
 
Protein summary from OSSMA Browser for excised gel band; Thesis Chapter 5 
 
Appendix II 
225 
Appendix II 
226 
 
 
Appendix II 
227 
 
 
Appendix II 
228 
 
Appendix II 
229 
 
Appendix II 
230 
 
Appendix II 
231 
 
Appendix II 
232 
 
Appendix II 
233 
 
Appendix III  
234 
 
 
 
 
 
 
 
 
 
Appendix III 
Appendix III  
235 
APPENDIX III 
 
Protein summary from OSSMA Browser for one excised gel spot from one wide range 
gel; Thesis Chapter 6 
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Protein summary from OSSMA Browser for two excised gel spots pooled from two 
wide range gels; Thesis Chapter 6 
 
 
Appendix III  
238 
 
 
Appendix III  
239 
Protein summary from OSSMA Browser for excised gel spots pooled from three 
narrow range gels; Thesis Chapter 6 
 
 
 
